

# EULAR recommendations for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: 2016 update

Annals of the Rheumatic Diseases

76, 960-977

DOI: [10.1136/annrheumdis-2016-210715](https://doi.org/10.1136/annrheumdis-2016-210715)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Depression in Rheumatoid Arthritis and its relation to disease activity. Pakistan Journal of Medical Sciences, 1969, 31, 393-7.	0.3	32
3	Terapia m�dica actual en reumatolog�a. Revista M�dica Cl�nica Las Condes, 2012, 23, 413-422.	0.2	0
4	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 2012, 71, 4-12.	0.5	405
5	Marine oil supplements for rheumatoid arthritis. The Cochrane Library, 2012, , .	1.5	0
6	Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis. Annals of Internal Medicine, 2012, 156, 329.	2.0	279
8	Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients. Joint Bone Spine, 2012, 79, 520-521.	0.8	0
9	�valuation des autoquestionnaires d'activit� dans la polyarthrite rhumato�de: �tude transversale sur 200 patients avec le RAPID3 et le RAI5 et �valuation de la pouss�e. Revue Du Rhumatisme (Edition) Tj ET Over	0.0	0
11	Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA. Best Practice and Research in Clinical Rheumatology, 2012, 26, 705-720.	1.4	16
13	Can the Medication in Patients With Rheumatoid Arthritis in Remission Be Stopped?. Reumatolog�a Cl�nica (English Edition), 2012, 8, 39-41.	0.2	1
14	Patient Survival and Safety With Biologic Therapy. Results of the Mexican National Registry Biobadamex 1.0. Reumatolog�a Cl�nica (English Edition), 2012, 8, 189-194.	0.2	8
15	Quels traitements sont arr�t�s ou diminu�s dans la PR en r�mission prolong�e (DAS 28) sous anti TNF�? Une �tude r�trospective chez 43 patients. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 483-485.	0.0	0
16	Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Research and Therapy, 2012, 14, R249.	1.6	61
17	Agreement of Turkish Physiatrists with the Assessment in Spondyloarthritis International Society and the European League Against Rheumatism Recommendations for the Management of Ankylosing Spondylitis and Rheumatoid Arthritis. Open Rheumatology Journal, 2012, 6, 1-5.	0.1	1
18	Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 977-985.	1.5	79
20	Patient perspective in outcome measures developed by OMERACT. Indian Journal of Rheumatology, 2013, 8, S17-S22.	0.2	8
23	Is there a place for initial treatment with biological DMARDs in the early phase of RA?. Best Practice and Research in Clinical Rheumatology, 2013, 27, 537-554.	1.4	8
24	What is the best treatment strategy for early RA?. Best Practice and Research in Clinical Rheumatology, 2013, 27, 523-536.	1.4	11
25	A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open, 2013, 3, e002468.	0.8	55

#	ARTICLE	IF	CITATIONS
26	Monoclonal antibodies in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 541-556.	0.3	8
27	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 665-671.	0.5	110
28	Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 3-6.	0.5	98
29	Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. <i>Biosimilars (Auckland, New Zealand)</i> , 2013, , 1.	0.4	4
30	Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. <i>Biologics: Targets and Therapy</i> , 2013, 8, 1.	3.0	22
31	Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 381-389.	0.5	90
32	Pharmacokinetics of T-614 after Single Oral Administration in Healthy Korean Volunteers. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2013, 21, 150.	0.1	1
33	South African recommendations for the management of rheumatoid arthritis: An algorithm for the standard of care in 2013. <i>South African Medical Journal</i> , 2013, 103, 576.	0.2	34
34	Extraskelatal Manifestations in Rheumatoid Arthritis - Clinical Cases. , 0, , .		0
35	Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. <i>International Journal of Nanomedicine</i> , 2014, 9, 4911.	3.3	44
36	Tocilizumab in the treatment of rheumatoid arthritis and beyond. <i>Drug Design, Development and Therapy</i> , 2014, 8, 349.	2.0	70
37	AB0436â€¦Do Patients Diagnosed with Chronic Inflammatory Arthropathies Treated with Rituximab Need Retreatment with the Same Dosage in Posterior Cycles? Analysis of the Sustained Response after Retreatment at A Lower Dose. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 952.1-952.	0.5	0
38	Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. <i>Biologics: Targets and Therapy</i> , 2014, 8, 141.	3.0	45
39	Pain in rheumatoid arthritis: a critical review. <i>Reumatismo</i> , 2014, 66, 18-27.	0.4	47
40	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. <i>Reumatismo</i> , 2014, 66, 285-303.	0.4	5
41	Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 313.	0.9	5
42	Methotrexate in rheumatoid arthritis: benefits, limitations and the emerging value of subcutaneous administration. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 345-351.	0.3	0
43	The future of biological agents in the treatment of rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 475-486.	0.3	0

#	ARTICLE	IF	CITATIONS
44	Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 393.	0.8	28
45	Actualización en el tratamiento de la artritis reumatoide. <i>Medicine</i> , 2014, 11, 4112-4121.	0.0	1
46	Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. <i>Patient Preference and Adherence</i> , 2014, 8, 1051.	0.8	5
47	Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. <i>BMJ Open</i> , 2014, 4, e005297-e005297.	0.8	19
48	Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 327-339.	0.3	0
49	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. <i>Journal of Rheumatology</i> , 2014, 41, 2370-2378.	1.0	9
50	Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2219-2220.	0.5	16
52	The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 389.	0.8	12
53	Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 449.	0.8	23
54	The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 104.	1.5	33
55	Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2014, 6, 159-168.	1.2	8
56	Biosimilars: lights and shadows in rheumatology. <i>Rheumatology Reports</i> , 2014, 6, .	0.1	1
57	Reduction of Biological Agent Dose in Rheumatic Diseases: Descriptive Analysis of 153 Patients in Clinical Practice Conditions. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 10-16.	0.2	7
58	Ex vivo gene delivery to synovium using foamy viral vectors. <i>Journal of Gene Medicine</i> , 2014, 16, 166-178.	1.4	7
59	Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?. <i>Immunologic Research</i> , 2014, 60, 289-310.	1.3	91
60	Triple terapia en la artritis reumatoide. <i>Reumatología Clínica</i> , 2014, 10, 275-277.	0.2	5
61	Triple therapy in rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 275-277.	0.2	1
62	Taux de rétention de l'adalimumab, de l'etanercept et de l'infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 483-490.	0.0	0

#	ARTICLE	IF	CITATIONS
63	Toxidermie survenant sous tocilizumab au cours de la polyarthrite rhumatoïde. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 512-513.	0.0	0
64	Le polymorphisme du TNFR11 est associé à la réponse aux anti-TNF $\pm$ dans la polyarthrite rhumatoïde chez les patients sans anticorps anti-CCP. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 349-351.	0.0	0
65	The "Dirty Little Secret" Exposed in the 2013 EULAR Recommendations for Rheumatoid Arthritis Therapy. Clinical Therapeutics, 2014, 36, 1114-1116.	1.1	3
66	Biologic agents for rheumatoid arthritis: Can we hypothesize new strategies of treatment?. Medical Hypotheses, 2014, 82, 117-121.	0.8	3
67	Potential Sources of Quantification Error When Retrospectively Assessing Metacarpal Bone Loss From Historical Radiographs by Using Digital X-ray Radiogrammetry: An Experimental Study. Journal of Clinical Densitometry, 2014, 17, 104-108.	0.5	4
68	Update of the Mexican College of Rheumatology Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. Reumatología Clínica (English Edition), 2014, 10, 227-240.	0.2	14
69	Treating to Target with Etanercept in Rheumatoid Arthritis: Cost-Effectiveness of Dose Reductions When Remission Is Achieved. Value in Health, 2014, 17, 537-544.	0.1	18
70	The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, S1.	1.6	22
71	New insights into the impact of neuro-inflammation in rheumatoid arthritis. Frontiers in Neuroscience, 2014, 8, 357.	1.4	48
72	Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. BMJ Open, 2014, 4, e006058.	0.8	16
73	The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects. Arthritis Research and Therapy, 2014, 16, S2.	1.6	94
74	Circadian rhythms in rheumatology - a glucocorticoid perspective. Arthritis Research and Therapy, 2014, 16, S3.	1.6	55
76	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week 112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Care and Research, 2015, 67, 1627-1636.	1.5	13
77	Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 1656-1663.	1.5	32
78	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. Arthritis and Rheumatology, 2015, 67, 3104-3112.	2.9	21
79	Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. Clinical and Experimental Dental Research, 2015, 1, 63-73.	0.8	31
80	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. RMD Open, 2015, 1, e000155-e000155.	1.8	34
81	Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23288.	0.5	24

#	ARTICLE	IF	CITATIONS
82	Glucocorticoids: bad or safe for the bones?. RMD Open, 2015, 1, e000050.	1.8	8
83	Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment. RMD Open, 2015, 1, e000018.	1.8	4
84	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open, 2015, 1, e000019-e000019.	1.8	90
85	Organizing Pneumonia in Rheumatoid Arthritis Patients: A Case-Based Review. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23327.	0.5	14
86	Biosimilars: what do patients need to consider?. RMD Open, 2015, 1, e000141.	1.8	16
87	Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow. Current Treatment Options in Rheumatology, 2015, 1, 334-349.	0.6	6
88	Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace. Drugs - Real World Outcomes, 2015, 2, 205-215.	0.7	4
89	Comparison of two different folic acid doses with methotrexate â€” a randomized controlled trial (FOLVARI Study). Arthritis Research and Therapy, 2015, 17, 156.	1.6	28
90	Response to â€”Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisâ€™. Arthritis Research and Therapy, 2015, 17, 166.	1.6	1
91	Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Research and Therapy, 2015, 17, 232.	1.6	88
92	Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 206.	1.6	10
93	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Research and Therapy, 2015, 17, 157.	1.6	37
94	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. International Journal of Clinical Rheumatology, 2015, 10, 425-431.	0.3	0
95	A nurse-led rheumatology clinic versus rheumatologist-led clinic in monitoring of patients with chronic inflammatory arthritis undergoing biological therapy: a cost comparison study in a randomised controlled trial. BMC Musculoskeletal Disorders, 2015, 16, 354.	0.8	31
96	Response to â€”Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisâ€™ â€” authorsâ€™ reply. Arthritis Research and Therapy, 2015, 17, 171.	1.6	0
97	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research and Therapy, 2015, 17, 245.	1.6	22
98	Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Research and Therapy, 2015, 17, 281.	1.6	58
99	Continuously elevated serum matrix metalloproteinase-3 for 3â€”6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Research and Therapy, 2015, 17, 289.	1.6	34

#	ARTICLE	IF	CITATIONS
100	Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 322.	1.6	37
101	SAT0064â€¦Moving Towards Personalized Medicine in Rheumatoid Arthritis: Atic Polymorphisms as Pharmacogenetic Predictors of Methotrexate Therapeutic Outcome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 671.2-671.	0.5	0
102	SAT0066â€¦Value of Antinuclear Antibodies in the Therapeutic Efficacy of Biologics in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 672.1-672.	0.5	0
103	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 1345-1353.	1.5	72
104	Proteomics in Rheumatoid Arthritis Research. <i>Immune Network</i> , 2015, 15, 177.	1.6	30
105	Biological therapy for Rheumatoid Arthritis Â– an update. <i>Journal of Armed Forces Medical College Bangladesh</i> , 2015, 10, 99-102.	0.1	0
106	Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1325.	0.9	12
107	Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR. <i>Archives of Rheumatology</i> , 2015, 30, 271-284.	0.3	0
108	Factors Associated with the Initiation of Biologic Disease-Modifying Antirheumatic Drugs in Texas Medicaid Patients with Rheumatoid Arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 401-407.	0.5	21
109	Drug usage analysis and health care resources consumption in na&uml;ve patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2015, 9, 119.	3.0	11
110	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. <i>World Journal of Hepatology</i> , 2015, 7, 344.	0.8	61
111	Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure â€œ results of the Polish survey in the context of EULAR recommendations. <i>Reumatologia</i> , 2015, 4, 200-206.	0.5	1
112	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. <i>Current Biomarker Findings</i> , 2015, , 69.	0.4	2
113	Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 409-423.	0.5	86
114	Biologic monotherapy in the treatment of rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2015, 9, 35.	3.0	16
115	The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0119683.	1.1	75
116	Remission of Collagen-Induced Arthritis through Combination Therapy of Microfracture and Transplantation of Thermogel-Encapsulated Bone Marrow Mesenchymal Stem Cells. <i>PLoS ONE</i> , 2015, 10, e0120596.	1.1	22
117	Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0123392.	1.1	14

#	ARTICLE	IF	CITATIONS
118	Management of rheumatoid arthritis in People's Republic of China – focus on tocilizumab and patient considerations. <i>International Journal of General Medicine</i> , 2015, 8, 187.	0.8	24
119	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	19
120	Polish Rheumatologists and Rheumatoid Arthritis Patients Differ in Their Opinions About Treatment Inefficacy. <i>Archives of Rheumatology</i> , 2015, 30, 238-243.	0.3	2
121	Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? - Results of a survey. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 109.	0.8	2
122	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 74.	1.6	53
123	Advances in the treatment of polyarticular juvenile idiopathic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 505-510.	2.0	30
124	Co-morbidity index in rheumatoid arthritis: time to think. <i>Clinical Rheumatology</i> , 2015, 34, 1995-2000.	1.0	18
125	Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2015, 54, 1200-1209.	0.9	64
126	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	1.6	53
127	Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs). <i>SpringerPlus</i> , 2015, 4, 462.	1.2	9
128	How does established rheumatoid arthritis develop, and are there possibilities for prevention?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 527-542.	1.4	15
130	Review of rheumatoid arthritis disease outcome measures: Recommendations and its relevance in private practice. <i>Indian Journal of Rheumatology</i> , 2015, 10, 133-139.	0.2	0
131	The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 124.	1.6	14
132	Toxidemia under treatment with tocilizumab for rheumatoid arthritis. <i>Joint Bone Spine</i> , 2015, 82, 69-70.	0.8	4
133	Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 3-9.	0.5	125
134	High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. <i>Rheumatology International</i> , 2015, 35, 1377-1384.	1.5	30
135	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	3.5	372
136	Methotrexate revisited: considerations for subcutaneous administration in RA. <i>Clinical Rheumatology</i> , 2015, 34, 201-205.	1.0	9



#	ARTICLE	IF	CITATIONS
137	The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. <i>Rheumatology International</i> , 2015, 35, 1149-1161.	1.5	17
138	Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?. <i>Clinical Rheumatology</i> , 2015, 34, 1-8.	1.0	12
139	Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2015, 18, 366-375.	1.0	2
140	Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 564-568.	0.5	39
141	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
142	Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. <i>Clinical Rheumatology</i> , 2015, 34, 935-942.	1.0	19
143	Anti-Interleukin-6 Receptor Antibody Therapy Against Autoimmune Inflammatory Diseases. , 2015, , 515-525.		0
144	Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 741-748.	1.0	8
145	A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 861-869.	1.0	12
147	Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. <i>BMJ, The</i> , 2015, 350, h1046-h1046.	3.0	59
148	Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations. <i>Drugs and Aging</i> , 2015, 32, 515-524.	1.3	22
149	Consideraciones a las recomendaciones terapéuticas para la artritis reumatoide. <i>Reumatología Clínica</i> , 2015, 11, 193-195.	0.2	4
150	Consensus on the Use of Methotrexate Beyond the Clinical Recommendation: Adjusted Dose and Pharmacogenetics. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 261-262.	0.2	0
151	Optimizing treatment in paediatric rheumatology—lessons from oncology. <i>Nature Reviews Rheumatology</i> , 2015, 11, 493-499.	3.5	4
152	Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. <i>Arthritis and Rheumatology</i> , 2015, 67, 1474-1480.	2.9	50
153	Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects. <i>Inflammation Research</i> , 2015, 64, 647-659.	1.6	14
154	Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2015, 350, h1269-h1269.	3.0	98
155	Considerations on treatment recommendations for rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 193-195.	0.2	1

#	ARTICLE	IF	CITATIONS
156	Special Issue on Glucocorticoid Therapy in Rheumatic Diseases: Introduction. <i>NeuroImmunoModulation</i> , 2015, 22, 3-5.	0.9	6
157	Consenso sobre el uso de metotrexato más allá de la recomendación clínica: dosis ajustada y farmacogenética. <i>Reumatología Clínica</i> , 2015, 11, 261-262.	0.2	0
158	Advances in use of immunomodulatory agents—a rheumatology perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 363-368.	8.2	14
159	Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. <i>Expert Review of Vaccines</i> , 2015, 14, 891-908.	2.0	30
160	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. <i>Journal of Rheumatology</i> , 2015, 42, 2442-2447.	1.0	22
162	Factors Associated With Sustained Remission in Patients With Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 237-241.	0.2	3
165	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	1.6	49
166	Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 349-356.	3.5	91
168	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 97.	1.6	38
169	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Lancet, The</i> , 2015, 386, 258-265.	6.3	487
170	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1640-1649.	0.9	13
172	Education for patients with rheumatoid arthritis in Latin America and the Caribbean. <i>Clinical Rheumatology</i> , 2015, 34, 45-49.	1.0	12
173	Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. <i>Clinical Rheumatology</i> , 2015, 34, 1787-1793.	1.0	25
174	Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study. <i>Rheumatology International</i> , 2015, 35, 1825-1836.	1.5	8
175	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. <i>RMD Open</i> , 2015, 1, e000057.	1.8	98
176	Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. <i>RMD Open</i> , 2015, 1, e000147.	1.8	11
177	The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. <i>Advances in Therapy</i> , 2015, 32, 742-756.	1.3	127
178	Perceptions of physical activity engagement among adults with rheumatoid arthritis and rheumatologists. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 67-77.	0.3	17

#	ARTICLE	IF	CITATIONS
179	Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?. <i>Arthritis Research and Therapy</i> , 2015, 17, 181.	1.6	59
180	Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. <i>RMD Open</i> , 2015, 1, e000078-e000078.	1.8	15
181	Access to an optimal treatment. Current situation. <i>Clinical Rheumatology</i> , 2015, 34, 59-66.	1.0	18
182	Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA). <i>Medical Hypotheses</i> , 2015, 85, 433-440.	0.8	5
183	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 176.	0.8	36
184	Addressing comorbidities in systemic inflammatory disorders. <i>Nature Reviews Rheumatology</i> , 2015, 11, 689-691.	3.5	2
186	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
188	Challenges faced in Latin America for the implementation of an ideal health-care model for rheumatoid arthritis patients: are we ready?. <i>Clinical Rheumatology</i> , 2015, 34, 79-93.	1.0	5
189	Rheumatoid arthritis in Latin America. Important challenges to be solved. <i>Clinical Rheumatology</i> , 2015, 34, 1-3.	1.0	20
190	How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. <i>BMJ, The</i> , 2015, 351, h3658.	3.0	11
191	Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 193.	1.6	7
193	Management of perioperative tumour necrosis factor inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. <i>Rheumatology</i> , 2016, 55, kev364.	0.9	41
195	Factores asociados a remisi3n sostenida en pacientes con artritis reumatoide. <i>ReumatologÃa ClÃnica</i> , 2015, 11, 237-241.	0.2	4
196	Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future. <i>European Journal of Pharmacology</i> , 2015, 747, 200-205.	1.7	16
197	Initial High-Dose Prednisolone Combination Therapy Using COBRA and COBRA-Light in Early Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2015, 22, 51-56.	0.9	12
198	Recommendations for the Use of Methotrexate in Rheumatoid Arthritis: Up and Down Scaling of the Dose and Administration Routes. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2015, 11, 3-8.	0.2	11
199	Asymptomatic colitis induced by low-dose methotrexate. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217771.	0.2	5
200	Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study. <i>Archives of Rheumatology</i> , 2016, 31, 127-132.	0.3	0

#	ARTICLE	IF	CITATIONS
201	Comparative analysis of educational needs of patients with rheumatic diseases selected based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT). <i>Reumatologia</i> , 2016, 4, 153-160.	0.5	4
202	Developments in the Treatment of Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis. , 0, , .		0
203	Japanese physicians&rsquo; preferences for decision making in rheumatoid arthritis treatment. <i>Patient Preference and Adherence</i> , 2016, 10, 107.	0.8	9
204	Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2217-2228.	0.8	64
205	Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1763-1776.	0.9	11
206	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. <i>Journal of Korean Medical Science</i> , 2016, 31, 1907.	1.1	7
207	Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case&acirc;Control Study. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016, 9, CMAMD.S38442.	0.3	3
208	Posttranslational Modifications and the Immunogenicity of Biotherapeutics. <i>Journal of Immunology Research</i> , 2016, 2016, 1-15.	0.9	93
209	Rheumatoid Arthritis, Kartagener&acirc;TMs Syndrome, and Hyperprolactinemia: Who Started It?. <i>Case Reports in Rheumatology</i> , 2016, 2016, 1-5.	0.2	1
210	The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	10
211	Rheumatoid polyarthritis suspected in an HIV patient with scleritis, peripheral ulcerative keratitis, and anterior uveitis. <i>International Medical Case Reports Journal</i> , 2016, 9, 19.	0.3	2
212	Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. <i>Patient Preference and Adherence</i> , 2016, 10, 1079.	0.8	23
213	Secukinumab for rheumatology: development and its potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2069-2080.	2.0	37
214	Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study. <i>Reumatismo</i> , 2016, 68, 90-96.	0.4	5
215	Personalized medicine in rheumatology. <i>Reumatologia</i> , 2016, 54, 177-186.	0.5	14
216	Rate of Proven Rheumatic Diseases in a Large Collective of Referrals to an Outpatient Rheumatology Clinic under Routine Conditions. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016, 9, CMAMD.S40361.	0.3	12
217	FRI0181&acirc;...Changing Use of Methotrexate (MTX) and Biologics in The Treatment of Rheumatoid Arthritis (RA) in The United States (US): Results of A Comprehensive Pharmaceutical Claims Analysis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 495.2-495.	0.5	1
218	FRI0093&acirc;...Immunogenicity of TNF Inhibitors in Patients with Rheumatoid Arthritis or Polyarticular Psoriatic Arthritis in Clinical Remission or Low Disease Activity: A One-Year Multicentre Prospective Study (The Immunoremar Study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 461.1-461.	0.5	0

#	ARTICLE	IF	CITATIONS
219	Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 159.	1.6	38
220	A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 190.	1.6	24
221	Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs. <i>Arthritis Research and Therapy</i> , 2016, 18, 252.	1.6	18
222	Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases. <i>PLoS ONE</i> , 2016, 11, e0154744.	1.1	45
223	Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0166691.	1.1	8
224	Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. <i>Patient Preference and Adherence</i> , 2016, 10, 1101.	0.8	26
226	Impact of tofacitinib on patient outcomes in rheumatoid arthritis &ndash; review of clinical studies. <i>Patient Related Outcome Measures</i> , 2016, 7, 1.	0.7	25
227	Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 2083-2089.	2.9	42
228	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. <i>RMD Open</i> , 2016, 2, e000323.	1.8	13
229	Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1595-1598.	0.5	15
230	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1336-1342.	0.5	55
231	Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2016, 18, 211.	1.6	44
232	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.5	160
233	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	1.8	57
234	Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area. <i>Scientific Reports</i> , 2016, 6, 29443.	1.6	38
235	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1763-1769.	0.5	70
236	Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. <i>RMD Open</i> , 2016, 2, e000237.	1.8	52
237	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1917-1923.	0.5	81

#	ARTICLE	IF	CITATIONS
238	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open, 2016, 2, e000171.	1.8	40
239	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases, 2016, 75, 1081-1091.	0.5	152
240	Correlation between clinical activity measured by DAS-28 and ultrasound in patients with rheumatoid arthritis. Revista Colombiana De ReumatologÃa (English Edition), 2016, 23, 159-169.	0.1	0
241	Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. RMD Open, 2016, 2, e000265.	1.8	20
242	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open, 2016, 2, e000221.	1.8	38
243	Preservation of cartilage and bone architecture is the most important aspect for maintaining functionality in longstanding experimental arthritis. DMM Disease Models and Mechanisms, 2016, 9, 1329-1338.	1.2	39
244	Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe. Rheumatology and Therapy, 2016, 3, 77-89.	1.1	19
245	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open, 2016, 2, e000228.	1.8	15
246	Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe. Rheumatology and Therapy, 2016, 3, 245-256.	1.1	29
247	Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open, 2016, 2, e000009.	1.8	39
248	Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open, 2016, 2, e000203.	1.8	51
249	Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment. Annals of Internal Medicine, 2016, 164, 523.	2.0	95
250	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 151, 97-109.e4.	0.6	120
251	Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatology International, 2016, 36, 613-625.	1.5	60
252	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. Seminars in Arthritis and Rheumatism, 2016, 46, 81-87.	1.6	18
253	Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches. Experimental and Therapeutic Medicine, 2016, 11, 1177-1183.	0.8	33
254	Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. Drug Safety, 2016, 39, 823-840.	1.4	28
255	Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration. Advances in Therapy, 2016, 33, 369-378.	1.3	75

#	ARTICLE	IF	CITATIONS
256	Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. <i>Drugs and Aging</i> , 2016, 33, 97-107.	1.3	44
257	The NICE position on indications for biologics and biosimilars. <i>Nature Reviews Rheumatology</i> , 2016, 12, 255-256.	3.5	2
258	Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 146.	0.8	43
259	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	0.9	20
260	Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study. <i>Pharmacology</i> , 2016, 98, 73-78.	0.9	2
261	Treatment of rheumatoid arthritis (RA) in India—how and by whom: results from a speciality clinic—use of low-dose methotrexate (MTX) was inexplicably suboptimal. <i>Clinical Rheumatology</i> , 2016, 35, 2163-2173.	1.0	4
263	Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2016, 35, 1659-1668.	1.0	23
264	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	1.5	43
265	Artritis reumatoide temprana: resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia. <i>Revista Colombiana De Reumatología</i> , 2016, 23, 148-154.	0.0	1
266	Pharmacogenetics of methotrexate in rheumatoid arthritis: A systematic review. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2016, 23, 102-114.	0.1	2
268	Amélioration des résultats rapportés par les patients atteints de polyarthrite rhumatoïde traités par rituximab: Évaluation ouverte de 175 patients. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 457-460.	0.0	0
269	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016, 44, 113-118.	0.4	12
270	Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 405.	0.8	23
272	Long-term outcomes of destructive seronegative (rheumatoid) arthritis — description of four clinical cases. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 246.	0.8	13
273	Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. <i>Clinical Rheumatology</i> , 2016, 35, 2915-2923.	1.0	25
274	Combination therapy with biologic agents in rheumatic diseases: current and future prospects. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 192-202.	1.2	32
275	Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1303-1309.	1.4	21
276	Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses. <i>International Immunopharmacology</i> , 2016, 39, 236-245.	1.7	3

#	ARTICLE	IF	CITATIONS
277	Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2016, 186, 157-163.	1.1	36
278	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 107-118.	1.2	21
279	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	1.5	27
280	Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?. <i>Clinical Rheumatology</i> , 2016, 35, 3053-3056.	1.0	1
282	Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis. <i>Inflammopharmacology</i> , 2016, 24, 189-196.	1.9	32
283	Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 358.	0.8	8
284	Nonâ€“TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1172.	3.8	160
285	Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. <i>Current Rheumatology Reports</i> , 2016, 18, 50.	2.1	27
286	Emerging Therapies for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2016, 3, 31-42.	1.1	26
287	Efficacy and safety of an anti-CD20 monoclonal antibody (Redituxâ„¢) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. <i>Clinical Rheumatology</i> , 2016, 35, 1931-1935.	1.0	6
289	EXXELERATE: a negative trial with importance for clinical practice. <i>Lancet, The</i> , 2016, 388, 2718-2719.	6.3	1
290	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). <i>The Cochrane Library</i> , 2016, 2016, CD012437.	1.5	27
291	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 1627-1632.	1.5	5
292	Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 460.	0.8	9
293	Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor. <i>Journal of International Medical Research</i> , 2016, 44, 90-94.	0.4	8
294	Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 790-795.	1.0	1
295	Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice. <i>Scientific Reports</i> , 2016, 5, 18288.	1.6	14
296	Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice. <i>Scientific Reports</i> , 2016, 6, 35804.	1.6	44



#	ARTICLE	IF	CITATIONS
297	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	1.6	177
298	Folypolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 35615.	1.6	35
299	A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 351.	0.8	11
300	Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources. <i>Rheumatology and Therapy</i> , 2016, 3, 337-352.	1.1	27
301	Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence. <i>BioDrugs</i> , 2016, 30, 489-523.	2.2	32
302	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. <i>BMJ, The</i> , 2016, 354, i4205.	3.0	200
303	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. <i>RMD Open</i> , 2016, 2, e000263.	1.8	6
304	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. <i>BMJ, The</i> , 2016, 353, i1777.	3.0	155
305	Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000241.	1.8	8
306	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. <i>RMD Open</i> , 2016, 2, e000245.	1.8	15
307	Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists. <i>RMD Open</i> , 2016, 2, e000195.	1.8	8
308	AB0377â€¦Differences in Baseline Predictive Factors for Remission at 52 Weeks by Concomitant MTX Use during Tocilizumab Treatment Using Propensity Score Matched Groups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1033.1-1033.	0.5	0
309	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 461.	0.8	22
310	The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database. <i>Rheumatology and Therapy</i> , 2016, 3, 167-177.	1.1	5
311	Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases. <i>SAGE Open Medicine</i> , 2016, 4, 205031211665440.	0.7	17
312	Correlaci3n entre la actividad cl3nica por DAS-28 y ecograf3a en pacientes con artritis reumatoide. <i>Revista Colombiana De Reumatolog3a</i> , 2016, 23, 159-169.	0.0	0
313	Use of Low3 Literacy Decision Aid to Enhance Knowledge and Reduce Decisional Conflict Among a Diverse Population of Adults With Rheumatoid Arthritis: Results of a Pilot Study. <i>Arthritis Care and Research</i> , 2016, 68, 889-898.	1.5	40
314	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2016, 2016, CD012183.	1.5	51

#	ARTICLE	IF	CITATIONS
315	Prediction of radiographic progression in synovitis-positive joints on maximum intensity projection of magnetic resonance imaging in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 873-878.	1.0	6
316	Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1547-1558.	1.6	92
317	Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2345.	3.8	87
318	Beyond methotrexate monotherapy for early rheumatoid arthritis. <i>Lancet, The</i> , 2016, 388, 309-310.	6.3	0
321	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). <i>Rheumatology and Therapy</i> , 2016, 3, 129-141.	1.1	3
322	Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. <i>Rheumatology and Therapy</i> , 2016, 3, 103-115.	1.1	8
323	Rheumatoid arthritis at present. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 112-114.	0.1	0
324	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 33.	0.8	2
325	Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. <i>Arthritis Research and Therapy</i> , 2016, 18, 72.	1.6	11
326	Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. <i>Arthritis Research and Therapy</i> , 2016, 18, 60.	1.6	23
327	Rheumatoid arthritis and metabolic syndrome. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 93-94.	0.7	0
329	Sensitivity and specificity of assessment instruments of quality of life in rheumatoid arthritis. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 406-413.	0.7	1
330	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 491-498.	0.9	80
331	Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1065-1069.	1.0	7
332	A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. <i>Rheumatology International</i> , 2016, 36, 685-695.	1.5	201
333	Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study. <i>Advances in Therapy</i> , 2016, 33, 46-57.	1.3	21
334	Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis. <i>Clinical Rheumatology</i> , 2016, 35, 1153-1159.	1.0	8
335	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1057-1064.	0.5	125

#	ARTICLE	IF	CITATIONS
336	Development of a sensitive enzyme-linked immunosorbent assay for the measurement of biologically active etanercept in patients with ankylosing spondylitis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1008, 219-224.	1.2	4
337	Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients. <i>Clinical Rheumatology</i> , 2016, 35, 219-225.	1.0	3
338	Farmacogenética del metotrexato en artritis reumatoide. Revisión sistemática. <i>Revista Colombiana De Reumatología</i> , 2016, 23, 102-114.	0.0	6
339	Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis. <i>Inflammation Research</i> , 2016, 65, 347-354.	1.6	5
341	Biosimilar DMARDs: What Does the Future Hold?. <i>Drugs</i> , 2016, 76, 629-637.	4.9	11
342	Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis. <i>Experimental and Molecular Medicine</i> , 2016, 48, e211-e211.	3.2	30
343	Gist and verbatim communication concerning medication risks/benefits. <i>Patient Education and Counseling</i> , 2016, 99, 988-994.	1.0	7
344	Safety and efficacy of intra-articular anti-tumor necrosis factor $\pm$ agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	1.0	32
345	Iguratimod in combination with methotrexate in active rheumatoid arthritis. <i>Zeitschrift Fur Rheumatologie</i> , 2016, 75, 828-833.	0.5	28
346	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 19-23.	1.0	10
347	Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. <i>MAbs</i> , 2016, 8, 141-149.	2.6	82
348	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 75-83.	0.5	94
349	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	1.5	10
350	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2016, 16, 137-140.	0.9	31
351	Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1126-1132.	0.5	85
353	Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 385-393.	0.6	27
354	Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 15-22.	0.7	8
355	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64.	0.5	146

#	ARTICLE	IF	CITATIONS
356	Eficacia a 2 años de tocilizumab en pacientes con artritis reumatoide activa en la práctica clínica habitual. <i>Reumatología Clínica</i> , 2017, 13, 78-84.	0.2	4
357	Biosimilars in rheumatology: understanding the rigor of their development. <i>Rheumatology</i> , 2017, 56, 187-197.	0.9	30
358	Clinical pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2017, 17, 412-418.	0.9	12
359	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	0.9	19
360	Impacto de variantes genéticas del transportador de membrana que une ATP B1, la aicar transformilasa/IMP ciclohidrolasa, la folilpoliglutamatosintetasa y la metilen-tetrahidrofolatorreductasa en la toxicidad de metotrexato. <i>Reumatología Clínica</i> , 2017, 13, 318-325.	0.2	6
361	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017, 36, 753-761.	1.0	28
362	Indice de masse corporelle et réponse au rituximab dans la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 37-41.	0.0	0
364	Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients. <i>Clinical Drug Investigation</i> , 2017, 37, 375-386.	1.1	14
365	Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 975-982.	1.5	8
366	Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1143-1148.	1.0	26
367	IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. <i>Scientific Reports</i> , 2017, 7, 41143.	1.6	24
368	Cardiac Diseases in Rheumatoid Arthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 227-263.	0.1	1
369	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.5	83
370	Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1-year of the ACT-SOLO study. <i>RMD Open</i> , 2017, 3, e000340.	1.8	6
371	Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts. <i>Current Rheumatology Reports</i> , 2017, 19, 12.	2.1	6
372	No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis. <i>RMD Open</i> , 2017, 3, e000352.	1.8	19
373	Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?. <i>European Journal of Hospital Pharmacy</i> , 2017, 24, 85-90.	0.5	8
374	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD012591.	1.5	44

#	ARTICLE	IF	CITATIONS
375	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136.	0.5	195
376	Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. <i>Clinical Rheumatology</i> , 2017, 36, 1013-1022.	1.0	20
377	Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1053-1064.	1.5	14
378	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. <i>RMD Open</i> , 2017, 3, e000404.	1.8	43
379	Improved survival in rheumatoid arthritis: a general population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 408-413.	0.5	85
380	Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. <i>RMD Open</i> , 2017, 3, e000363.	1.8	70
381	Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 7.	0.4	3
382	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. <i>Rheumatology and Therapy</i> , 2017, 4, 1-24.	1.1	34
383	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. <i>RMD Open</i> , 2017, 3, e000382.	1.8	71
384	Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study. <i>Rheumatology International</i> , 2017, 37, 891-896.	1.5	15
385	Steroids and Autoimmunity. <i>Frontiers of Hormone Research</i> , 2017, 48, 121-132.	1.0	29
386	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1228-1236.	0.5	70
387	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1348-1356.	0.5	36
388	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor+methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000371.	1.8	26
389	Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 33.	1.6	42
390	R�le de lâ�chographie dans le suivi de la polyarthrite rhumato�de. <i>Revue Du Rhumatisme (Edition) Tj ETQq1,0,0.784314 rgBT</i>	1.0	0
391	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
393	Dosing down with biologic therapies: a systematic review and cliniciansâ€™ perspective. <i>Rheumatology</i> , 2017, 56, 1847-1856.	0.9	59

#	ARTICLE	IF	CITATIONS
394	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2017, 44, 773-779.	1.0	3
395	CTLA-4 expressed by FOXP3 <sup>+</sup> regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis. <i>Immunology</i> , 2017, 152, 125-137.	2.0	18
396	Glucocorticoids in rheumatoid arthritis: the picture is shaping up. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1785-1787.	0.5	20
397	Response to: "2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?" by Misra et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e48-e48.	0.5	4
398	An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions. <i>Journal of International Medical Research</i> , 2017, 45, 733-743.	0.4	11
399	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 5, CD012657.	1.5	47
401	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. <i>Clinical Rheumatology</i> , 2017, 36, 1237-1245.	1.0	23
402	EULAR recommendations for disease management: guidance not guidelines. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 935-938.	0.5	8
403	Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e49-e49.	0.5	2
404	Response to: "The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis" by PiriÅ et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e50-e50.	0.5	0
405	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. <i>Trials</i> , 2017, 18, 161.	0.7	19
406	Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment. <i>Arthritis Research and Therapy</i> , 2017, 19, 78.	1.6	7
407	Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 791-798.	1.0	2
408	Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. <i>Clinical Rheumatology</i> , 2017, 36, 1-8.	1.0	25
409	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	2.9	39
410	Managing rheumatic and musculoskeletal diseases "past, present and future. <i>Nature Reviews Rheumatology</i> , 2017, 13, 443-448.	3.5	117
411	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 457-468.	6.3	360
412	Treating active rheumatoid arthritis with Janus kinase inhibitors. <i>Lancet, The</i> , 2017, 390, 431-432.	6.3	6

#	ARTICLE	IF	CITATIONS
413	What the Rheumatologist Is Looking for and What the Radiologist Should Know in Imaging for Rheumatoid Arthritis. <i>Radiologic Clinics of North America</i> , 2017, 55, 905-916.	0.9	7
414	Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 1484-1494.	1.5	39
415	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	0.9	71
416	Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. <i>Rheumatology International</i> , 2017, 37, 1441-1452.	1.5	6
417	Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up. <i>Rheumatology International</i> , 2017, 37, 1701-1708.	1.5	2
418	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. <i>Rheumatology International</i> , 2017, 37, 1111-1123.	1.5	10
419	Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. <i>Clinical Rheumatology</i> , 2017, 36, 1493-1500.	1.0	103
420	Novel treatment strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017, 389, 2338-2348.	6.3	697
421	CT-P13 in the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 653-666.	1.3	1
422	Cyclocurcumin, a curcumin derivative, exhibits immune-modulating ability and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method. <i>International Journal of Molecular Medicine</i> , 2017, 39, 1164-1172.	1.8	26
423	Maintenance of remission with combination etanercept DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. <i>Rheumatology International</i> , 2017, 37, 1469-1479.	1.5	16
424	Abatacept: A Review in Rheumatoid Arthritis. <i>Drugs</i> , 2017, 77, 1221-1233.	4.9	143
425	Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study. <i>BMJ Open</i> , 2017, 7, e016154.	0.8	16
426	The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2017, 189, 12-20.	1.1	65
427	Two-year Efficacy of tocilizumab in Patients With Active Rheumatoid Arthritis in Clinical Practice. <i>Reumatología Clínica (English Edition)</i> , 2017, 13, 78-84.	0.2	2
428	Improved disease activity with fosdagrocorat (<sc>PF</sc>04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 960-970.	0.9	27
429	Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. <i>Arthritis Research and Therapy</i> , 2017, 19, 68.	1.6	66
430	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naïve patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1279-1284.	0.5	64

#	ARTICLE	IF	CITATIONS
431	“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1179-1187.	1.4	126
432	Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?. <i>Rheumatology International</i> , 2017, 37, 905-913.	1.5	10
433	A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 1347-1356.	1.5	7
434	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 57-69.	1.1	11
435	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107.	0.5	131
436	2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e47-e47.	0.5	11
438	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136.	0.5	277
439	Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 369-376.	1.5	17
440	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017, 69, 953-963.	2.9	27
441	Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors. <i>Clinical Rheumatology</i> , 2017, 36, 941-946.	1.0	1
442	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	1.0	33
443	Disease activity dynamics in rheumatoid arthritis: patients’ self-assessment of disease activity via WebApp. <i>Rheumatology</i> , 2017, 56, 1707-1712.	0.9	29
444	Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. <i>Rheumatology</i> , 2017, 56, iv30-iv48.	0.9	32
445	Évaluation de l’activité de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 343-346.	0.0	0
446	Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor- $\kappa$ B expression in monocytes from patients with early rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000365.	1.8	18
447	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017, 3, e000465.	1.8	10
448	Tocilizumab: A Review in Rheumatoid Arthritis. <i>Drugs</i> , 2017, 77, 1865-1879.	4.9	283
449	Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. <i>Rheumatology and Therapy</i> , 2017, 4, 391-404.	1.1	5



#	ARTICLE	IF	CITATIONS
450	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. <i>Advances in Therapy</i> , 2017, 34, 2422-2435.	1.3	28
451	Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. <i>Clinical Rheumatology</i> , 2017, 36, 2743-2750.	1.0	32
452	Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. <i>Rheumatology International</i> , 2017, 37, 2049-2058.	1.5	13
453	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients. <i>Scientific Reports</i> , 2017, 7, 12023.	1.6	17
454	Impact of Genetic Variants of ATP Binding Cassette B1, AICAR Transformylase/IMP Cyclohydrolase, Foyl-polyglutamate Synthetase, and Methylenetetrahydrofolate Reductase on Methotrexate Toxicity. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2017, 13, 318-325.	0.2	1
455	Response to eLetter: "Discussion of methotrexate dosage"™ by Maguire et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrhumdis-2017-212380.	0.5	0
456	Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 249-262.	1.2	88
457	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	1.8	5
458	Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. <i>Rheumatology International</i> , 2017, 37, 2079-2085.	1.5	56
459	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. <i>Scientific Reports</i> , 2017, 7, 13293.	1.6	41
460	The role of nurse practitioners in delivering rheumatology care and services. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 673-681.	0.5	13
461	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017, 16, 1185-1195.	2.5	67
462	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779.	0.9	49
463	Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. <i>Rheumatology</i> , 2017, 56, iv49-iv62.	0.9	37
464	Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. <i>Rheumatology</i> , 2017, 56, 2179-2189.	0.9	5
465	Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. <i>RMD Open</i> , 2017, 3, e000453.	1.8	2
466	Treatment with Biologics in Rheumatoid Arthritis: An Overview. <i>Rheumatology and Therapy</i> , 2017, 4, 247-261.	1.1	115
467	Filgotinib for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1181-1187.	1.9	36

#	ARTICLE	IF	CITATIONS
468	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 309-332.	1.1	20
469	A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1525-1533.	0.9	19
470	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. <i>The Cochrane Library</i> , 2017, 2017, CD007649.	1.5	40
471	Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative. <i>Clinical Rheumatology</i> , 2017, 36, 2421-2430.	1.0	11
472	Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?. <i>RMD Open</i> , 2017, 3, e000492.	1.8	15
473	Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis. <i>Scientific Reports</i> , 2017, 7, 11353.	1.6	13
474	Prognostic Factors for Permanent Work Disability in Patients With Rheumatoid Arthritis Who Received Combination Therapy of Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 376-382.	0.5	5
475	Discussion of Methotrexate Dosage. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212358.	0.5	1
476	Two new drugs for rheumatoid arthritis. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 102.1-105.	0.3	2
477	Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis. <i>Innate Immunity</i> , 2017, 23, 606-614.	1.1	4
478	Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
479	Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. <i>Clinical Therapeutics</i> , 2017, 39, 1618-1627.	1.1	14
480	Efficacy of baricitinib in the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1399-1407.	0.9	28
481	Terapia biol3gica en la artritis reumatoide temprana: eficacia en la remisi3n de la enfermedad. <i>Revista Colombiana De ReumatologAa</i> , 2017, 24, 164-176.	0.0	1
482	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis), Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 1	2.5	107
483	Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes. <i>Inflammation Research</i> , 2017, 66, 999-1009.	1.6	10
484	Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 371-393.	2.9	52
485	Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 293-308.	1.1	17

#	ARTICLE	IF	CITATIONS
486	Beyond disease activity to overall disease severity in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 624-626.	3.7	5
487	Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study. <i>Clinical Rheumatology</i> , 2017, 36, 1989-1996.	1.0	10
488	Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 923-933.	1.3	22
489	Muscle Weakness in Rheumatoid Arthritis: The Role of Ca <sup>2+</sup> and Free Radical Signaling. <i>EBioMedicine</i> , 2017, 23, 12-19.	2.7	30
490	Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions. <i>Medicine (United States)</i> , 2017, 96, e6021.	0.4	20
491	The Reliability of Disease Activity Score in 28 Jointsâ€”C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 102-106.	0.5	27
492	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	1.0	21
493	Correlation between hand bone mineral density and joint destruction in established rheumatoid arthritis. <i>Journal of Orthopaedics</i> , 2017, 14, 461-465.	0.6	7
494	Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2031-2037.	0.5	53
495	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
496	StratÃ©gie de prise en charge de la polyarthrite rhumatoÃ¯de: traitement prÃ©coce et traitement ciblÃ©. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 377-381.	0.0	1
497	DMARD de-escalation â€” let the patient guide you. <i>Nature Reviews Rheumatology</i> , 2017, 13, 637-638.	3.5	14
498	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861.	0.5	83
499	Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. <i>Journal of Market Access &amp; Health Policy</i> , 2017, 5, 1345580.	0.8	33
500	Is There a Renaissance of Glucocorticoids in Rheumatoid Arthritis?. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 574-577.	2.3	8
501	Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. <i>Clinical Rheumatology</i> , 2017, 36, 2187-2192.	1.0	6
503	Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. <i>Advances in Therapy</i> , 2017, 34, 2316-2332.	1.3	10
504	Drug updates and approvals. <i>Nurse Practitioner</i> , 2017, 42, 8-16.	0.2	2

#	ARTICLE	IF	CITATIONS
505	Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data. <i>Dermatology and Therapy</i> , 2017, 7, 485-492.	1.4	20
506	Tofacitinib: A Review in Rheumatoid Arthritis. <i>Drugs</i> , 2017, 77, 1987-2001.	4.9	181
507	REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients. <i>Heliyon</i> , 2017, 3, e00452.	1.4	7
508	Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. <i>Nature Reviews Rheumatology</i> , 2017, 13, 707-718.	3.5	139
509	Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries. <i>Clinical Rheumatology</i> , 2017, 36, 2789-2797.	1.0	14
510	Clinical Outcome and Long-term Remission in JIA. <i>Current Rheumatology Reports</i> , 2017, 19, 75.	2.1	26
511	Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study. <i>Clinical Rheumatology</i> , 2017, 36, 517-525.	1.0	6
512	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 843-857.	1.5	17
513	Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain. <i>Inflammation Research</i> , 2017, 66, 855-862.	1.6	9
514	Évaluer les lésions structurales de la PR: radiographie standard, échographie et IRM. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 369-375.	0.0	1
515	Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 7.	0.8	12
516	Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 51.	1.5	21
517	It's so hard taking pills when you don't know what they're for: a qualitative study of patients' medicine taking behaviours and conceptualisation of medicines in the context of rheumatoid arthritis. <i>BMC Health Services Research</i> , 2017, 17, 303.	0.9	13
518	Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 110.	1.0	23
519	Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. <i>Arthritis Research and Therapy</i> , 2017, 19, 92.	1.6	17
520	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	2.9	32
521	The benefits of early treatment after decades. <i>Nature Reviews Rheumatology</i> , 2017, 13, 458-459.	3.5	5
522	Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature. <i>Clinical Rheumatology</i> , 2017, 36, 1699-1706.	1.0	12

#	ARTICLE	IF	CITATIONS
523	Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). <i>Clinical Rheumatology</i> , 2017, 36, 59-66.	1.0	13
524	Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2017, 69, 277-290.	2.9	146
525	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 313-322.	1.5	32
526	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. <i>Clinical Rheumatology</i> , 2017, 36, 15-24.	1.0	22
527	Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis. <i>Patient Education and Counseling</i> , 2017, 100, 126-132.	1.0	4
528	The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. <i>Clinical Rheumatology</i> , 2017, 36, 35-43.	1.0	30
530	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	2.9	310
532	Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. <i>Experimental Biology and Medicine</i> , 2017, 242, 355-373.	1.1	72
533	cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. <i>Immunologic Research</i> , 2017, 65, 307-325.	1.3	10
534	Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 459-468.	1.0	59
536	EULAR recommendations for the management of rheumatoid arthritis: what is new in 2017 and its applicability in our local setting. <i>Hong Kong Bulletin on Rheumatic Diseases</i> , 2017, 17, 47-52.	0.1	1
537	Biological therapy in early rheumatoid arthritis: Efficacy in disease remission. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2017, 24, 164-176.	0.1	0
538	Certolizumab pegol administration devices: a profile of their use and usability. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 515-522.	0.3	5
539	FRIO180-...Multiple sclerosis risk-alleles study in patients with demyelinating side effects on anti tnf alpha therapy. , 2017, , .		0
540	Janus kinase inhibitors for autoimmune disorders. <i>The Prescriber</i> , 2017, 28, 33-37.	0.1	6
541	Biosimilars: considerations for clinical practice. <i>Considerations in Medicine</i> , 2017, 1, 13-18.	0.0	18
542	Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. <i>RMD Open</i> , 2017, 3, e000538.	1.8	18
543	Recent therapeutic advances in juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 476-487.	1.4	9

#	ARTICLE	IF	CITATIONS
544	FRIO183â€¦Assessing adherence of ra patients treated with etanercept using etanercept serum trough concentrations and patient self-report. , 2017, , .		0
545	Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open, 2017, 3, e000491.	1.8	33
546	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Frontiers in Pharmacology, 2017, 8, 322.	1.6	21
547	Tamarixinin A Alleviates Joint Destruction of Rheumatoid Arthritis by Blockade of MAPK and NF-Î²B Activation. Frontiers in Pharmacology, 2017, 8, 538.	1.6	19
548	Managing the drug treatment of rheumatoid arthritis. Australian Prescriber, 2017, 40, 51-58.	0.5	57
549	Diagnosis and Treatment of Inflammatory Joint Disease. Hip and Pelvis, 2017, 29, 211.	0.6	39
550	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Design, Development and Therapy, 2017, Volume 11, 1969-1978.	2.0	11
551	Patients&rsquo; conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis. Patient Preference and Adherence, 2017, Volume 11, 1057-1067.	0.8	4
552	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Design, Development and Therapy, 2017, Volume11, 211-223.	2.0	17
553	Isoegomaketone Alleviates the Development of Collagen Antibody-Induced Arthritis in Male Balb/c Mice. Molecules, 2017, 22, 1209.	1.7	10
554	Phytomedicine in Joint Disorders. Nutrients, 2017, 9, 70.	1.7	80
555	Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia, 2017, 55, 290-297.	0.5	9
556	Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. Frontiers in Immunology, 2017, 8, 799.	2.2	21
557	Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis. Frontiers in Immunology, 2017, 8, 1191.	2.2	24
558	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. International Journal of Rheumatology, 2017, 2017, 1-15.	0.9	24
559	The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice. International Journal of Rheumatology, 2017, 2017, 1-8.	0.9	6
560	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	93
561	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design, Development and Therapy, 2017, Volume 11, 1593-1603.	2.0	85

#	ARTICLE	IF	CITATIONS
562	Etanercept (Enbrel&lt;sup>®&reg;&lt;/sup>) alternative storage at ambient temperature. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 87-99.	0.8	6
563	Diagnostic delays in rheumatic diseases with associated arthritis. <i>Reumatologia</i> , 2017, 55, 169-176.	0.5	28
564	Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1253-1264.	0.8	5
565	European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 14, 15-29.	0.9	20
566	Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 67-79.	0.8	77
567	Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. <i>Frontiers in Endocrinology</i> , 2017, 8, 179.	1.5	20
568	Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0177057.	1.1	23
569	Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. <i>PLoS ONE</i> , 2017, 12, e0179179.	1.1	37
570	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. <i>PLoS ONE</i> , 2017, 12, e0183294.	1.1	30
571	Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. <i>PLoS ONE</i> , 2017, 12, e0183928.	1.1	33
572	Glucocorticoid management in rheumatoid arthritis: morning or night low dose?. <i>Reumatologia</i> , 2017, 55, 189-197.	0.5	28
573	Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 332.	0.8	19
574	Opportunities and challenges in rheumatology research in Central Europe. <i>Arthritis Research and Therapy</i> , 2017, 19, 196.	1.6	3
575	Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. <i>Arthritis Research and Therapy</i> , 2017, 19, 170.	1.6	16
576	A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study. <i>Arthritis Research and Therapy</i> , 2017, 19, 185.	1.6	11
577	IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 182.	1.6	35
578	Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 193.	1.6	14
579	Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning. <i>Arthritis Research and Therapy</i> , 2017, 19, 220.	1.6	4

#	ARTICLE	IF	CITATIONS
580	Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 241.	1.6	3
581	Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 251.	1.6	68
582	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 258.	1.6	3
584	Treatment of rheumatoid arthritis with biological agents as a typical and common immune-mediated inflammatory disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 600-608.	1.6	10
585	Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S20-S28.	1.0	1
586	The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study. <i>Reumatologia</i> , 2017, 4, 177-182.	0.5	5
587	Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6735-6746.	3.3	79
588	Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 95-106.	0.8	15
589	Age-related trends in injection site reaction incidence induced by the tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. <i>International Journal of Medical Sciences</i> , 2017, 14, 102-109.	1.1	21
590	Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. <i>Reumatologia</i> , 2017, 55, 284-289.	0.5	6
591	Therapies for Active Rheumatoid Arthritis after Methotrexate Failure. <i>Rheumatology (Sunnyvale, Calif)</i> 17(10):1000-1008	0.8	0
592	Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1133-1142.	0.8	14
593	Rheumatoid Arthritis Comorbidity Index (RACI): Development and Validation of a New Comorbidity Index for Rheumatoid Arthritis Patients. <i>Journal of Arthritis</i> , 2017, 06, .	0.3	2
594	Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. <i>Oncotarget</i> , 2017, 8, 48375-48384.	0.8	11
597	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 539-545.	0.9	14
598	Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1014-1021.	2.9	18
599	Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and scRNA Sequencing Data. <i>Arthritis and Rheumatology</i> , 2018, 70, 690-701.	2.9	157
600	Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212597.	0.5	21



#	ARTICLE	IF	CITATIONS
601	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging Techniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid Arthritis (RA) patients (PREDICTRA). <i>BMJ Open</i> , 2018, 8, e019007.	0.8	7
602	Influence of the different "patient global assessment" formulations on disease activity score by different indices in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1963-1969.	1.0	14
603	Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 658-666.	0.5	22
604	Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , 2018, 5, 185-201.	1.1	11
605	Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis. <i>Annals of Pharmacotherapy</i> , 2018, 52, 780-791.	0.9	41
606	Dual-energy CT: a new imaging modality for bone marrow oedema in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213152.	0.5	45
607	Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan. <i>Rheumatology and Therapy</i> , 2018, 5, 135-148.	1.1	8
608	Management of rheumatoid arthritis. <i>Medicine</i> , 2018, 46, 216-221.	0.2	12
609	A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. <i>Rheumatology and Therapy</i> , 2018, 5, 21-42.	1.1	97
610	Prediction of response to methotrexate in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 419-429.	1.3	23
611	Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF $\pm$ Monoclonal Antibody. <i>AAPS Journal</i> , 2018, 20, 63.	2.2	14
612	Therapeutic Approaches to Type I Interferonopathies. <i>Current Rheumatology Reports</i> , 2018, 20, 32.	2.1	23
613	Starting biologic therapy in rheumatoid arthritis. A Colombian experience. <i>Revista Colombiana De Reumatología</i> , 2018, 25, 1-2.	0.0	0
614	ER Stress: A Therapeutic Target in Rheumatoid Arthritis?. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 610-623.	4.0	65
615	Hot joints: myth or reality? A thermographic joint assessment of inflammatory arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 2567-2571.	1.0	16
617	Immunogenicity of biologic therapies: causes and consequences. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 513-523.	1.3	51
618	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 43-55.	1.1	4
619	"No evidence of disease activity"™ " is it an appropriate surrogate in multiple sclerosis?. <i>European Journal of Neurology</i> , 2018, 25, 1107.	1.7	55

#	ARTICLE	IF	CITATIONS
620	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564.	1.8	29
621	Biologicals in de praktijk van de reumatoloog. <i>Bijblijven</i> (Amsterdam, Netherlands), 2018, 34, 139.	0.0	0
622	Influence of large joint involvement on patientâ€“physician discordance in global assessment of rheumatoid arthritis disease activity analyzed by a novel joint index. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1237-1245.	0.9	8
623	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. <i>Clinical Rheumatology</i> , 2018, 37, 2043-2053.	1.0	9
624	Interleukin-2 shapes the cytotoxic T cell proteome and immune environmentâ€“sensing programs. <i>Science Signaling</i> , 2018, 11, .	1.6	67
625	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1419-1428.	2.9	21
626	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. <i>Clinical Rheumatology</i> , 2018, 37, 1417-1420.	1.0	1
627	Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients. <i>Rheumatology</i> , 2018, 57, 865-872.	0.9	17
628	The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1192-1199.	2.9	18
629	Openâ€“Label, Nonâ€“Mandatory Transitioning From Originator Etanercept to Biosimilar <sc>SB</sc>4. <i>Arthritis and Rheumatology</i> , 2018, 70, 1408-1418.	2.9	90
630	Role of Methotrexate in the Management of Psoriatic Arthritis. <i>Drugs</i> , 2018, 78, 611-619.	4.9	20
631	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. <i>Clinical Immunology</i> , 2018, 191, 67-74.	1.4	12
632	Tumor necrosis factorâ€“alpha inhibitors and risk of nonâ€“Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	2.3	42
633	Clinical connection between rheumatoid arthritis and liver damage. <i>Rheumatology International</i> , 2018, 38, 715-724.	1.5	40
634	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212934.	0.5	19
635	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.5	183
636	Effectiveness and safety of anakinra in gout patients with stage 4â€“5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. <i>Joint Bone Spine</i> , 2018, 85, 755-760.	0.8	29
637	Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly. <i>Drugs and Aging</i> , 2018, 35, 379-387.	1.3	7

#	ARTICLE	IF	CITATIONS
638	Guidelines for management of rheumatic diseases in developing countries from basics to real-world situation: relevance, need, and processes for development. <i>Rheumatology International</i> , 2018, 38, 549-556.	1.5	5
639	Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 230-237.	1.0	10
640	Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-1 $\alpha$ in rheumatoid arthritis: focus on mavrimumab. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 29-38.	1.2	25
641	Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. <i>Clinical Rheumatology</i> , 2018, 37, 1189-1197.	1.0	44
642	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908.	0.9	47
643	Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. <i>BMJ Open</i> , 2018, 8, e019325.	0.8	13
644	Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole. <i>Clinical Rheumatology</i> , 2018, 37, 3215-3220.	1.0	17
645	Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. <i>Current Opinion in Rheumatology</i> , 2018, 30, 266-275.	2.0	18
646	Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy. <i>Canadian Pharmacists Journal</i> , 2018, 151, 94-97.	0.4	1
647	Using technology to support clinical care and research in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 276-281.	2.0	41
648	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	55
649	Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 61-67.	1.2	26
650	Rheumatoid arthritis treatment in patients with a history of cancer. <i>Current Opinion in Rheumatology</i> , 2018, 30, 288-294.	2.0	15
651	Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 320-328.	1.0	28
653	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
654	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 203-214.	1.1	10
655	Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. <i>Clinical Therapeutics</i> , 2018, 40, 309-319.	1.1	18
656	Experience and Context Shape Patient and Clinician Goals For Treatment of Rheumatoid Arthritis: A Qualitative Study. <i>Arthritis Care and Research</i> , 2018, 70, 1614-1620.	1.5	16

#	ARTICLE	IF	CITATIONS
657	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 832-840.	2.9	103
658	Sleep disorders associated with risk of rheumatoid arthritis. <i>Sleep and Breathing</i> , 2018, 22, 1083-1091.	0.9	9
659	Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). <i>Rheumatology</i> , 2018, 57, 337-344.	0.9	92
660	An e-health interactive self-assessment website (Sanoia®) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients. <i>Joint Bone Spine</i> , 2018, 85, 709-714.	0.8	51
661	High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1689-1694.	1.0	8
662	Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 505-506.	0.6	18
663	Lessons learned from rheumatoid arthritis registries. <i>Joint Bone Spine</i> , 2018, 85, 271-274.	0.8	8
664	Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Modern Rheumatology</i> , 2018, 28, 789-799.	0.9	59
665	Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 684-689.	0.5	52
666	Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. <i>Rheumatology International</i> , 2018, 38, 599-606.	1.5	6
667	Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 901-908.	1.0	11
668	Normalizing fibromyalgia as a chronic illness. <i>Postgraduate Medicine</i> , 2018, 130, 9-18.	0.9	27
670	The clinical course of patients with rheumatoid arthritis who underwent orthopaedic surgeries under disease control by tofacitinib. <i>Modern Rheumatology</i> , 2018, 28, 1063-1065.	0.9	8
671	Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. <i>Rheumatology</i> , 2018, 57, 309-317.	0.9	12
672	Glucocorticoids, Inflammation and Bone. <i>Calcified Tissue International</i> , 2018, 102, 592-606.	1.5	59
673	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , 2018, 41, 473-488.	1.4	30
674	Les enseignements apportés par les registres de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 57-60.	0.0	0
675	Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 673-687.	0.9	6

#	ARTICLE	IF	CITATIONS
676	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. <i>Ophthalmology</i> , 2018, 125, 757-773.	2.5	178
677	Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 50.	1.6	28
678	Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry. <i>BMC Rheumatology</i> , 2018, 2, 1.	0.6	15
679	Methotrexate pre-filled autoinjector pen (Nordimet <sup>®</sup> ) for subcutaneous injection: a profile of its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 197-202.	0.3	1
680	Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2018, 14, 142-149.	0.2	3
681	Pneumopathies non infectieuses induites par les biothĀrapies ciblĀes. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 184-190.	0.0	1
682	Baricitinib: A Review in Rheumatoid Arthritis. <i>Drugs</i> , 2018, 78, 761-772.	4.9	103
683	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. <i>Current Opinion in Pharmacology</i> , 2018, 40, 110-119.	1.7	63
684	Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. <i>Bone Research</i> , 2018, 6, 15.	5.4	947
685	Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naĀve and Experienced Patients. <i>Internal Medicine</i> , 2018, 57, 663-670.	0.3	30
686	Morning Stiffness in Elderly Patients with Rheumatoid Arthritis: What is Known About the Effect of Biological and Targeted Agents?. <i>Drugs and Aging</i> , 2018, 35, 477-483.	1.3	5
687	Baseline autoantibody profile in rheumatoid arthritisĀs associated with early treatment response but not long-term outcomes. <i>Arthritis Research and Therapy</i> , 2018, 20, 33.	1.6	39
688	Biologic agents in inflammatory arthritis. <i>British Journal of General Practice</i> , 2018, 68, 204-205.	0.7	4
689	Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial. <i>Rheumatology and Therapy</i> , 2018, 5, 123-134.	1.1	8
690	Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2018, 2, 6.	0.6	8
691	Systems approach for classifying the response to biological therapies in patients with rheumatoid arthritis in clinical practice. <i>European Journal of Integrative Medicine</i> , 2018, 19, 65-71.	0.8	1
692	Therapeutic strategy for rheumatoid arthritis patients who have achieved remission. <i>Joint Bone Spine</i> , 2018, 85, 679-685.	0.8	7
693	Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study. <i>Clinical Rheumatology</i> , 2018, 37, 2027-2034.	1.0	6

#	ARTICLE	IF	CITATIONS
694	Etanercept for the treatment of rheumatoid arthritis. <i>Immunotherapy</i> , 2018, 10, 433-445.	1.0	107
695	Patient Satisfaction and Costs of Multidisciplinary Models of Care in Rheumatology: a Review of the Recent Literature. <i>Current Rheumatology Reports</i> , 2018, 20, 19.	2.1	12
696	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	1.8	20
697	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , 2018, 57, 1896-1907.	0.9	43
698	Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 935-947.	1.5	89
699	Treat to Target in Juvenile Idiopathic Arthritis: Challenges and Opportunities. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 29-43.	0.6	3
700	The use of glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1316-1317.	0.9	7
701	Tocilizumab in the treatment of adult rheumatoid arthritis. <i>Immunotherapy</i> , 2018, 10, 447-464.	1.0	15
702	Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study. <i>Clinical Rheumatology</i> , 2018, 37, 1763-1771.	1.0	8
703	Predicting methotrexate resistance in rheumatoid arthritis patients. <i>Inflammopharmacology</i> , 2018, 26, 699-708.	1.9	22
704	Hematologic and serologic status of military working dogs given standard diet containing natural botanical supplements. <i>Toxicology Reports</i> , 2018, 5, 343-347.	1.6	4
705	Characteristics of rheumatoid arthritis patients undergoing reverse shoulder arthroplasty. <i>Clinical Rheumatology</i> , 2018, 37, 339-343.	1.0	6
706	Rheumatoid Arthritis Patientsâ€™ Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens. <i>Arthritis Care and Research</i> , 2018, 70, 533-541.	1.5	18
707	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
708	A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1085-1086.	0.5	5
709	Pharmacokinetics of ABT-122, a TNF-Î± and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. <i>Clinical Pharmacokinetics</i> , 2018, 57, 613-623.	1.6	17
710	Toward cellular biomarkers for rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 10-11.	0.9	27
711	Patientsâ€™ Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. <i>Arthritis Care and Research</i> , 2018, 70, 525-532.	1.5	40

#	ARTICLE	IF	CITATIONS
712	Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. <i>Value in Health</i> , 2018, 21, 193-202.	0.1	11
713	Tofacitinib in the treatment of active rheumatoid arthritis in adults. <i>Immunotherapy</i> , 2018, 10, 39-56.	1.0	12
714	Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patientsâ€”an intervention study. <i>Clinical Rheumatology</i> , 2018, 37, 331-337.	1.0	11
715	Response to: â€œConcerns on glucocorticoid use for Japanese patients with established rheumatoid arthritisâ€” by Oiwa. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e36-e36.	0.5	1
716	Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 1005-1014.	1.0	45
717	Heterocyclic homoprostanoid derivative attenuates monoarthritis in rats: An in vitro and in vivo preclinical paradigm. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 320-329.	1.9	1
718	Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2018, 28, 599-605.	0.9	3
719	Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 104-110.	0.5	131
720	Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 85-91.	0.5	51
721	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 484-487.	0.5	59
722	Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. <i>Arthritis Care and Research</i> , 2018, 70, 834-841.	1.5	5
723	Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 40-48.	2.9	104
724	What have we learned from BeSt?. <i>Clinical Immunology</i> , 2018, 186, 74-78.	1.4	3
725	Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 199-204.	1.0	6
726	Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 444-451.	0.9	6
727	Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 801-806.	1.5	26
728	La place de la e-santé et les objets connectés dans le traitement de patients atteints de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 66-70.	0.0	1
729	A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. <i>Advances in Medical Sciences</i> , 2018, 63, 22-29.	0.9	66

#	ARTICLE	IF	CITATIONS
730	Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e35-e35.	0.5	2
731	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 9-16.	0.9	63
732	Perception des poussées de polyarthrite rhumatoïde de telles que rapportées par les patients: sous-analyse de l'essai STRASS sur les stratégies de diminution progressive du traitement. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 353-358.	0.0	0
733	An update on hearing impairment in patients with rheumatoid arthritis. <i>Journal of Otology</i> , 2018, 13, 1-4.	0.4	10
734	Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 515-522.	0.5	46
735	Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 650-657.	0.5	36
736	Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1185-1191.	1.5	38
737	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.5	22
738	Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 336-342.	0.5	57
739	Response to: "Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis" by Mathieu et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e66-e66.	0.5	0
740	Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 40-44.	1.0	32
741	Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. <i>Rheumatology International</i> , 2018, 38, 579-587.	1.5	13
742	Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 278-289.	1.4	5
743	Will we ever have better glucocorticoids?. <i>Clinical Immunology</i> , 2018, 186, 64-66.	1.4	24
745	Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456.	2.3	223
746	Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. <i>World Journal of Gastroenterology</i> , 2018, 24, 2363-2372.	1.4	18
747	Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2018, 5, 160-164.	1.3	10
748	Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e12658.	0.4	37



#	ARTICLE	IF	CITATIONS
750	Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 869-886.	1.4	73
751	Reasons to stop drinking alcohol among patients with rheumatoid arthritis in Sweden: a mixed-methods study. <i>BMJ Open</i> , 2018, 8, e024367.	0.8	10
752	Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. <i>Chinese Medical Journal</i> , 2018, 131, 2683-2692.	0.9	28
753	Starting biologic therapy in rheumatoid arthritis. A Colombian experience. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , 2018, 25, 1-2.	0.1	0
754	Treatment of chronic inflammatory rheumatism by biotherapy in Gabon: eligibility and follow-up of the first 8 patients in sub-Saharan Africa. <i>Medecine Et Sante Tropicales</i> , 2018, 28, 197-200.	0.3	5
756	Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies. <i>Revista Colombiana De Reumatolog�a</i> , 2018, 25, 233-244.	0.0	3
757	Targeting IL-6: A review of data. <i>Considerations in Medicine</i> , 2018, 2, 12-18.	0.0	3
758	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	1.8	17
759	An update on research advances in rheumatoid arthritis: from clinic to basic science. <i>Journal of Laboratory and Precision Medicine</i> , 2018, 3, 54-54.	1.1	4
760	Lymphoproliferative disorder in an elderly rheumatoid arthritis patient after longterm oral methotrexate administration: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 293-296.	0.4	4
761	Considering new lessons about the use of IL-6 inhibitors in arthritis. <i>Considerations in Medicine</i> , 2018, 2, 7-11.	0.0	4
762	Prise en charge pratique des patients sous inhibiteurs de Janus Kinases (JAKi). Fiches pratiques �labor�es par le Club Rhumatismes et Inflammation (CRI), Association reconnue par la Soci�t� Fran�saise de Rhumatologie (SFR). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 1-108.	0.0	0
763	Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2018, 54, .	1.2	2
767	Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , 2018, 25, 233-244.	0.1	0
768	Methods for measuring adherence to oral disease-modifying drugs in rheumatoid arthritis and factors associated with low adherence to pharmacological treatment. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , 2018, 25, 261-270.	0.1	0
769	Recognition of gout in rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e13540.	0.4	3
770	Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 733-747.	0.8	18
771	Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. <i>Open Access Rheumatology: Research and Reviews</i> , 2018, Volume 10, 103-111.	0.8	11

#	ARTICLE	IF	CITATIONS
772	Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China. <i>BMJ Open</i> , 2018, 8, e023798.	0.8	0
773	eDRAM: Effective early disease risk assessment with matrix factorization on a large-scale medical database: A case study on rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0207579.	1.1	18
774	Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 211.	1.0	30
775	The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. <i>Arthritis Research and Therapy</i> , 2018, 20, 256.	1.6	10
776	Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3799-3805.	2.0	13
777	Defining the target: clinical aims in axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, vi18-vi22.	0.9	17
778	Patients&rsquo;, physicians&rsquo;, nurses&rsquo;, and pharmacists&rsquo; preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2153-2168.	0.8	15
779	MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 47.	0.3	2
780	“Methotrexate and <sc>NSAID</sc>s in rheumatoid arthritis” <sc>C</sc>onfirmation of a known <sc>NSAID</sc>s adverse effect rather than a dangerous combination” • <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1429-1429.	0.9	1
781	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 57-70.	2.0	99
782	Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases (Review). <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 1024-1029.	0.8	26
783	Cas clinique n° 1 : Innocent, suspect, coupable : quel est votre verdict ? Atteintes iatrogéniques respiratoires : exemple de la polyarthrite rhumatoïde et du méthotrexate. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 3-10.	0.0	0
784	Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 1-9.	0.8	1
785	An audit of the use of hydroxychloroquine in rheumatology clinics. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky013.	0.3	3
786	Radiomics “the value of the numbers in present and future radiology. <i>Polish Journal of Radiology</i> , 2018, 83, 171-174.	0.5	10
787	Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. <i>Archives of Rheumatology</i> , 2018, 33, 251-272.	0.3	3
788	Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , 2018, 4, e000813.	1.8	11
789	EULAR “points to consider”™ for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	1.8	16

#	ARTICLE	IF	CITATIONS
790	Serum adiponectin as a predictor of laboratory response to anti-TNF therapy in rheumatoid arthritis. <i>Central-European Journal of Immunology</i> , 2018, 43, 289-294.	0.4	3
791	The Clinical Value of Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 339.	1.2	64
792	Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. <i>PLoS ONE</i> , 2018, 13, e0208240.	1.1	23
793	DC32, a Dihydroartemisinin Derivative, Ameliorates Collagen-Induced Arthritis Through an Nrf2-p62-Keap1 Feedback Loop. <i>Frontiers in Immunology</i> , 2018, 9, 2762.	2.2	39
794	Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Various Biologic DMARDs. <i>Frontiers in Pharmacology</i> , 2018, 9, 1303.	1.6	7
795	Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study. <i>RMD Open</i> , 2018, 4, e000754.	1.8	6
796	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. <i>RMD Open</i> , 2018, 4, e000809.	1.8	17
797	Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2097-2111.	0.9	4
798	Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. <i>RMD Open</i> , 2018, 4, e000752.	1.8	37
799	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773.	1.8	9
800	20 years of experience with tumour necrosis factor inhibitors: what have we learned?. <i>Rheumatology</i> , 2018, 57, vii5-vii10.	0.9	34
801	Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?. <i>Rheumatology</i> , 2018, 57, vii1-vii4.	0.9	1
802	Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014. <i>Archives of Medical Science</i> , 2018, 14, 569-571.	0.4	7
803	Effects of a 15-month anti-TNF treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 211.	1.6	13
804	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e498.	3.1	81
805	Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1070.	1.6	30
806	Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2018, 33, 154-159.	0.3	3
807	Switch to a biosimilar: Whatever the cost?. <i>Joint Bone Spine</i> , 2018, 85, 651-654.	0.8	4

#	ARTICLE	IF	CITATIONS
808	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. <i>Reumatologia</i> , 2018, 56, 203-211.	0.5	21
809	Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. <i>Rheumatology International</i> , 2018, 38, 2289-2296.	1.5	6
810	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. <i>BioDrugs</i> , 2018, 32, 397-404.	2.2	82
811	Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2938.	1.8	152
813	Diagnosis and Management of Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1360.	3.8	1,257
814	A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1537-1555.	0.8	11
816	What Is Most Important in Rheumatoid Arthritis Treatment “Where You Are, Who You Are, or Where You Are Going?”. <i>Journal of Rheumatology</i> , 2018, 45, 1341-1343.	1.0	1
817	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	0.9	24
818	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	1.1	9
819	Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 495-505.	0.9	10
820	Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylolation revisited. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 331-334.	0.4	11
821	Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii32-vii41.	0.9	1
822	Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. <i>PLoS ONE</i> , 2018, 13, e0205125.	1.1	14
823	Clinical and radiologic analysis of on-demand use of etanercept for disease flares in patients with rheumatoid arthritis for 2 years. <i>Medicine (United States)</i> , 2018, 97, e12462.	0.4	4
824	Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. <i>Rheumatology International</i> , 2018, 38, 2111-2120.	1.5	23
825	Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids. <i>Rheumatology and Therapy</i> , 2018, 5, 525-536.	1.1	10
826	Psychometric validation of an empowerment scale for Spanish-speaking patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 244.	1.6	3
827	Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). <i>PLoS ONE</i> , 2018, 13, e0205134.	1.1	9

#	ARTICLE	IF	CITATIONS
828	Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1943-1950.	0.9	3
829	Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide Korean College of Rheumatology BIOlogics (KOBIO) registry. <i>PLoS ONE</i> , 2018, 13, e0205651.	1.1	13
830	Targeted Intracellular Delivery of Antibodies: The State of the Art. <i>Frontiers in Pharmacology</i> , 2018, 9, 1208.	1.6	144
831	Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets. <i>Frontiers in Immunology</i> , 2018, 9, 2228.	2.2	139
832	Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. <i>Arthritis Research and Therapy</i> , 2018, 20, 230.	1.6	25
833	Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2007-2014.	0.8	5
834	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	3
835	Intensive therapy and remissions in rheumatoid arthritis: a systematic review. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 389.	0.8	25
836	Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. <i>Rheumatology and Therapy</i> , 2018, 5, 551-565.	1.1	9
837	Relationship between neutrophilâ€lymphocyte, plateletâ€lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 2122-2127.	0.9	38
838	Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes. <i>Frontiers in Immunology</i> , 2018, 9, 2351.	2.2	10
839	Dihydroartemisinin derivative DC32 attenuates collagen-induced arthritis in mice by restoring the Treg/Th17 balance and inhibiting synovitis through down-regulation of IL-6. <i>International Immunopharmacology</i> , 2018, 65, 233-243.	1.7	32
840	Optimization of fermentation conditions for an <i>Escherichia coli</i> strain engineered using the response surface method to produce a novel therapeutic DNA vaccine for rheumatoid arthritis. <i>Journal of Biological Engineering</i> , 2018, 12, 22.	2.0	13
841	Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis. <i>Inflammopharmacology</i> , 2018, 26, 1375-1381.	1.9	9
842	The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trial. <i>Trials</i> , 2018, 19, 471.	0.7	7
843	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0196793.	1.1	13
844	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2018, 31, 572-582.	0.4	19
845	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.5	83

#	ARTICLE	IF	CITATIONS
846	Treating Fatigue in Rheumatoid Arthritis: Does Patient Age Matter?. <i>Drugs and Aging</i> , 2018, 35, 871-876.	1.3	10
847	Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNF $\pm$ therapy. <i>Immunotherapy</i> , 2018, 10, 1033-1039.	1.0	3
848	Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECOrd-linkage On Rheumatic Diseases study on health care administrative databases. <i>BMJ Open</i> , 2018, 8, e021447.	0.8	29
849	A public health perspective on personalized periodontics. <i>Periodontology 2000</i> , 2018, 78, 195-200.	6.3	20
850	A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 375-397.	0.8	7
851	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 275-284.	0.7	14
852	A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy. <i>Current Rheumatology Reports</i> , 2018, 20, 64.	2.1	6
853	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 349-358.	0.8	19
854	Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e11609.	0.4	3
855	UK&ndash;South Asian patients&rsquo; experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 489-497.	0.8	8
856	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. <i>PLoS ONE</i> , 2018, 13, e0203084.	1.1	43
857	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. <i>Drug Safety</i> , 2018, 41, 1013-1022.	1.4	38
858	Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky005.	0.3	33
859	Janus kinase inhibitors clear to land. <i>Rheumatology</i> , 2018, 57, 1131-1132.	0.9	4
860	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	1.1	9
861	Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2018, 57, 1453-1460.	0.9	53
863	Effect of cumulative exposure to corticosteroid and DMARD on radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. <i>Rheumatology</i> , 2018, 57, 1563-1573.	0.9	8
864	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1268-1275.	0.5	43

#	ARTICLE	IF	CITATIONS
865	Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1261-1267.	0.5	32
866	Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	14
867	Methotrexate-associated lymphoproliferative disorder complicated by severe acute respiratory failure and ileal perforation: a case report. <i>Fukushima Journal of Medical Sciences</i> , 2018, 64, 82-88.	0.1	6
868	Drugs Used in Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, 15, 39-76.	0.1	2
869	The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. <i>Rheumatology International</i> , 2018, 38, 1911-1918.	1.5	23
870	Biosimilars Have Arrived: Rituximab. <i>Arthritis</i> , 2018, 2018, 1-6.	2.0	30
871	Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1421-1425.	0.5	25
872	Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	33
873	Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. <i>Rheumatology International</i> , 2018, 38, 1465-1470.	1.5	7
874	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. <i>Rheumatology and Therapy</i> , 2018, 5, 383-401.	1.1	11
875	Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2018, 45, 1353-1360.	1.0	7
878	Overdiagnosis and overtreatment in rheumatology: a little caution is in order. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1394-1396.	0.5	62
879	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602.	1.8	13
880	T Follicular Regulatory Cells Are Decreased in Patients With Established Treated Rheumatoid Arthritis With Active Disease: Comment on the Article by Liu et Al. <i>Arthritis and Rheumatology</i> , 2018, 70, 1893-1895.	2.9	14
882	Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. <i>Archives of Rheumatology</i> , 2018, 33, 108-127.	0.3	5
883	Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials. <i>Rheumatology</i> , 2018, 57, 1830-1837.	0.9	51
884	Emerging anti-osteoclast therapy for rheumatoid arthritis. <i>Journal of Orthopaedic Science</i> , 2018, 23, 717-721.	0.5	25
885	Combination of NF- $\kappa$ B targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis. <i>Journal of Nanobiotechnology</i> , 2018, 16, 58.	4.2	74

#	ARTICLE	IF	CITATIONS
886	Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1923-1932.	2.9	26
887	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572.	0.5	23
888	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. <i>Frontiers in Pharmacology</i> , 2018, 9, 794.	1.6	22
889	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. <i>Clinical Rheumatology</i> , 2018, 37, 2381-2390.	1.0	26
890	Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 165.	1.6	33
891	Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. <i>Yonsei Medical Journal</i> , 2018, 59, 452.	0.9	27
892	Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease. <i>Inflammopharmacology</i> , 2018, 26, 1183-1188.	1.9	14
893	Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models. <i>Frontiers in Pharmacology</i> , 2018, 9, 20.	1.6	31
894	Stevens-Johnson syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature. <i>Biomedical Reports</i> , 2018, 9, 37-41.	0.9	8
895	2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. <i>Advances in Rheumatology</i> , 2018, 58, 2.	0.8	25
896	Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. <i>Rheumatology</i> , 2018, 57, 2022-2031.	0.9	19
897	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1685-1695.	2.0	80
898	Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study. <i>Rheumatology</i> , 2018, 57, 2012-2021.	0.9	21
899	Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1151-1166.	0.8	41
900	Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 1825-1831.	1.5	1
901	Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with) Tj ETQq1 1 0.784314 rgBT /Overl... CZP-SPEED Study. <i>Advances in Therapy</i> , 2018, 35, 1153-1168.	1.3	11
902	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. <i>Current Therapeutic Research</i> , 2018, 89, 1-6.	0.5	19
903	Synovial tissue quantitative proteomics analysis reveals paeoniflorin decreases LIFR and ASPN proteins in experimental rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 463-473.	2.0	13



#	ARTICLE	IF	CITATIONS
904	The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 105.	1.6	13
905	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. <i>Arthritis Research and Therapy</i> , 2018, 20, 160.	1.6	16
906	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. <i>Open Access Rheumatology: Research and Reviews</i> , 2018, Volume 10, 97-101.	0.8	3
907	Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation. <i>Frontiers in Immunology</i> , 2018, 9, 1662.	2.2	39
908	Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker. <i>Frontiers in Immunology</i> , 2017, 8, 2007.	2.2	44
909	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 621.	2.2	21
910	Targeting B Cells and Plasma Cells in Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 835.	2.2	204
911	Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice. <i>Frontiers in Immunology</i> , 2018, 9, 950.	2.2	29
912	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. <i>Frontiers in Immunology</i> , 2018, 9, 1510.	2.2	89
913	Methods for high-dimensional analysis of cells dissociated from cryopreserved synovial tissue. <i>Arthritis Research and Therapy</i> , 2018, 20, 139.	1.6	93
914	Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. <i>Genes</i> , 2018, 9, 64.	1.0	20
915	Tetraspanin CD82 affects migration, attachment and invasion of rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1619-1626.	0.5	26
916	Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1413-1420.	0.5	69
917	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1405-1412.	0.5	117
918	Essential and Optional Drugs for Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, , 77-96.	0.1	0
919	Monitoring of Disease and Treatment of Patients With Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, , 97-125.	0.1	2
920	Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1739.	1.8	30
921	The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 146.	1.6	18

#	ARTICLE	IF	CITATIONS
922	Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. <i>Nature Communications</i> , 2018, 9, 2755.	5.8	140
923	The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0200023.	1.1	17
924	The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2018, 57, 1947-1955.	0.9	23
925	Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. <i>RMD Open</i> , 2018, 4, e000710.	1.8	19
926	Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1513-1521.	0.8	3
927	Rheumatology science and practice in India. <i>Rheumatology International</i> , 2018, 38, 1587-1600.	1.5	18
928	Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. <i>Arthritis Research and Therapy</i> , 2018, 20, 1.	1.6	53
929	Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. <i>Arthritis Research and Therapy</i> , 2018, 20, 39.	1.6	26
930	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 67.	0.7	32
931	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8.	1.6	29
932	Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?. <i>Arthritis Research and Therapy</i> , 2018, 20, 15.	1.6	8
933	Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 60.	1.6	46
934	Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. <i>Arthritis Research and Therapy</i> , 2018, 20, 81.	1.6	8
935	Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2018, 38, 7.	1.5	17
936	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. <i>Inflammation and Regeneration</i> , 2018, 38, 4.	1.5	32
937	Personalized medicine for connective tissue disease: Historical and future perspectives. <i>Personalized Medicine Universe</i> , 2018, 7, 1-6.	0.1	0
938	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2018, 8, 7342.	1.6	18
939	Antiarthritic Effects of Sorafenib in Rats with Adjuvant-Induced Arthritis. <i>Anatomical Record</i> , 2018, 301, 1519-1526.	0.8	8

#	ARTICLE	IF	CITATIONS
940	A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States. <i>Rheumatology and Therapy</i> , 2018, 5, 255-270.	1.1	13
941	EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212662.	0.5	173
942	Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1276-1282.	0.5	51
943	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. <i>Rheumatology</i> , 2018, 57, 1423-1431.	0.9	31
944	Musculoskeletal ultrasound for predicting remission in patients with rheumatoid arthritis: results from a 1-year prospective study. <i>Rheumatology International</i> , 2018, 38, 1891-1899.	1.5	6
945	Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000637.	1.8	5
946	Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. <i>Reumatologia</i> , 2018, 56, 3-9.	0.5	5
947	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. <i>Reumatologia</i> , 2018, 56, 140-148.	0.5	7
948	Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adoption of the 2015 American College of Rheumatology guidelines. <i>Clinical Rheumatology</i> , 2018, 37, 2947-2959.	1.0	13
949	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 57.	2.1	53
950	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
951	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 1533-1540.	0.9	20
952	Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. <i>Journal of Translational Medicine</i> , 2018, 16, 156.	1.8	6
953	The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 4-11.	0.5	23
954	Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0202601.	1.1	12
955	Era of steroid sparing in the management of immune-mediated inflammatory diseases. <i>Immunological Medicine</i> , 2018, 41, 6-11.	1.4	13
956	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1421-1429.	2.0	13
957	Dr. Johnson and Dr. BahÅse-AltuntaÅ reply. <i>Journal of Rheumatology</i> , 2018, 45, 876.2-876.	1.0	0

#	ARTICLE	IF	CITATIONS
958	Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?. <i>Frontiers in Medicine</i> , 2018, 5, 140.	1.2	7
959	Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATAâ€™a retrospective, exploratory cohort study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky008.	0.3	3
960	Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	123
961	Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 105-116.	0.9	37
962	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>Advances in Therapy</i> , 2018, 35, 1535-1563.	1.3	56
963	Excessive Pricing Causes Poor Access to Biologics. <i>Journal of Rheumatology</i> , 2018, 45, 876.1-876.	1.0	2
964	Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. <i>Translational Research</i> , 2018, 199, 24-38.	2.2	13
965	Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). <i>BioDrugs</i> , 2018, 32, 377-390.	2.2	10
966	Pharmacokinetics of low-dose methotrexate in healthy beagle dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018, 41, 659-669.	0.6	3
967	Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212612.	0.5	19
968	The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1283-1289.	0.5	62
969	Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. <i>Drugs</i> , 2018, 78, 929-940.	4.9	66
970	Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1391-1393.	0.5	5
971	Feasibility of Measurement and Adherence to System Performance Measures for Rheumatoid Arthritis in 5 Models of Care. <i>Journal of Rheumatology</i> , 2018, 45, 1501-1508.	1.0	15
972	Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2503-2512.	6.3	280
973	Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study. <i>PLoS ONE</i> , 2018, 13, e0195550.	1.1	48
974	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2513-2524.	6.3	316
975	The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. <i>Modern Rheumatology</i> , 2019, 29, 581-588.	0.9	17

#	ARTICLE	IF	CITATIONS
976	Vaccination with a Novel Antigen-Specific Tolerizing DNA Vaccine Encoding <i>CCOL2A1</i> Protects Rats from Experimental Rheumatoid Arthritis. <i>Human Gene Therapy</i> , 2019, 30, 69-78.	1.4	7
977	Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019, 71, 620-628.	1.5	12
978	The incidence rate and the early management of rheumatoid arthritis in Slovenia. <i>Clinical Rheumatology</i> , 2019, 38, 273-278.	1.0	3
979	Combined gemfibrozil (peroxisome proliferator-activated receptor alpha agonist) with reduced steroid dose gives a similar management picture as the full steroid dose in a rat adjuvant-induced arthritis model. <i>Modern Rheumatology</i> , 2019, 29, 602-611.	0.9	2
980	Treat to target strategy in early rheumatoid arthritis versus routine care – A comparative clinical practice study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 808-814.	1.6	23
981	Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 163-170.	0.5	7
982	Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF- $\kappa$ B and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years –™ treatment for Japanese rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2019, 29, 418-429.	0.9	18
983	Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. <i>Modern Rheumatology</i> , 2019, 29, 413-417.	0.9	32
984	Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 115-126.	0.5	11
985	Inflammatory arthritis in systemic sclerosis: What to do?. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 3-16.	1.0	6
986	Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. <i>Biological Psychiatry</i> , 2019, 85, 35-48.	0.7	99
987	Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 597-602.	1.6	33
988	The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend. <i>Rheumatology</i> , 2019, 58, 580-587.	0.9	20
989	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.5	35
990	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019, 71, 1132-1140.	1.5	22
991	Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance. <i>Modern Rheumatology</i> , 2019, 29, 737-746.	0.9	5
992	The price of good health care. <i>Rheumatology</i> , 2019, 58, 931-932.	0.9	1
993	The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 775-781.	0.9	14

#	ARTICLE	IF	CITATIONS
994	1,25-Dihydroxyvitamin D3 attenuates disease severity and induces synoviocyte apoptosis in a concentration-dependent manner in rats with adjuvant-induced arthritis by inactivating the NF- $\kappa$ B signaling pathway. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 430-440.	1.3	6
995	Correspondence to viewpoint "Defining refractory rheumatoid arthritis"™ by Buch. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e105-e105.	0.5	4
996	Effects of Language, Insurance, and Race/Ethnicity on Measurement Properties of the PROMIS Physical Function Short Form 10a in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 925-935.	1.5	9
997	Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019, 86, 195-201.	0.8	17
998	Management of inflammatory rheumatic conditions in the elderly. <i>Rheumatology</i> , 2019, 58, 748-764.	0.9	24
999	Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. <i>Arthritis Care and Research</i> , 2019, 71, 71-79.	1.5	5
1000	Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1097-1105.	1.4	21
1001	Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1237.	1.0	19
1003	Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review. <i>Cells</i> , 2019, 8, 818.	1.8	101
1004	Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 2232-2245.	1.3	17
1005	Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. <i>Rheumatology and Therapy</i> , 2019, 6, 461-471.	1.1	52
1006	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
1007	Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 3381-3390.	1.0	20
1008	Glucocorticoids" All-Rounders Tackling the Versatile Players of the Immune System. <i>Frontiers in Immunology</i> , 2019, 10, 1744.	2.2	170
1009	Hybrid micelles containing methotrexate-conjugated polymer and co-loaded with microRNA-124 for rheumatoid arthritis therapy. <i>Theranostics</i> , 2019, 9, 5282-5297.	4.6	36
1010	Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). <i>Drugs</i> , 2019, 79, 1511-1528.	4.9	35
1011	The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. <i>Pharmacological Research</i> , 2019, 147, 104392.	3.1	62
1012	Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. <i>Clinical Rheumatology</i> , 2019, 38, 3391-3400.	1.0	16

#	ARTICLE	IF	CITATIONS
1013	The Abnormal CD4+T Lymphocyte Subset Distribution and Vbeta Repertoire in New-onset Rheumatoid Arthritis Can Be Modulated by Methotrexate Treatment. <i>Cells</i> , 2019, 8, 871.	1.8	18
1014	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. <i>Rheumatology and Therapy</i> , 2019, 6, 503-520.	1.1	12
1015	Dose-Dependent Efficacy of Gold Clusters on Rheumatoid Arthritis Therapy. <i>ACS Omega</i> , 2019, 4, 14092-14099.	1.6	18
1016	Types of pain and their psychosocial impact in women with rheumatoid arthritis. <i>Women's Midlife Health</i> , 2019, 5, 3.	0.5	25
1017	Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study. <i>Rheumatology International</i> , 2019, 39, 2015-2024.	1.5	2
1018	Development of adult T-cell leukaemia/lymphoma during the treatment of rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 87-91.	0.3	6
1020	Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2019, 36, 2287-2295.	1.3	9
1021	Treatâ€œtarget and shared decision making in rheumatoid arthritis treatment: Is it feasible?. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1706-1713.	0.9	8
1022	Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0220178.	1.1	51
1023	Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). <i>BMJ Open</i> , 2019, 9, e028517.	0.8	19
1024	Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 182.	1.6	21
1025	Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. <i>Arthritis Research and Therapy</i> , 2019, 21, 183.	1.6	181
1026	Serum Soluble Interleukin-2 Receptor Is a Biomarker for &lt;i>Pneumocystis jirovecii&/i>; Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 248, 209-216.	0.5	6
1027	Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: Results of a multicentric survey in France among health professionals and patients. <i>Joint Bone Spine</i> , 2019, 86, 747-752.	0.8	14
1028	Evidence to support or guide glucocorticoid tapering in rheumatoid arthritis is lacking. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1733-1734.	0.5	9
1029	Health-related quality of life in patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 34.	0.6	47
1030	A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. <i>Microbiome</i> , 2019, 7, 107.	4.9	101
1031	&lt;p>&lt;/p>Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis&lt;/p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1969-1984.	2.0	13

#	ARTICLE	IF	CITATIONS
1032	A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study. <i>Rheumatology International</i> , 2019, 39, 1537-1546.	1.5	7
1033	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. <i>ReumatologĀa ClĀnica</i> , 2019, 15, 311-314.	0.2	0
1034	Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. <i>Clinical Rheumatology</i> , 2019, 38, 3049-3059.	1.0	3
1035	Effectiveness and Safety of Tacrolimus in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-modifying Anti-rheumatic Drugs: The TREASURE Study. <i>Journal of Rheumatic Diseases</i> , 2019, 26, 20.	0.4	1
1036	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. <i>Rheumatology</i> , 2020, 59, 213-223.	0.9	22
1037	Polymorphism in Organic Anion-Transporting Polypeptide Gene Related to Methotrexate Response in Rheumatoid Arthritis Treatment. <i>Journal of Nippon Medical School</i> , 2019, 86, 149-158.	0.3	2
1038	Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden. <i>Rheumatology</i> , 2019, 59, 205-212.	0.9	4
1039	Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2019, 39, 1483-1497.	1.5	9
1040	Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. <i>Journal of Autoimmunity</i> , 2019, 105, 102298.	3.0	34
1041	The therapeutic journey of biologic agents: There will be an end?. <i>Pharmacological Research</i> , 2019, 147, 104340.	3.1	3
1042	Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-blind, Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1788-1800.	2.9	284
1043	Trends in gabapentinoid prescribing in patients with osteoarthritis: a United Kingdom national cohort study in primary care. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 1437-1444.	0.6	22
1044	Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking. <i>Clinical Rheumatology</i> , 2019, 38, 3217-3225.	1.0	15
1045	Validation of a risk perception questionnaire developed for patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0219921.	1.1	5
1046	IL-6 Mediated Transcriptional Programming of Na <sup>+</sup> ve CD4 <sup>+</sup> T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. <i>Frontiers in Immunology</i> , 2019, 10, 1535.	2.2	17
1047	Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0220142.	1.1	7
1048	Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	3
1049	Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 879-887.	0.5	6



#	ARTICLE	IF	CITATIONS
1050	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	5
1051	Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. Chinese Medical Journal, 2019, 132, 1009-1014.	0.9	10
1052	&lt;p&gt;Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment&lt;p&gt;. Patient Preference and Adherence, 2019, Volume 13, 1199-1211.	0.8	16
1053	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology, 2019, 2019, 1-5.	0.2	8
1054	Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide populationâ€based cohort study in Taiwan. International Journal of Rheumatic Diseases, 2019, 22, 1544-1552.	0.9	10
1055	Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients. Arthritis Research and Therapy, 2019, 21, 157.	1.6	25
1056	Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score. International Journal of Rheumatic Diseases, 2019, 22, 1572-1577.	0.9	5
1057	Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Revista Colombiana De ReumatologÃa (English Edition), 2019, 26, 11-23.	0.1	0
1059	Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. Journal of Clinical Medicine, 2019, 8, 938.	1.0	127
1060	Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada. Rheumatology International, 2019, 39, 1621-1630.	1.5	5
1061	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. Rheumatic Disease Clinics of North America, 2019, 45, 315-324.	0.8	1
1062	Predictors and the optimal duration of sustained remission in rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 3033-3039.	1.0	5
1063	Imaging of Common Rheumatic Joint Diseases Affecting the Upper Limbs. Radiologic Clinics of North America, 2019, 57, 1001-1034.	0.9	3
1064	Multimodal Optical Diagnostics of the Microhaemodynamics in Upper and Lower Limbs. Frontiers in Physiology, 2019, 10, 416.	1.3	13
1065	Optimising lowâ€dose methotrexate for rheumatoid arthritisâ€A review. British Journal of Clinical Pharmacology, 2019, 85, 2228-2234.	1.1	36
1066	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 164.	1.6	24
1067	Role of biological agents in treatment of rheumatoid arthritis. Pharmacological Research, 2019, 150, 104497.	3.1	36
1068	Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?. Journal of Rheumatology, 2019, 46, 1256-1258.	1.0	6

#	ARTICLE	IF	CITATIONS
1069	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. <i>Lancet Rheumatology</i> , The, 2019, 1, e103-e110.	2.2	38
1070	The Combined Effects of Sr(II) and Poly(Acrylic Acid) on the Morphology of Calcite. <i>Materials</i> , 2019, 12, 3339.	1.3	4
1071	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). <i>Rheumatology and Therapy</i> , 2019, 6, 559-571.	1.1	15
1072	Two-year abatacept retention rate in clinical practice in the French ACTION cohort. <i>Joint Bone Spine</i> , 2019, 86, 753-759.	0.8	3
1073	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1454-1462.	0.5	115
1074	Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 560-570.	0.9	11
1075	Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 1268-1280.	0.5	1
1076	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e145-e153.	2.2	19
1077	Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2019, 6, 573-586.	1.1	29
1078	Nanomedicine "advantages for their use in rheumatoid arthritis theranostics. <i>Journal of Controlled Release</i> , 2019, 316, 302-316.	4.8	59
1079	An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance. <i>Frontiers in Endocrinology</i> , 2019, 10, 729.	1.5	17
1080	The Regulation of Bone Metabolism and Disorders by Wnt Signaling. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5525.	1.8	214
1081	Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions. <i>Rheumatology and Therapy</i> , 2019, 6, 473-477.	1.1	2
1082	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1313-1322.	1.3	10
1083	The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 43.	0.6	25
1084	Quality of life in Ecuadorian patients with rheumatoid arthritis: A cross-sectional study. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 296-300.	0.2	1
1085	On Research Progress of Western and Chinese Medicine Treatment on Pre-Rheumatoid Arthritis. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 643-647.	0.7	7
1086	Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 1218-1228.	0.5	1

#	ARTICLE	IF	CITATIONS
1087	Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan. <i>Frontiers in Pharmacology</i> , 2019, 10, 1214.	1.6	8
1088	Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1914745.	2.8	41
1089	The "Treat to Target" Approach to Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 487-504.	0.8	17
1090	Treat to Target in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 477-485.	0.8	31
1091	Subclinical Treatment Targets in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 593-604.	0.8	3
1092	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. <i>ACR Open Rheumatology</i> , 2019, 1, 471-479.	0.9	5
1093	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019, 18, 102398.	2.5	75
1094	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	2.5	6
1095	Subclinical coronary artery disease in recent-onset of rheumatoid arthritis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2019, 40, 202-203.	0.5	0
1096	Should we combine biologics with methotrexate in axial spondyloarthritis?. <i>Autoimmunity Reviews</i> , 2019, 18, 102402.	2.5	1
1097	Subjective well-being among rheumatoid arthritis patients. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1863-1870.	0.9	5
1098	Can we wean patients with inflammatory arthritis from biological therapies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102399.	2.5	5
1099	The slippery road of adherence in chronically ill individuals. <i>Rheumatology</i> , 2020, 59, 9-11.	0.9	0
1100	A systematic review of guidelines for managing rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 42.	0.6	50
1101	Methotrexate an Old Drug with New Tricks. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5023.	1.8	231
1102	The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz035.	0.3	11
1103	Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 2199-2205.	0.9	7
1104	CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2747-2758.	1.1	12

#	ARTICLE	IF	CITATIONS
1105	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1305-1319.	0.5	95
1106	Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. <i>Arthritis Research and Therapy</i> , 2019, 21, 216.	1.6	20
1107	&lt;p&gt;Remicade&lt;sup&gt;Â®&lt;/sup&gt;Â;(infliximab):Â20 years of contributions to science and medicine&lt;/p&gt;. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 139-178.	3.0	78
1108	Could a methotrexate blood assay improve adherence?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 577-578.	3.5	0
1110	Traditional Chinese Medicine as a Treatment for Rheumatoid Arthritis: From Empirical Practice to Evidence-Based Therapy. <i>Engineering</i> , 2019, 5, 895-906.	3.2	32
1112	The use of leukocytesâ€™ secretome to individually target biological therapy in autoimmune arthritis: a case report. <i>Clinical and Translational Medicine</i> , 2019, 8, 19.	1.7	5
1113	Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases. <i>In Vivo</i> , 2019, 33, 1599-1604.	0.6	3
1114	Top 100 cited articles on rheumatoid arthritis. <i>Medicine (United States)</i> , 2019, 98, e14523.	0.4	35
1115	Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence. <i>PLoS ONE</i> , 2019, 14, e0221290.	1.1	8
1116	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. <i>Clinical Rheumatology</i> , 2019, 38, 3331-3350.	1.0	19
1117	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019, 79, 1741-1755.	4.9	39
1118	Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. <i>Bone Research</i> , 2019, 7, 27.	5.4	19
1119	G-MDSC-derived exosomes attenuate collagen-induced arthritis by impairing Th1 and Th17 cell responses. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165540.	1.8	49
1120	Shifting from a Rheumatologic Point of View toward Patient-centered Care in Rheumatoid Arthritis with an Integrated Management of Comorbidities. <i>Journal of Rheumatology</i> , 2019, 46, 545-547.	1.0	7
1122	Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. <i>Lancet Rheumatology, The</i> , 2019, 1, e23-e34.	2.2	25
1123	Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent. <i>Journal of Nanobiotechnology</i> , 2019, 17, 94.	4.2	12
1124	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019, 8, 1394.	1.0	35
1125	Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 936.	3.8	88

#	ARTICLE	IF	CITATIONS
1126	Effective JAK inhibitor therapy in rheumatoid arthritis: can methotrexate be discontinued?. <i>Lancet Rheumatology</i> , The, 2019, 1, e4-e5.	2.2	0
1127	What is the best treatment for early rheumatoid arthritis?. <i>Rheumatology</i> , 2019, 58, 2086-2088.	0.9	2
1128	TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients. <i>Journal of Immunology Research</i> , 2019, 2019, 1-6.	0.9	30
1129	Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4541.	1.8	115
1130	Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?. <i>BMC Rheumatology</i> , 2019, 3, 36.	0.6	7
1132	Maintien thérapeutique à deux ans de l'abatacept en pratique courante. Résultats de la cohorte française de l'étude ACTION. <i>Revue Du Rhumatisme (Edition Française)</i> , 2019, 86, 483-489.	0.0	1
1133	Associations of TRAF1/C5 rs10818488 and rs3761847 polymorphisms with genetic susceptibility to rheumatoid arthritis: a case-control study and updated meta-analysis. <i>Central-European Journal of Immunology</i> , 2019, 44, 159-173.	0.4	7
1134	Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. <i>Clinical Rheumatology</i> , 2019, 38, 2967-2976.	1.0	37
1135	Detecting joints with erosion(s) in rheumatoid arthritis: a novel individualized-ultrasound method performs better than existing methods. <i>Japanese Journal of Radiology</i> , 2019, 37, 793-797.	1.0	2
1136	Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries. <i>Rheumatology and Therapy</i> , 2019, 6, 529-542.	1.1	23
1138	Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1987430.	1.2	14
1139	Quality of life in Ecuadorian patients with established rheumatoid arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 199-205.	0.8	5
1140	Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience. <i>Reumatologia</i> , 2019, 57, 192-198.	0.5	3
1141	Efficacité et sécurité de l'anakinra dans la goutte associée à une insuffisance rénale chronique de stade 4 ou 5 ou à une transplantation rénale: étude prospective multicentrique. <i>Revue Du Rhumatisme (Edition Française)</i> , 2019, 86, 511-517.	0.0	0
1142	The B side of rheumatoid arthritis pathogenesis. <i>Pharmacological Research</i> , 2019, 149, 104465.	3.1	13
1143	Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: A cross-sectional controlled study with real-time two-dimensional shear wave elastography. <i>European Journal of Internal Medicine</i> , 2019, 69, 57-63.	1.0	14
1144	Nouveaux concepts destinés à réduire la toxicité des glucocorticoïdes. <i>Revue Du Rhumatisme (Edition Française)</i> , 2019, 86, 511-517.	0.0	0
1145	Simultaneous Development of Progressive Multifocal Leukoencephalopathy and Cryptococcal Meningitis during Methotrexate and Infliximab Treatment. <i>Internal Medicine</i> , 2019, 58, 2703-2709.	0.3	3

#	ARTICLE	IF	CITATIONS
1146	Targeted hexagonal Pd nanosheet combination therapy for rheumatoid arthritis <i>via</i> the photothermal controlled release of MTX. <i>Journal of Materials Chemistry B</i> , 2019, 7, 112-122.	2.9	37
1148	The value of the simplified RAMRIS-5 in early RA patients under methotrexate therapy using high-field MRI. <i>Arthritis Research and Therapy</i> , 2019, 21, 21.	1.6	7
1149	Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 99-110.	0.7	0
1150	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
1151	Treat-to-target in rheumatoid arthritis “are we there yet?”. <i>Nature Reviews Rheumatology</i> , 2019, 15, 180-186.	3.5	86
1152	<p>Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 157-163.	0.8	4
1153	Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. <i>Rheumatology</i> , 2019, 58, 1367-1377.	0.9	22
1154	Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 29.	1.6	13
1155	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0210459.	1.1	31
1156	The intensity of joint pain in relation to changes in serum TNF $\alpha$ during therapy with anti-TNF $\alpha$ inhibitors. <i>Inflammopharmacology</i> , 2019, 27, 679-683.	1.9	8
1157	Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 852-859.	0.9	0
1158	Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 258-263.	0.5	8
1159	Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 717-722.	0.8	1
1160	Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 572-578.	1.0	2
1161	Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease. <i>Journal of Breath Research</i> , 2019, 13, 026008.	1.5	21
1162	Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 461.	3.8	70
1163	Structural efficacy of NSAIDs, COX-2 inhibitor and glucocorticoid compared with TNF $\alpha$ blocker: a study in adjuvant-induced arthritis rats. <i>Rheumatology</i> , 2019, 58, 1099-1103.	0.9	5
1164	Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019, 5, e000900.	1.8	67

#	ARTICLE	IF	CITATIONS
1165	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 465-476.	0.8	5
1166	The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets. <i>Current Drug Targets</i> , 2019, 20, 970-981.	1.0	29
1167	Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?. <i>Frontiers in Medicine</i> , 2019, 6, 144.	1.2	18
1168	A randomized study comparing regular care with a nurse-led clinic based on tight disease activity control and person-centred care in patients with rheumatoid arthritis with moderate/high disease activity: A 6-month evaluation. <i>Musculoskeletal Care</i> , 2019, 17, 215-225.	0.6	8
1169	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 573-581.	1.9	33
1170	Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. <i>Rheumatology</i> , 2019, 58, 1883-1884.	0.9	4
1171	Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry: reply. <i>Rheumatology</i> , 2019, 58, 1885-1886.	0.9	0
1172	Authors reply to comment on axial SpA recommendations. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1346-1347.	0.9	0
1173	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. <i>BMC Rheumatology</i> , 2019, 3, 3.	0.6	4
1174	Ultrasound-triggered perfluorocarbon-derived nanobombs for targeted therapies of rheumatoid arthritis. <i>Journal of Materials Chemistry B</i> , 2019, 7, 4581-4591.	2.9	22
1175	Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 439-447.	0.6	7
1176	The "totality-of-the-evidence"™ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481985253.	1.4	11
1177	"Living a normal life" a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 2.	0.6	13
1178	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. <i>Rheumatology</i> , 2019, 58, 2221-2229.	0.9	11
1179	A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2019, 21, 153.	1.6	71
1180	A General Introduction to Glucocorticoid Biology. <i>Frontiers in Immunology</i> , 2019, 10, 1545.	2.2	323
1181	Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. <i>Rheumatology</i> , 2019, 58, 2284-2294.	0.9	42
1182	<p>Abatacept: from a budget impact model to cost-effectiveness analysis " data from RCT and real life</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 405-409.	0.7	1

#	ARTICLE	IF	CITATIONS
1183	Novel DMARD monotherapy in rheumatoid arthritis. <i>Lancet, The</i> , 2019, 393, 2277-2278.	6.3	4
1184	Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. <i>BMJ Open</i> , 2019, 9, e028197.	0.8	13
1185	Upregulation of sphingosine-1-phosphate receptor 3 on fibroblast-like synoviocytes is associated with the development of collagen-induced arthritis via increased interleukin-6 production. <i>PLoS ONE</i> , 2019, 14, e0218090.	1.1	19
1186	Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1346-1356.	0.5	60
1187	Development and validation of a methotrexate adherence assay. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1192-1197.	0.5	13
1188	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2019, 5, e000898.	1.8	14
1189	Cardiorespiratory fitness in patients with rheumatoid arthritis is associated with the patient global assessment but not with objective measurements of disease activity. <i>RMD Open</i> , 2019, 5, e000912.	1.8	16
1190	Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata <sup>®</sup> clinical database and registry. <i>Arthritis Research and Therapy</i> , 2019, 21, 138.	1.6	28
1191	JAK inhibitors in 2019, synthetic review in 10 points. <i>European Journal of Internal Medicine</i> , 2019, 66, 9-17.	1.0	27
1192	Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1033-1040.	0.5	39
1193	Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 639-648.	2.4	4
1194	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 934-941.	0.9	6
1196	Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. <i>Musculoskeletal Care</i> , 2019, 17, 161-169.	0.6	9
1197	Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. <i>BMJ Open</i> , 2019, 9, e027456.	0.8	20
1198	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. <i>Clinical Rheumatology</i> , 2019, 38, 2737-2746.	1.0	10
1199	Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders. <i>Clinical Rheumatology</i> , 2019, 38, 2747-2756.	1.0	4
1200	Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a AUS Observational Cohort. <i>Clinical Therapeutics</i> , 2019, 41, 1057-1065.e3.	1.1	0
1201	Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy. <i>Clinical Rheumatology</i> , 2019, 38, 2727-2736.	1.0	16



#	ARTICLE	IF	CITATIONS
1202	Methotrexate for Prevention of Cardiovascular Events. <i>New England Journal of Medicine</i> , 2019, 380, 2276-2277.	13.9	2
1203	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , 2019, 58, 2193-2202.	0.9	34
1204	The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2019, 8, 826.	1.0	11
1205	Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2019, 41, 1346-1354.	1.1	28
1206	Patients' perspective of a dedicated biologic clinic for inflammatory arthritis. <i>International Journal of Health Care Quality Assurance</i> , 2019, 32, 879-886.	0.2	1
1207	Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1333-1338.	0.5	15
1208	Preventing Rheumatoid Arthritis: A Global Challenge. <i>Clinical Therapeutics</i> , 2019, 41, 1355-1365.	1.1	10
1209	Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2019, 41, 1376-1396.	1.1	25
1210	Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. <i>Rheumatology and Therapy</i> , 2019, 6, 339-352.	1.1	21
1211	Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. <i>Rheumatology International</i> , 2019, 39, 1331-1341.	1.5	17
1212	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet, The</i> , 2019, 393, 2303-2311.	6.3	237
1213	Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. <i>BMJ Open</i> , 2019, 9, e028466.	0.8	140
1214	Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-. <i>PLoS ONE</i> , 2019, 14, e0216624.	1.1	46
1215	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 415-425.	1.0	33
1216	Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis. <i>Immunological Medicine</i> , 2019, 42, 29-38.	1.4	10
1217	Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis. <i>Clinical Rheumatology</i> , 2019, 38, 2451-2459.	1.0	8
1218	Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial. <i>Clinical Rheumatology</i> , 2019, 38, 2461-2471.	1.0	7
1219	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 890-898.	0.5	22

#	ARTICLE	IF	CITATIONS
1220	European Qualitative research project on Patient-preferred outcomes in Early Rheumatoid Arthritis (EQPERA): rationale, design and methods of a multinational, multicentre, multilingual, longitudinal qualitative study. <i>BMJ Open</i> , 2019, 9, e023606.	0.8	6
1221	Eight-year survival study of first-line tumour necrosis factor $\pm$ inhibitors in rheumatoid arthritis: real-world data from a university centre registry. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz007.	0.3	21
1222	Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. <i>Arthritis Research and Therapy</i> , 2019, 21, 115.	1.6	7
1223	Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry. <i>BMC Rheumatology</i> , 2019, 3, 16.	0.6	6
1224	Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 902.	2.2	9
1225	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 116.	1.6	23
1226	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , 2019, 58, 2000-2008.	0.9	10
1227	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. <i>Rheumatology</i> , 2019, 58, 1509-1510.	0.9	0
1228	ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. <i>Arthritis Research and Therapy</i> , 2019, 21, 121.	1.6	20
1230	Centre effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review. <i>Rheumatology</i> , 2019, 58, 1991-1999.	0.9	1
1231	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?â€”MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.	1.0	54
1232	Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. <i>Journal of Rheumatology</i> , 2019, 46, 874-886.	1.0	3
1233	Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate. <i>ACR Open Rheumatology</i> , 2019, 1, 145-155.	0.9	3
1234	Biosimilars in the Americas: the future by consensus. <i>Clinical Rheumatology</i> , 2019, 38, 1497-1499.	1.0	3
1235	Rituximab in connective tissue diseaseâ€”associated interstitial lung disease. <i>Clinical Rheumatology</i> , 2019, 38, 2001-2009.	1.0	36
1236	Personalized Medicine in Autoimmunity. , 2019, , 619-624.		0
1237	Small Molecules. , 2019, , 629-637.		0
1238	Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 266-270.	0.6	11

#	ARTICLE	IF	CITATIONS
1239	Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review. <i>Current Rheumatology Reports</i> , 2019, 21, 24.	2.1	7
1240	Diagnostic. , 2019, , 163-178.		0
1241	Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target. <i>Joint Bone Spine</i> , 2019, 86, 594-599.	0.8	6
1243	Tofacitinib for the treatment of rheumatoid arthritis: an update. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 577-588.	1.3	21
1244	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 693-700.	1.3	31
1245	Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports. <i>BMC Rheumatology</i> , 2019, 3, 13.	0.6	10
1246	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Advances in Therapy</i> , 2019, 36, 1337-1357.	1.3	11
1247	Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz010.	0.3	7
1248	Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2501-2508.	1.0	2
1249	Challenges in the treatment of Rheumatoid Arthritis. <i>Autoimmunity Reviews</i> , 2019, 18, 706-713.	2.5	138
1250	R�ponse clinique pr�coce et progression radiographique � long terme dans la polyarthrite rhumato�de d�butante: la r�mission clinique � 6 mois reste l'objectif � atteindre. <i>Revue Du Rhumatisme</i> , 2019, 86, 367-372.	0.0	0
1251	Methotrexate in Our Hearts. <i>Journal of Rheumatology</i> , 2019, 46, 447-449.	1.0	1
1252	The superb microvascular imaging is more sensitive than conventional power Doppler imaging in detection of active synovitis in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2613-2620.	1.0	21
1253	Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019, 101, 121-130.	3.0	5
1254	Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 73.	1.0	3
1256	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 58, 1767-1776.	0.9	24
1257	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1755-1766.	0.9	201
1258	Targeting Interleukin-6 Signaling in Clinic. <i>Immunity</i> , 2019, 50, 1007-1023.	6.6	570

#	ARTICLE	IF	CITATIONS
1259	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. <i>Arthritis Research and Therapy</i> , 2019, 21, 91.	1.6	36
1260	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
1261	Primus inter pares: the choice of biologic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1325-1326.	0.9	1
1262	Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 6.	0.6	24
1263	Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1332.	1.8	49
1264	Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. <i>Arthritis Research and Therapy</i> , 2019, 21, 79.	1.6	28
1265	Current Status and Future Prospects of Clinically Exploiting Cancer-specific Metabolism—Why Is Tumor Metabolism Not More Extensively Translated into Clinical Targets and Biomarkers?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1385.	1.8	12
1266	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1094-1106.	0.9	12
1267	The many facets of macrophages in rheumatoid arthritis. <i>Biochemical Pharmacology</i> , 2019, 165, 152-169.	2.0	144
1268	Useful message in choosing optimal biological agents for patients with autoimmune arthritis. <i>Biochemical Pharmacology</i> , 2019, 165, 99-111.	2.0	9
1269	Pharmacologic Nonbiologic Treatment of Axial Spondyloarthritis. , 2019, , 217-226.		0
1270	Rheumatology practice in Japan: challenges and opportunities. <i>Rheumatology International</i> , 2019, 39, 1499-1505.	1.5	2
1271	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. <i>RMD Open</i> , 2019, 5, e000742.	1.8	28
1272	Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, i34-i42.	0.9	170
1273	Genetic and epigenetic alteration of the programmed cell death 1 in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13094.	1.7	7
1274	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019, 14, e0213073.	1.1	19
1275	Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort. <i>PLoS ONE</i> , 2019, 14, e0213219.	1.1	6
1276	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 222-228.	1.6	42

#	ARTICLE	IF	CITATIONS
1277	Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. <i>Annals of Pharmacotherapy</i> , 2019, 53, 947-953.	0.9	98
1278	Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 461-467.	0.5	22
1279	Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib. <i>Frontiers in Immunology</i> , 2019, 10, 541.	2.2	30
1280	Percentage of progressors in imaging: can we ignore regressors?. <i>RMD Open</i> , 2019, 5, e000848.	1.8	12
1281	Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. <i>Journal of Clinical Medicine</i> , 2019, 8, 302.	1.0	10
1282	&lt;p&gt;&lt;/p&gt;New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 275-284.	0.9	15
1283	MicroRNAâ€19â€3p promotes rheumatoid arthritis fibroblastâ€like synoviocytes via targeting SOCS3. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11624-11632.	1.2	13
1284	Selective Inhibitors of T Cell Receptor Recognition of Antigenâ€MHC Complexes for Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 644-649.	1.3	10
1285	Efficacy and safety of addâ€on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1115-1122.	0.9	7
1286	AsociaciÃ³n Colombiana de ReumatologÃ­a. Consenso sobre recomendaciones para disminuciÃ³n y discontinuaciÃ³n de la terapia biolÃ³gica en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriÃ¡sica. <i>Revista Colombiana De ReumatologÃ­a</i> , 2019, 26, 11-23.	0.0	2
1287	Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FÎ±sT-CAN study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1983115.	1.2	4
1288	Comorbidities and multimorbidity in rheumatic diseases. <i>Reumatologia</i> , 2019, 57, 1-2.	0.5	4
1289	Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. <i>Rheumatology and Therapy</i> , 2019, 6, 217-230.	1.1	18
1290	Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1565889.	0.8	7
1291	In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 72.	1.6	39
1292	Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies. <i>Rheumatology and Therapy</i> , 2019, 6, 231-243.	1.1	8
1293	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-Î± agents in patients with rheumatoid arthritis: a retrospective chart review analysis. <i>Rheumatology International</i> , 2019, 39, 859-868.	1.5	28
1294	Synovial Tissue: Turning the Page to Precision Medicine in Arthritis. <i>Frontiers in Medicine</i> , 2019, 6, 46.	1.2	27

#	ARTICLE	IF	CITATIONS
1295	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1616-1625.	2.9	14
1296	MicroRNAs in rheumatoid arthritis: what is the latest with regards to diagnostics?. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 363-366.	1.5	17
1297	Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz002.	0.3	9
1298	Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1130-1137.	0.9	11
1299	The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity. <i>PLoS ONE</i> , 2019, 14, e0214717.	1.1	2
1300	Secreted Protein Acidic and Rich in Cysteine Mediated Biomimetic Delivery of Methotrexate by Albumin-Based Nanomedicines for Rheumatoid Arthritis Therapy. <i>ACS Nano</i> , 2019, 13, 5036-5048.	7.3	122
1301	Medication Adherence and Coping Strategies in Patients with Rheumatoid Arthritis: A Cross-Sectional Study. <i>International Journal of Rheumatology</i> , 2019, 2019, 1-8.	0.9	17
1302	Risks and benefits of corticosteroids in arthritic diseases in the clinic. <i>Biochemical Pharmacology</i> , 2019, 165, 112-125.	2.0	22
1303	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019, 10, 279.	1.6	89
1304	Rheumatology in Poland. <i>Rheumatology International</i> , 2019, 39, 757-767.	1.5	8
1305	Rate of remission among rheumatoid arthritis patients being treated by rheumatologists in routine practice. <i>Joint Bone Spine</i> , 2019, 86, 799-800.	0.8	0
1306	Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?. <i>Clinical Drug Investigation</i> , 2019, 39, 565-575.	1.1	8
1307	Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. <i>Frontiers in Immunology</i> , 2019, 10, 382.	2.2	62
1308	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019, 18, 583-592.	2.5	64
1309	Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 746-753.	0.5	42
1310	Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the Scope of Treating to Target. <i>Arthritis Care and Research</i> , 2019, 71, 1566-1575.	1.5	20
1311	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. <i>Drugs and Aging</i> , 2019, 36, 493-510.	1.3	16
1312	Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. <i>Clinical Rheumatology</i> , 2019, 38, 1413-1424.	1.0	21

#	ARTICLE	IF	CITATIONS
1313	&lt;p&gt;Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient&lt;/p&gt;. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 117-128.	0.7	7
1314	Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction. Advanced Science, 2019, 6, 1801671.	5.6	60
1315	The Greek (Hellenic) rheumatology over the years: from ancient to modern times. Rheumatology International, 2019, 39, 947-955.	1.5	4
1316	Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey. Rheumatology and Therapy, 2019, 6, 195-206.	1.1	14
1317	Methotrexate improves the anti-arthritic effects of Paeoniflorin-6'-O-benzene sulfonate by enhancing its pharmacokinetic properties in adjuvant-induced arthritis rats. Biomedicine and Pharmacotherapy, 2019, 112, 108644.	2.5	12
1318	Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study. Respiratory Investigation, 2019, 57, 172-182.	0.9	4
1319	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. Journal of Rheumatology, 2019, 46, 1409-1414.	1.0	14
1320	Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 384-396.	0.7	12
1321	Corticosteroid, Other Biologic and Small Molecule Therapies in Systemic Autoinflammatory Disorders. , 2019, , 775-791.		0
1322	Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan. International Journal of Rheumatic Diseases, 2019, 22, 860-868.	0.9	4
1323	Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis. Radiologia Medica, 2019, 124, 1071-1086.	4.7	23
1324	Abatacept for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2019, 15, 319-326.	1.3	34
1325	Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach. International Journal for Equity in Health, 2019, 18, 22.	1.5	9
1326	MR and ultrasound of the hands and wrists in rheumatoid arthritis. Part II. Added clinical value. Skeletal Radiology, 2019, 48, 837-857.	1.2	12
1327	Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology, 2019, 58, i17-i26.	0.9	130
1328	Clinical efficacy of new JAK inhibitors under development. Just more of the same?. Rheumatology, 2019, 58, i27-i33.	0.9	44
1329	2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 357-375.	0.9	115
1330	Advances in antibody engineering for rheumatic diseases. Nature Reviews Rheumatology, 2019, 15, 197-207.	3.5	47

#	ARTICLE	IF	CITATIONS
1331	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019, 71, 1317-1325.	1.5	41
1332	Long-term Survival of Subcutaneous Anti-tumor Necrosis Factor Biological Drugs Administered Between 2008 and 2012 in a Cohort of Rheumatoid Arthritis Patients. <i>Reumatologia Clínica (English)</i> Tj ETQq1 1 0.784314ogBT /Ov		
1333	&lt;p&gt;Comparison of health-related quality of life in patients with rheumatoid arthritis during conventional or conventional plus biological therapy in Poland&lt;p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 223-231.	0.8	6
1334	The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22862.	0.9	9
1335	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor 1± inhibitors: systematic literature review and network meta-analyses. <i>RMD Open</i> , 2019, 5, e000798.	1.8	14
1336	Current advances in the treatment of giant cell arteritis: the role of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1982722.	1.2	9
1337	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 211-217.	1.6	62
1338	Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 562-569.	0.5	17
1339	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. <i>RMD Open</i> , 2019, 5, e001017.	1.8	9
1340	SAT0152â€...PREVALENCE AND SUCCESS OF â€TRY AND SEEâ€™ SUBCUTANEOUS BIOLOGIC DMARD DOSE REDUCTION IN ROUTINE CARE AND COST SAVING IMPLICATIONS. , 2019, , .		0
1341	AB0261â€...TARGET SETTING OF FUNCTIONAL REMISSION FOR HAND AND WRIST SURGERIES USING GRIP POWER AND PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. , 2019, , .		0
1342	AB0411â€...TNF ALPHA INHIBITORS INFLUENCE THE CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
1343	AB0244â€...THE IMPORTANCE OF TREATMENT STRATEGY FOR THE OUTCOME OF EARLY RHEUMATOID ARTHRITIS PATIENTS NOT RESPONDERS TO THE FIRST LINE THERAPY WITH METHOTREXATE. , 2019, , .		0
1344	SAT0106â€...NOVEL SUBCLASS OF INTRAVASCULAR NON-CLASSICAL SYNOVIAL MONOCYTES ARE CRITICAL FOR RHEUMATOID ARTHRITIS. , 2019, , .		0
1345	AB1164â€...EDUCATION ON PEDIATRIC MUSCULOSKELETAL ULTRASOUND: A SYSTEMATIC LITERATURE AND EVENTS REVIEW. , 2019, , .		0
1346	SAT0151â€...TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR. , 2019, , .		0
1347	A systematic review of the factors associated with the initiation of biologics in patients with rheumatological conditions. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 163-169.	0.5	4
1348	AB0410â€...DISCONTINUATION OF ORAL GLUCOCORTICOID AFTER INITIATION OF BIOLOGICAL DMARD DUE TO A HIGHER DOSE OF METHOTREXATE; A RETROSPECTIVE OBSERVATIONAL STUDY BASED ON DATA FROM A JAPANESE MULTICENTER REGISTRY STUDY. , 2019, , .		0



#	ARTICLE	IF	CITATIONS
1349	AB1163â€¦CAN A MUSCULOSKELETAL ULTRASOUND REPORT CHANGE A RHEUMATOLOGISTâ€™S OPINION?. , 2019, , .		0
1350	AB0245â€¦PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE). , 2019, , .		0
1351	AB0260â€¦TREATMENT WITH BIOTECHNOLOGICAL DRUGS ACCORDING TO PRE-DEFINED SELECTION CRITERIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SINGLE COHORT. , 2019, , .		0
1352	SAT0153â€¦1,25(OH)2D AND IL-6 BLOCKADE SYNERGISTICALLY REGULATES RHEUMATOID ARTHRITIS VIA SUPPRESSION OF TH17 AND OSTEOCLASTOGENESIS. , 2019, , .		0
1353	AB0259â€¦FOUR COMORBIDITY INDEXES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
1354	AB1251â€¦ASSOCIATION BETWEEN VITAMIN D DEFICIENCY AND A HIGHER RATE OF DISEASE ACTIVITY IN PATIENTS WITH SPONDYLOARTHRITIS. , 2019, , .		0
1355	AB1250â€¦SLE AND SEXUAL FUNCTION: ARE WE FORGETTING MEN?. , 2019, , .		0
1356	SAT0105â€¦HAND DISABILITY IN RHEUMATOID ARTHRITIS: AN ENGINEERED GLOVE FOR THE COMPUTERISED QUANTIFICATION OF THE DAMAGE. , 2019, , .		0
1357	AB1249â€¦HOSPITAL ADMISSIONS IN PATIENTS WITH CHRONIC RHEUMATIC DISEASESRECEIVING ADALIMUMAB. DESCRIPTIVE STUDY OF A COHORT. , 2019, , .		0
1358	AB0242â€¦RADIOLOGICAL EVALUATION OF FOREFOOT INVOLVEMENT IN RHEUMATOID ARTHRITIS. , 2019, , .		0
1359	SP0122â€¦OPTIMIZING HOLLISTIC TREATMENTS: THE CHALLENGE OF IMPLEMENTATION. , 2019, , .		0
1361	Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study. <i>BMJ Open</i> , 2019, 9, e031467.	0.8	8
1362	Management of rheumatoid arthritis in Poland â€œ where daily practice might not always meet evidence-based guidelines. <i>Archives of Medical Science</i> , 2021, 17, 1286-1293.	0.4	6
1363	Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry. <i>RMD Open</i> , 2019, 5, e000969.	1.8	4
1364	Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. <i>RMD Open</i> , 2019, 5, e000993.	1.8	29
1365	Health-care professionalsâ€™ perceptions of interacting with patients of South Asian origin attending early inflammatory arthritis clinics. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz042.	0.3	2
1366	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. <i>RMD Open</i> , 2019, 5, e000931.	1.8	1
1367	When the first visit to the rheumatologist is established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101479.	1.4	4

#	ARTICLE	IF	CITATIONS
1368	Body Mass Index and Clinical Response to Tocilizumab in Patients With Rheumatoid Arthritis. Archives of Rheumatology, 2019, 34, 406-413.	0.3	3
1369	Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF- $\alpha$ Transgenic Mice. Mediators of Inflammation, 2019, 2019, 1-12.	1.4	2
1370	The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis. Reumatismo, 2019, 71, 22-49.	0.4	12
1371	Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future. Chinese Medical Journal, 2019, 132, 2972-2983.	0.9	8
1372	Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study. BMJ Open, 2019, 9, e027059.	0.8	10
1373	Marine oil supplements for rheumatoid arthritis. The Cochrane Library, 2019, , .	1.5	0
1374	Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. RMD Open, 2019, 5, e001050.	1.8	14
1375	Six-month prospective trial in early and long-standing rheumatoid arthritis: evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score. RMD Open, 2019, 5, e000951.	1.8	16
1376	Extraction of Rheumatoid Arthritis Disease Activity Measures From Electronic Health Records Using Automated Processing Algorithms. ACR Open Rheumatology, 2019, 1, 632-639.	0.9	1
1377	Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. Arthritis Research and Therapy, 2019, 21, 243.	1.6	13
1378	Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine, 2019, 86, eS2-eS103.	0.8	8
1379	How thorough clinical observational studies on rheumatoid arthritis can have an impact on the field. Arthritis Research and Therapy, 2019, 21, 227.	1.6	0
1380	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library, 2019, 2019, CD010455.	1.5	33
1381	Treat to Target in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2019, 45, 537-548.	0.8	13
1382	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open, 2019, 5, e001040.	1.8	28
1383	Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia, 2019, 57, 257-263.	0.5	12
1384	Factors that influence rheumatologists' anti-tumor necrosis factor alpha prescribing decisions: a qualitative study. BMC Rheumatology, 2019, 3, 47.	0.6	4
1385	Janus kinase inhibitors as a therapeutic option in rheumatoid arthritis and associated interstitial lung disease. Report of four cases. Revista Colombiana De Reumatología (English Edition), 2019, 26, 137-139.	0.1	7

#	ARTICLE	IF	CITATIONS
1386	Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases. <i>PLoS ONE</i> , 2019, 14, e0226255.	1.1	16
1387	Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 369-375.	0.4	3
1388	Anakinra in children and adults with Stillé's disease. <i>Rheumatology</i> , 2019, 58, vi9-vi22.	0.9	75
1389	Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	1.4	22
1390	Emerging quantitative MR imaging biomarkers in inflammatory arthritides. <i>European Journal of Radiology</i> , 2019, 121, 108707.	1.2	6
1391	Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2019, 21, 257.	1.6	19
1392	Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2019, 21, 263.	1.6	29
1393	Exercise Exacerbates the Transcriptional Profile of Hypoxia, Oxidative Stress and Inflammation in Rats with Adjuvant-Induced Arthritis. <i>Cells</i> , 2019, 8, 1493.	1.8	10
1394	Ethosuximide improves chronic pain-induced anxiety- and depression-like behaviors. <i>European Neuropsychopharmacology</i> , 2019, 29, 1419-1432.	0.3	16
1395	What factors could influence physicians' management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia. <i>BMC Health Services Research</i> , 2019, 19, 863.	0.9	12
1396	Addition Of A Sleeve To The Etanercept Autoinjector (Enbrel®) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 Medical Devices: Evidence and Research, 2019, Volume 12, 443-450.	0.4	0
1397	Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e516-e524.	0.5	24
1398	Long-term remarkable remission of SAPHO syndrome in response to short-term systemic corticosteroids treatment in an immunoglobulin E elevated patient. <i>Medicine (United States)</i> , 2019, 98, e16045.	0.4	3
1399	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1609-1615.	0.5	33
1400	Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 145-155.	0.3	17
1401	Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide. <i>Medicine (United States)</i> Tj ETQq1 1 0,784314 rgBT /Overlock 10 Tf 50 30	0.4	0
1402	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. <i>Arthritis Research and Therapy</i> , 2019, 21, 281.	1.6	34
1403	Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics. <i>Arthritis Research and Therapy</i> , 2019, 21, 280.	1.6	10

#	ARTICLE	IF	CITATIONS
1404	Total knee arthroplasty for treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2019, 98, e16558.	0.4	5
1405	Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices. <i>Current Opinion in Rheumatology</i> , 2019, 31, 264-270.	2.0	19
1406	Oral steroid decreases the progression of joint destruction of large joints in the lower extremities in rheumatoid arthritis. <i>Medicine (United States)</i> , 2019, 98, e17968.	0.4	3
1407	Cultural Adaptation and Validation of the Methotrexate Intolerance Severity Score in Brazilian Portuguese for Adults With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, S168-S172.	0.5	4
1408	Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. <i>Arthritis Research and Therapy</i> , 2019, 21, 256.	1.6	18
1409	Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 264.	1.6	7
1410	Safety of Intra-articular Methotrexate Injection With and Without Electroporation for Inflammatory Small Joints in Patients With Rheumatoid Arthritis. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2019, 12, 117954411988630.	0.3	3
1411	Bone Marrow Mesenchymal Stem Cells Decrease the Expression of RANKL in Collagen-Induced Arthritis Rats via Reducing the Levels of IL-22. <i>Journal of Immunology Research</i> , 2019, 2019, 1-9.	0.9	9
1412	Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. <i>JAMA Network Open</i> , 2019, 2, e1917053.	2.8	15
1413	Development and validation of a deep-learning model for scoring of radiographic finger joint destruction in rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz047.	0.3	42
1414	Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes. <i>Frontiers in Immunology</i> , 2019, 10, 2992.	2.2	8
1415	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. <i>Reumatologia Clínica (English Edition)</i> , 2019, 15, 311-314.	0.2	0
1416	&lt;p&gt;How Much Information and Participation Do Patients with Inflammatory Rheumatic Diseases Prefer in Interaction with Physicians? Results of a Participatory Research Project&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 2145-2158.	0.8	11
1417	Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 81-89.	0.9	1
1418	Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system. <i>Modern Rheumatology</i> , 2019, 29, 910-918.	0.9	13
1419	Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 976-982.	1.6	20
1420	An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients. <i>Internal Medicine</i> , 2019, 58, 511-519.	0.3	3
1421	The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 131-134.	0.9	14

#	ARTICLE	IF	CITATIONS
1422	Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 207-213.	0.9	15
1423	Regulation of biosimilar medicines and current perspectives on interchangeability and policy. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1-11.	0.8	54
1424	Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study. <i>Acta Clinica Belgica</i> , 2019, 74, 342-350.	0.5	3
1425	High Burden of Sexual Dysfunction in Female Patients with Rheumatoid Arthritis: Results of a Cross-sectional Study. <i>Journal of Rheumatology</i> , 2019, 46, 19-26.	1.0	17
1426	Modulation of immune response to induced arthritis by low-level laser therapy. <i>Journal of Biophotonics</i> , 2019, 12, e201800120.	1.1	7
1427	Mobile Phone Text Messages and Effect on Treatment Adherence in Patients Taking Methotrexate for Rheumatoid Arthritis: A Randomized Pilot Study. <i>Arthritis Care and Research</i> , 2019, 71, 1344-1352.	1.5	27
1428	Evaluation of factors associated with locomotive syndrome in Japanese elderly and younger patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 733-736.	0.9	9
1429	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.5	66
1430	Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial. <i>Phytomedicine</i> , 2019, 57, 403-410.	2.3	53
1431	Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. <i>Current Medical Research and Opinion</i> , 2019, 35, 497-502.	0.9	12
1432	Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 15.	1.0	65
1433	Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 35-42.	1.6	32
1434	Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study. <i>Rheumatology and Therapy</i> , 2019, 6, 47-60.	1.1	13
1435	Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors. <i>Rheumatology</i> , 2019, 58, 110-119.	0.9	29
1436	Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators. <i>International Immunopharmacology</i> , 2019, 67, 487-489.	1.7	37
1437	Measuring disease activity and response to treatment in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 135-145.	1.3	10
1438	Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2019, 170, ITC1.	2.0	464
1439	Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 214-221.	0.9	28

#	ARTICLE	IF	CITATIONS
1440	To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 192-200.	0.5	123
1441	The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. <i>Clinical Rheumatology</i> , 2019, 38, 949-954.	1.0	13
1442	Upadacitinib for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 13-25.	1.3	50
1443	The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 445-462.	1.0	22
1444	Persistence with biological drugs in patients treated in rheumatology practices in Germany. <i>Rheumatology International</i> , 2019, 39, 525-531.	1.5	8
1445	Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. <i>Rheumatology International</i> , 2019, 39, 131-140.	1.5	16
1446	Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. <i>Rheumatology International</i> , 2019, 39, 239-243.	1.5	17
1447	Bulgarian rheumatology: science and practice in a cost-constrained environment. <i>Rheumatology International</i> , 2019, 39, 417-429.	1.5	11
1448	Metering the METEOR in methotrexate failure: is propensity score a falling star?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e131-e131.	0.5	3
1449	IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. <i>Modern Rheumatology</i> , 2019, 29, 258-267.	0.9	134
1450	Perioperative Management of the Rheumatoid Patient. <i>Clinics in Podiatric Medicine and Surgery</i> , 2019, 36, 115-130.	0.2	9
1451	FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 517-531.	1.0	33
1452	Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 251-252.	0.6	9
1453	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019, 5, e000585.	1.8	41
1454	Lymphoproliferative disease in a patient with Takayasu arteritis and ulcerative colitis. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 34-37.	0.3	1
1455	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	24
1456	Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 14-18.	1.1	38
1457	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2019, 46, 701-709.	1.0	21

#	ARTICLE	IF	CITATIONS
1458	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
1459	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. <i>Joint Bone Spine</i> , 2019, 86, 135-150.	0.8	90
1460	Adherence to Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the OBSERVAR Study. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 264-270.	0.2	1
1461	Methotrexate in Patients With Rheumatoid Arthritis in Spain: Subanalysis of the AR Excellence Project. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 338-342.	0.2	1
1462	Melatonin attenuates TNF- $\alpha$ and IL-1 $\beta$ expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. <i>Journal of Pineal Research</i> , 2019, 66, e12560.	3.4	115
1463	Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. <i>Immunotherapy</i> , 2019, 11, 321-333.	1.0	28
1464	Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 153-154.	0.5	0
1465	Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2019, 38, 727-738.	1.0	50
1466	First-degree relatives of axial spondyloarthritis patients of the pre-SpA cohort would consider using medication in a preventive setting. <i>Clinical Rheumatology</i> , 2019, 38, 755-759.	1.0	5
1467	Potential value of serum progranulin as an activity biomarker in rheumatoid arthritis patients: Relation to musculoskeletal ultrasonographic evaluation. <i>Egyptian Rheumatologist</i> , 2019, 41, 93-97.	0.5	3
1468	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 967-975.	1.6	46
1469	Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores. <i>Clinical Rheumatology</i> , 2019, 38, 437-445.	1.0	9
1470	Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 352-360.	0.9	17
1471	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. <i>Modern Rheumatology</i> , 2019, 29, 767-774.	0.9	10
1472	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 958-966.	1.6	9
1473	Clinical immunity in bone and joints. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 2-8.	1.3	45
1474	Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2019, 71, 1459-1472.	1.5	28
1475	How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 25-30.	0.5	14

#	ARTICLE	IF	CITATIONS
1476	Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. <i>Rheumatology</i> , 2019, 58, 481-491.	0.9	17
1477	Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database. <i>Modern Rheumatology</i> , 2019, 29, 788-794.	0.9	11
1478	Abnormal brown adipose tissue mitochondrial structure and function in IL10 deficiency. <i>EBioMedicine</i> , 2019, 39, 436-447.	2.7	22
1479	Mansoa alliacea extract presents antinociceptive effect in a chronic inflammatory pain model in mice through opioid mechanisms. <i>Neurochemistry International</i> , 2019, 122, 157-169.	1.9	4
1481	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. <i>Modern Rheumatology</i> , 2019, 29, 756-766.	0.9	10
1482	Advances in rheumatology practice in Brazil. <i>Rheumatology International</i> , 2019, 39, 1125-1134.	1.5	7
1483	Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNF $\alpha$ treatment. <i>Joint Bone Spine</i> , 2019, 86, 401-403.	0.8	8
1486	Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. <i>Acta Clinica Belgica</i> , 2019, 74, 272-279.	0.5	31
1487	Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. <i>Journal of Advanced Research</i> , 2019, 15, 87-93.	4.4	44
1488	Predictors for progression of two different types of cervical lesions in rheumatoid arthritis treated with biologic agents. <i>Journal of Orthopaedic Science</i> , 2019, 24, 214-218.	0.5	8
1489	The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. <i>Modern Rheumatology</i> , 2019, 29, 795-801.	0.9	12
1490	Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 343-350.	1.0	17
1491	The folate receptor $\hat{1}^2$ as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis. <i>Drug Delivery and Translational Research</i> , 2019, 9, 366-378.	3.0	78
1492	Supervivencia a largo plazo de los fármacos biológicos anti-TNF subcutáneos administrados durante los años 2008-2012 en una cohorte de pacientes con artritis reumatoide. <i>Reumatología Clínica</i> , 2019, 15, 54-57.	0.2	1
1493	Calidad de vida en pacientes ecuatorianos con artritis reumatoide: un estudio transversal. <i>Reumatología Clínica</i> , 2019, 15, 296-300.	0.2	5
1494	Response to: "Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk" by Pareek <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e22-e22.	0.5	1
1495	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 577-578.	1.5	0
1496	Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden. <i>Rheumatology</i> , 2019, 58, 227-236.	0.9	37



#	ARTICLE	IF	CITATIONS
1497	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 333-345.	2.9	126
1498	Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 559-560.	0.9	2
1499	Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. <i>Modern Rheumatology</i> , 2019, 29, 314-323.	0.9	34
1500	Adherence and health literacy as related to outcome of patients treated for rheumatoid arthritis. <i>Zeitschrift Fur Rheumatologie</i> , 2019, 78, 74-81.	0.5	14
1501	Is remission achievable in most patients with rheumatoid arthritis? Results suggest not. <i>Rheumatology</i> , 2019, 58, 187-188.	0.9	4
1502	Adherencia al tratamiento con fármacos moduladores de la enfermedad sintomáticos en la artritis reumatoide. Resultados del estudio OBSERVAR. <i>Reumatología Clínica</i> , 2019, 15, 264-270.	0.2	3
1503	Metotrexato en pacientes con artritis reumatoide en España: subanálisis del proyecto AR Excellence. <i>Reumatología Clínica</i> , 2019, 15, 338-342.	0.2	4
1504	Inhibidor de Janus quinasas como opción terapéutica en artritis reumatoide y enfermedad pulmonar intersticial asociada: reporte de 4 casos. <i>Revista Colombiana De Reumatología</i> , 2019, 26, 137-139.	0.0	8
1505	Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. <i>Arthritis Care and Research</i> , 2020, 72, 27-35.	1.5	27
1506	Eficacia y seguridad de los glucocorticoides en la artritis reumatoide: revisión sistemática de la literatura. <i>Reumatología Clínica</i> , 2020, 16, 222-228.	0.2	9
1507	Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2020, 30, 58-63.	0.9	6
1508	Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.. <i>Modern Rheumatology</i> , 2020, 30, 50-57.	0.9	4
1509	Recomendaciones de experto sobre el bloqueo de la interleucina 6 en pacientes con artritis reumatoide. <i>Reumatología Clínica</i> , 2020, 16, 272-281.	0.2	2
1510	Eficacia y seguridad de la terapia combinada con fármacos modificadores de la enfermedad sintomáticos en la artritis reumatoide: revisión sistemática de la literatura. <i>Reumatología Clínica</i> , 2020, 16, 324-332.	0.2	4
1511	Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis. <i>Modern Rheumatology</i> , 2020, 30, 365-372.	0.9	10
1512	Automated Text Message-Enhanced Monitoring Versus Routine Monitoring in Early Rheumatoid Arthritis: A Randomized Trial. <i>Arthritis Care and Research</i> , 2020, 72, 319-325.	1.5	16
1513	Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives. <i>Arthritis Care and Research</i> , 2020, 72, 544-552.	1.5	16
1514	Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e81-e81.	0.5	6

#	ARTICLE	IF	CITATIONS
1515	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 1104-1111.	1.5	10
1516	Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2020, 72, 942-949.	1.5	4
1517	I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 360-368.	1.5	33
1518	Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. <i>Arthritis Care and Research</i> , 2020, 72, 1112-1121.	1.5	25
1519	Flares in rheumatoid arthritis: do patient-reported swollen and tender joints match clinical and ultrasonography findings?. <i>Rheumatology</i> , 2020, 59, 129-136.	0.9	18
1520	Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 493-501.	1.0	18
1521	Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. <i>Joint Bone Spine</i> , 2020, 87, 13-23.	0.8	8
1522	Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study. <i>Modern Rheumatology</i> , 2020, 30, 442-449.	0.9	2
1523	Clinical features and human T-cell leukemia virus type-1 (HTLV-1) proviral load in HTLV-1-positive patients with rheumatoid arthritis: Baseline data in a single center cohort study. <i>Modern Rheumatology</i> , 2020, 30, 471-480.	0.9	11
1524	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 20-27.	1.0	3
1525	Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 176-187.	1.0	45
1526	How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence. <i>Arthritis Care and Research</i> , 2020, 72, 489-497.	1.5	7
1527	Living With Rheumatoid Arthritis in Spain: A Qualitative Study of Patient Experience and the Role of Health Professionals. <i>Clinical Nursing Research</i> , 2020, 29, 551-560.	0.7	7
1528	Satisfacción, cumplimiento de expectativas y adherencia al fármaco biológico subcutáneo en pacientes con artritis reumatoide. Estudio ARCO. <i>Reumatología Clínica</i> , 2020, 16, 116-119.	0.2	4
1529	Effects of 1-year anti-TNF therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2020, 39, 167-175.	1.0	50
1530	Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. <i>Rheumatology</i> , 2020, 59, 1272-1280.	0.9	17
1531	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	1.6	25
1532	Factors associated with osteophyte formation in patients with rheumatoid arthritis undergoing total knee arthroplasty. <i>Modern Rheumatology</i> , 2020, 30, 937-939.	0.9	4

#	ARTICLE	IF	CITATIONS
1533	Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 87-95.	0.6	12
1534	Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis. <i>Current Medical Research and Opinion</i> , 2020, 36, 337-342.	0.9	5
1535	Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease. , 2020, 205, 107413.		14
1536	Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology. <i>Arthritis Care and Research</i> , 2020, 72, 166-175.	1.5	23
1537	Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. <i>Arthritis Care and Research</i> , 2020, 72, 176-183.	1.5	11
1538	Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. <i>Arthritis Care and Research</i> , 2020, 72, 959-964.	1.5	3
1539	“It can’t be zero!” Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2020, 59, 1137-1147.	0.9	19
1540	Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score. <i>Joint Bone Spine</i> , 2020, 87, 43-48.	0.8	6
1541	Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. <i>Joint Bone Spine</i> , 2020, 87, 267-269.	0.8	3
1542	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 39-52.	0.5	506
1543	Investigation of the predictors of the response to Igaratimod therapy: A post-hoc analysis of post-marketing surveillance study. <i>Modern Rheumatology</i> , 2020, 30, 626-632.	0.9	2
1544	Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1383-1391.	1.5	9
1545	Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study. <i>Modern Rheumatology</i> , 2020, 30, 434-441.	0.9	2
1546	Picture superiority effect as one of the potential advantages of musculoskeletal ultrasound complementation for verbal explanation. <i>Modern Rheumatology</i> , 2020, 30, 748-751.	0.9	2
1547	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. <i>Rheumatology International</i> , 2020, 40, 263-272.	1.5	10
1548	Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis. <i>PharmacoEconomics - Open</i> , 2020, 4, 105-117.	0.9	16
1549	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). <i>Modern Rheumatology</i> , 2020, 30, 239-248.	0.9	17
1550	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 17-24.	1.6	19

#	ARTICLE	IF	CITATIONS
1551	Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 7-11.	1.6	6
1552	2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 61-68.	0.5	84
1553	Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 324-334.	0.9	29
1554	Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort. <i>Joint Bone Spine</i> , 2020, 87, 99-100.	0.8	2
1555	Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 36-41.	1.6	6
1556	Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 129-137.	2.8	9
1557	Sepiapterin Reductase Inhibition Leading to Selective Reduction of Inflammatory Joint Pain in Mice and Increased Urinary Sepiapterin Levels in Humans and Mice. <i>Arthritis and Rheumatology</i> , 2020, 72, 57-66.	2.9	13
1558	Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 12-16.	1.6	13
1559	Patient Decision Aid (PDA) for Patients with Rheumatoid Arthritis Reduces Decisional Conflict and Improves Readiness for Treatment Decision Making. <i>Patient</i> , 2020, 13, 57-69.	1.1	17
1560	Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction: Post-hoc analysis of an all-case post-marketing surveillance study of iguratimod. <i>Modern Rheumatology</i> , 2020, 30, 633-639.	0.9	0
1561	A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. <i>Pharmacoeconomics</i> , 2020, 38, 39-56.	1.7	6
1562	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020, 40, 101-113.	1.2	14
1563	Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. <i>Joint Bone Spine</i> , 2020, 87, 137-139.	0.8	1
1564	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.5	307
1565	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.5	63
1566	Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 357-364.	1.0	30
1567	Diagnostic efficacy of ultrasound detection of enthesitis in peripheral spondyloarthritis. <i>Modern Rheumatology</i> , 2020, 30, 1060-1066.	0.9	6
1568	The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 85-99.	2.5	8

#	ARTICLE	IF	CITATIONS
1569	Association between periodontitis and the risk of inadequate disease control in patients with rheumatoid arthritis under biological treatment. <i>Journal of Clinical Periodontology</i> , 2020, 47, 148-159.	2.3	2
1570	Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review. <i>Reumatologia Clínica (English Edition)</i> , 2020, 16, 324-332.	0.2	4
1571	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	2.2	35
1572	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 401-408.	1.6	19
1573	Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial. <i>Rheumatology</i> , 2020, 59, 1170-1171.	0.9	0
1574	Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. <i>Wiener Medizinische Wochenschrift</i> , 2020, 170, 132-140.	0.5	4
1575	Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2020, 72, 36-40.	1.5	35
1576	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , 2020, 59, 1556-1565.	0.9	9
1577	Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis: A Brief Review. <i>Cells</i> , 2020, 9, 74.	1.8	13
1578	Co-Expression Profile of TNF Membrane-Bound Receptors Type 1 and 2 in Rheumatoid Arthritis on Immunocompetent Cells Subsets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 288.	1.8	5
1579	Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 165-171.	1.1	4
1580	Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM) <a href="#">Tj ETQq1 1 0.784314 rgBTj(Overlo</a>		
1581	Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 110, 102399.	3.0	25
1582	Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 779-786.	1.0	7
1583	From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. <i>Lancet Rheumatology, The</i> , 2020, 2, e50-e62.	2.2	17
1584	Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. <i>Rheumatology</i> , 2020, 59, 2325-2333.	0.9	6
1585	Physical exercise and low-level laser therapy on the nociception and leukocyte migration of Wistar rats submitted to a model of rheumatoid arthritis. <i>Lasers in Medical Science</i> , 2020, 35, 1277-1287.	1.0	12
1586	The Giants (biologics) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102421.	2.5	13

#	ARTICLE	IF	CITATIONS
1587	Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2020, 7, 121-131.	1.1	17
1588	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020, 59, 1709-1714.	0.9	8
1589	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	0.9	13
1590	The role of Chinese herbal medicine in the management of adverse drug reactions of leflunomide in treating rheumatoid arthritis. <i>Phytomedicine</i> , 2020, 68, 153136.	2.3	14
1591	Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2020, 16, 272-281.	0.2	2
1592	Severe Mononeuritis Multiplex due to Rheumatoid Vasculitis in Rheumatoid Arthritis in Sustained Clinical Remission for Decades. <i>Internal Medicine</i> , 2020, 59, 705-710.	0.3	4
1593	Can we shift the benefitĀrisk ratio of glucocorticoids?. <i>Lancet Rheumatology, The</i> , 2020, 2, e5-e6.	2.2	4
1594	<i>Geriatric Pharmacology.</i> , 2020, , 102-136.		0
1595	Intra-articular injection of indomethacinĀmethotrexate <i>in situ</i> hydrogel for the synergistic treatment of rheumatoid arthritis. <i>Journal of Materials Chemistry B</i> , 2020, 8, 993-1007.	2.9	46
1596	Acute Effects of Glucocorticoid Treatment, TNFĀ or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. <i>Calcified Tissue International</i> , 2020, 106, 371-377.	1.5	15
1597	Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0226754.	1.1	8
1598	A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 149-163.	1.1	11
1599	Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib. <i>Clinical Rheumatology</i> , 2020, 39, 613-614.	1.0	8
1600	Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice. <i>Clinical Rheumatology</i> , 2020, 39, 1449-1455.	1.0	5
1601	Pain and Self-reported Swollen Joints Are Main Drivers of Patient-reported Flares in Rheumatoid Arthritis: Results from a 12-month Observational Study. <i>Journal of Rheumatology</i> , 2020, 47, 1305-1313.	1.0	12
1603	The greater inflammatory pathwayĀhigh clinical potential by innovative predictive, preventive, and personalized medical approach. <i>EPMA Journal</i> , 2020, 11, 1-16.	3.3	24
1604	Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives. <i>Patient</i> , 2020, 13, 225-234.	1.1	12
1605	Risk of preventable hospitalization before and after diagnosis among rheumatoid arthritis patients compared to non-rheumatoid arthritis controls. <i>Joint Bone Spine</i> , 2020, 87, 149-156.	0.8	5

#	ARTICLE	IF	CITATIONS
1606	Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study. <i>Rheumatology</i> , 2020, 59, 2035-2042.	0.9	8
1607	Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. <i>Journal of Rheumatology</i> , 2020, 47, 1174-1181.	1.0	10
1608	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. <i>Modern Rheumatology</i> , 2020, 30, 799-806.	0.9	5
1609	Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care. <i>Modern Rheumatology</i> , 2020, 30, 948-958.	0.9	2
1611	Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study. <i>Pharmacogenomics Journal</i> , 2020, 20, 433-442.	0.9	5
1612	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. <i>BioDrugs</i> , 2020, 34, 159-170.	2.2	75
1613	Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 222-228.	0.2	1
1614	The rheumatoid arthritis patient global assessment: improve it or lose it!. <i>Rheumatology</i> , 2020, 59, 923-924.	0.9	5
1615	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. <i>Rheumatology</i> , 2020, 59, 1957-1968.	0.9	20
1616	Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1916-1926.	0.9	24
1617	MRI of the Rheumatic Spine. , 2020, , .		0
1618	Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted synthetic therapy for the treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 140-152.	0.9	0
1619	Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa020.	0.3	16
1620	One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa042.	0.3	8
1621	Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 488-497.	1.3	2
1622	Can the adherence to quality of care indicators for early rheumatoid arthritis in clinical practice reduce risk of hospitalisation? Retrospective cohort study based on the Record Linkage of Rheumatic Disease study of the Italian Society for Rheumatology. <i>BMJ Open</i> , 2020, 10, e038295.	0.8	8
1623	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	1.5	12
1624	Validation of the Italian Version of the Educational Needs Assessment Tool in Rheumatoid Arthritis Patients and Factors Associated with Educational Needs. <i>Journal of Personalized Medicine</i> , 2020, 10, 150.	1.1	3

#	ARTICLE	IF	CITATIONS
1625	Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 588-594.	0.9	3
1626	Factors associated with long-term persistence of rituximab in rheumatoid arthritis in clinical practice: RITAR Study. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 1-8.	0.1	2
1627	Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments. <i>Immunological Medicine</i> , 2020, 44, 1-10.	1.4	3
1628	Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S180-S186.	0.5	4
1629	Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. <i>Arthritis Research and Therapy</i> , 2020, 22, 226.	1.6	9
1630	Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 229.	1.6	3
1631	Predictors of Flares in Patients with Rheumatoid Arthritis Who Exhibit Low Disease Activity: A Nationwide Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3219.	1.0	2
1632	Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1532-1543.	0.5	23
1633	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. , 2020, 216, 107672.		52
1634	&lt;p&gt;JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data&lt;/p&gt;. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 519-531.	1.6	124
1635	Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs â€˜inâ€™ rheumatoid arthritis. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 737-742.	1.0	4
1636	Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life. <i>Journal of Clinical Medicine</i> , 2020, 9, 3319.	1.0	6
1637	Factors associated with disability in patients with rheumatoid arthritis with persistent moderate disease activity: a retrospective cohort study. <i>BMC Rheumatology</i> , 2020, 4, 63.	0.6	4
1638	Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during followâ€šups and predictors of achieving treatment target. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1719-1727.	0.9	3
1639	Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102920.	0.5	2
1640	Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19. <i>Food and Chemical Toxicology</i> , 2020, 145, 111694.	1.8	45
1641	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>ReumatologÃa ClÃnica</i> , 2022, 18, 33-41.	0.2	4
1643	Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. <i>RMD Open</i> , 2020, 6, e001091.	1.8	16



#	ARTICLE	IF	CITATIONS
1644	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093713.	1.2	10
1645	Lessons for rituximab therapy in patients with rheumatoid arthritis. <i>Lancet Rheumatology</i> , The, 2020, 2, e497-e509.	2.2	20
1646	Thermography in rheumatoid arthritis: a comparison with ultrasonography and clinical joint assessment. <i>Clinical Radiology</i> , 2020, 75, 963.e17-963.e22.	0.5	16
1647	Los biosimilares, una nueva era en la reumatologÃa en EspaÃ±a. <i>ReumatologÃa ClÃnica</i> , 2020, 16, 131-132.	0.2	1
1648	Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 930-937.	1.6	27
1649	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020, 6, e001211.	1.8	17
1650	Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib. <i>Rheumatology and Therapy</i> , 2020, 7, 657-665.	1.1	7
1651	Adherence to Mediterranean diet and patient perception of rheumatoid arthritis. <i>Complementary Therapies in Medicine</i> , 2020, 52, 102519.	1.3	11
1652	Treat-to-Target bei systemischem Lupus erythematodes. <i>Karger Kompass Autoimmun</i> , 2020, 2, 45-52.	0.0	0
1653	Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting. <i>International Immunopharmacology</i> , 2020, 86, 106748.	1.7	38
1654	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106101.	1.1	83
1655	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. <i>Life Sciences</i> , 2020, 257, 118097.	2.0	65
1656	Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Current Medical Research and Opinion</i> , 2020, 36, 1559-1567.	0.9	0
1657	Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13343.	1.7	2
1658	<p>Clinical Outcomes of Patients with Rheumatoid Arthritis Treated in a Disease Management Program: Real-World Results</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 249-256.	0.8	5
1659	Manejo clÃnico y discontinuaciÃ³n de tratamiento en pacientes con artritis reumatoide de inicio en una consulta de ReumatologÃa. <i>ReumatologÃa ClÃnica</i> , 2020, 18, 77-77.	0.2	2
1660	Tofacitinib Induced Psoriasiform Lesion in a Patient With Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2020, 35, 440-442.	0.3	0
1661	Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 741-757.	1.1	37

#	ARTICLE	IF	CITATIONS
1662	Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 276.	1.6	14
1663	The impact of different (rheumatoid) arthritis phenotypes on patients'™ lives. <i>Rheumatology</i> , 2021, 60, 3716-3726.	0.9	12
1664	JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9004.	1.8	25
1665	Is tocilizumab monotherapy as effective in preventing radiographic progression in rheumatoid arthritis as its combination with methotrexate?. <i>Arthritis Care and Research</i> , 2020, , .	1.5	4
1669	Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2020, 173, 870-878.	2.0	97
1670	Identification of Common Differentially Expressed Genes and Potential Therapeutic Targets in Ulcerative Colitis and Rheumatoid Arthritis. <i>Frontiers in Genetics</i> , 2020, 11, 572194.	1.1	14
1671	Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs. <i>Frontiers in Pharmacology</i> , 2020, 11, 572260.	1.6	1
1673	The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa041.	0.3	10
1674	Biotherapies in Uveitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3599.	1.0	30
1675	&lt;p&gt;Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases&lt;/p&gt;. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 241-253.	2.7	15
1676	Use of Disease-modifying Antirheumatic Drugs, Biologics, and Corticosteroids in Older Patients With Rheumatoid Arthritis Over 20 Years. <i>Journal of Rheumatology</i> , 2021, 48, 977-984.	1.0	14
1677	Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa015.	0.3	3
1678	GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2472.	1.0	12
1679	Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts. <i>Osteoporosis International</i> , 2020, 31, 2303-2311.	1.3	18
1680	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3732-3745.	1.3	11
1681	Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19. <i>Chemical Physics Letters</i> , 2020, 757, 137869.	1.2	41
1682	Relevant non-€pharmacologic topics for clinical research in rheumatic musculoskeletal diseases: The patient perspective. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1305-1310.	0.9	8
1683	Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 180.	1.6	9

#	ARTICLE	IF	CITATIONS
1684	Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1058-1063.	1.6	6
1685	Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database. <i>Clinical Drug Investigation</i> , 2020, 40, 1021-1040.	1.1	1
1686	New Rheumatoid Arthritis Treatments for â€™Oldâ€™™ Patients: Results of a Systematic Review. <i>Advances in Therapy</i> , 2020, 37, 3676-3691.	1.3	2
1687	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	6.3	78
1688	Tapering glucocorticoids in rheumatoid arthritis. <i>Lancet</i> , The, 2020, 396, 218-219.	6.3	6
1689	Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Longâ€™Term Use of Glucocorticoids. <i>Arthritis Care and Research</i> , 2021, 73, 1597-1605.	1.5	14
1690	Effects of sustainability on WoM intention and revisit intention, with environmental awareness as a moderator. <i>Management of Environmental Quality</i> , 2020, 31, 273-288.	2.2	23
1691	Efficacy and safety of intra-articular injection with triamcinolone acetonide for patients with rheumatoid arthritis. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 404-412.	0.3	1
1692	Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?. <i>Lancet Rheumatology</i> , The, 2020, 2, e454-e456.	2.2	3
1693	Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 915-922.	1.6	6
1694	Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. <i>RMD Open</i> , 2020, 6, e000991.	1.8	8
1695	Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents. <i>Frontiers in Immunology</i> , 2020, 11, 2042.	2.2	2
1696	The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1182-1190.	1.6	10
1697	A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-11.	0.6	12
1698	Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. <i>Cells</i> , 2020, 9, 1876.	1.8	27
1699	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188.	1.6	2
1700	Fibrinogen-Like Protein 1 Is a Novel Biomarker for Predicting Disease Activity and Prognosis of Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 579228.	2.2	21
1701	Exploring healthcare professionalsâ€™™ knowledge, attitudes and experiences of shared decision making in rheumatology. <i>RMD Open</i> , 2020, 6, e001121.	1.8	23

#	ARTICLE	IF	CITATIONS
1702	Response to abatacept is associated with the inhibition of proteasome $\beta$ 21i expression in T cells of patients with rheumatoid arthritis. RMD Open, 2020, 6, e001248.	1.8	3
1703	Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis. RMD Open, 2020, 6, e001142.	1.8	8
1704	YouTube for information about side effects of biologic therapy: A social media analysis. International Journal of Rheumatic Diseases, 2020, 23, 1645-1650.	0.9	15
1705	Growing Need for Diagnostic Precision in Rheumatoid Arthritis: Proposal of MR Imaging Criteria for Early Diagnosis. , 2020, , .		0
1706	Potential Advantages of Bioactive Compounds Extracted From Traditional Chinese Medicine to Inhibit Bone Destructions in Rheumatoid Arthritis. Frontiers in Pharmacology, 2020, 11, 561962.	1.6	18
1707	Increased monocyte chemoattractant protein-1 and nitrotyrosine are associated with increased body weight in patients with rheumatoid arthritis after etanercept therapy. Neuropeptides, 2020, 84, 102100.	0.9	5
1708	&lt;p&gt;Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment&lt;/p&gt;. Open Access Rheumatology: Research and Reviews, 2020, Volume 12, 203-206.	0.8	4
1709	DMARDsâ€œGut Microbiota Feedback: Implications in the Response to Therapy. Biomolecules, 2020, 10, 1479.	1.8	16
1710	Five Golden Rings to Measure Patientâ€™Centered Care in Rheumatology. Arthritis Care and Research, 2020, 72, 686-702.	1.5	8
1711	Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. Scientific Reports, 2020, 10, 18715.	1.6	10
1712	IL1B T-31C and VEGFA C+936T SNPs may be used as prognostic markers of rheumatoid arthritis treatment inefficiency. , 2020, , .		0
1713	Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study. Scientific Reports, 2020, 10, 14270.	1.6	4
1714	&lt;p&gt;â€œMastering a New Life Situationâ€•â€œ Patientsâ€™ Preferences of Treatment Outcomes in Early Rheumatoid Arthritis â€œ A Longitudinal Qualitative Study&lt;/p&gt;. Patient Preference and Adherence, 2020, Volume 14, 1421-1433.	0.8	11
1715	Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE. Rheumatology and Therapy, 2020, 7, 851-866.	1.1	18
1716	Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. PLoS Medicine, 2020, 17, e1003296.	3.9	52
1717	Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis. Zeitschrift Fur Rheumatologie, 2021, 80, 889-898.	0.5	8
1718	Interleukin (IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK/I $\beta$ B1 $\pm$ pathway. Arthritis Research and Therapy, 2020, 22, 222.	1.6	27
1719	Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis. Scientific Reports, 2020, 10, 15277.	1.6	4

#	ARTICLE	IF	CITATIONS
1720	What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001339.	1.8	9
1721	Rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2020, 40, 20.	1.5	52
1722	Development of piperidinyl dipyrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis. <i>Journal of Molecular Modeling</i> , 2020, 26, 235.	0.8	1
1723	Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1076-1081.	0.9	2
1724	Patients' perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEULIFE survey. <i>Musculoskeletal Care</i> , 2020, 18, 568-574.	0.6	3
1725	Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings. <i>Rheumatology and Therapy</i> , 2020, 7, 811-824.	1.1	3
1726	The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2760.	1.0	31
1727	Reduced skeletal muscle independently predicts 1-year aggravated joint destruction in patients with rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094622.	1.2	7
1728	Managing rheumatoid arthritis during COVID-19. <i>Clinical Rheumatology</i> , 2020, 39, 3237-3244.	1.0	43
1730	Arthritis and the role of endogenous glucocorticoids. <i>Bone Research</i> , 2020, 8, 33.	5.4	32
1731	Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1550-1556.	0.5	11
1732	Deciphering the Molecular Targets and Mechanisms of HCWD in the Treatment of Rheumatoid Arthritis via Network Pharmacology and Molecular Docking. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-13.	0.5	19
1733	Prevalence and correlates of prehypertension and hypertension among adults in Delta State, Nigeria: a cross-sectional community-based study. <i>Ghana Medical Journal</i> , 2020, 54, 48-57.	0.1	6
1734	Anti-cyclic citrullinated peptide but not rheumatoid factor is associated with ultrasound-detected bone erosion among rheumatoid arthritis patients with at least moderate disease activity. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1337-1343.	0.9	7
1735	Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN. <i>Arthritis Research and Therapy</i> , 2020, 22, 193.	1.6	1
1736	Association of genetic polymorphisms on methotrexate toxicity in patients with rheumatoid arthritis. <i>Archives of Medical Science</i> , 2020, , .	0.4	0
1737	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.3	3
1738	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200692.	1.0	9

#	ARTICLE	IF	CITATIONS
1739	Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095997.	1.2	10
1740	Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune-mediated inflammatory diseases: A longitudinal population-based analysis using claims data. <i>Health Science Reports</i> , 2020, 3, e216.	0.6	4
1741	Treatment targets in SLE: remission and low disease activity state. <i>Rheumatology</i> , 2020, 59, v19-v28.	0.9	26
1742	Neglected extra-articular manifestations in rheumatoid arthritis patients with normal body mass index: reduced skeletal muscle overlapping overfat. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097524.	1.1	3
1743	Prognostic factors for the short-term mortality of patients with rheumatoid arthritis admitted to intensive care units. <i>BMC Rheumatology</i> , 2020, 4, 64.	0.6	4
1744	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020, 6, e001395.	1.8	100
1745	Development of Monitoring System for Assessing Rheumatoid Arthritis within 5 Minutes Using a Drop of Bio-Fluids. <i>Journal of Clinical Medicine</i> , 2020, 9, 3499.	1.0	5
1746	The Effectiveness and Retention Rate of Igaratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. <i>Life</i> , 2020, 10, 261.	1.1	2
1747	Empirical evidence of disease activity thresholds used to indicate need for major therapeutic change in US veterans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 253.	1.6	0
1748	Methotrexate-Induced Pancytopenia and Mucositis Caused by Medication Error. <i>Ghana Medical Journal</i> , 2020, 54, 68-71.	0.1	5
1749	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
1750	Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019. <i>Arthritis Research and Therapy</i> , 2020, 22, 100.	1.6	11
1751	&lt;p&gt;Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis&lt;/p&gt;. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 213-222.	0.7	14
1752	Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. <i>Drug Safety</i> , 2020, 43, 711-725.	1.4	37
1753	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp's Usability Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3469.	1.2	5
1754	Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians. <i>Rheumatology and Therapy</i> , 2020, 7, 383-400.	1.1	14
1755	Periarticular osteophyte formation protects against total knee arthroplasty in rheumatoid arthritis patients with advanced joint damage. <i>Clinical Rheumatology</i> , 2020, 39, 3331-3339.	1.0	3
1756	Prevalence of Sexual Disorders in Patients With Rheumatoid Arthritis and Associated Factors. <i>Sexual Medicine</i> , 2020, 8, 510-516.	0.9	6

#	ARTICLE	IF	CITATIONS
1757	Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases. <i>JAMA Dermatology</i> , 2020, 156, 787.	2.0	45
1758	Ultrasound-targeted microbubble destruction augmented synergistic therapy of rheumatoid arthritis <i>via</i> targeted liposomes. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5245-5256.	2.9	30
1759	Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs). <i>Journal of Medical Economics</i> , 2020, 23, 1025-1031.	1.0	2
1760	DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability. <i>RMD Open</i> , 2020, 6, e001220.	1.8	33
1761	Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab. <i>Medicine (United States)</i> , 2020, 99, e20201.	0.4	3
1762	Biosimilars, a new era in rheumatology in Spain. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2020, 16, 131-132.	0.2	1
1763	Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2020, 40, 1873-1881.	1.5	4
1764	Effectiveness of duloxetine for remnant pain relief in patients with rheumatoid arthritis despite remission. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 288-292.	0.3	1
1765	Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 361-370.	0.6	1
1766	Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. <i>Joint Bone Spine</i> , 2020, 87, 475-479.	0.8	8
1767	Radiological Findings of the Cervical Spine in Rheumatoid Arthritis: What a Rheumatologist Should Know. <i>Current Rheumatology Reports</i> , 2020, 22, 19.	2.1	11
1768	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. <i>Rheumatology</i> , 2020, 59, 3458-3467.	0.9	6
1769	Treatment satisfaction with rheumatoid arthritis in patients with different disease severity and financial burden: A subgroup analysis of a nationwide survey in China. <i>Chinese Medical Journal</i> , 2020, 133, 892-898.	0.9	6
1770	Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and SjĀgrenĀ™s syndrome enrolled in a large observational US registry. <i>Rheumatology International</i> , 2020, 40, 1239-1248.	1.5	8
1771	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , The, 2020, 2, e347-e357.	2.2	51
1772	Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2020, 20, 784-791.	0.9	2
1773	Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232091602.	1.1	6
1774	Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies. <i>BMC Infectious Diseases</i> , 2020, 20, 359.	1.3	5

#	ARTICLE	IF	CITATIONS
1775	Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia—An interim report. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 803-810.	0.9	6
1776	Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. <i>Clinical Rheumatology</i> , 2020, 39, 3643-3652.	1.0	8
1777	Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study. <i>PLoS ONE</i> , 2020, 15, e0233159.	1.1	4
1778	Prevalence of Elbow Joint Arthritis and Enthesitis in Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1590.	1.0	6
1779	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. <i>Arthritis Research and Therapy</i> , 2020, 22, 139.	1.6	21
1781	Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab. <i>Joint Bone Spine</i> , 2020, 87, 596-602.	0.8	7
1782	A review of upadacitinib in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 779-787.	0.9	35
1783	Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis. <i>Systematic Reviews</i> , 2020, 9, 140.	2.5	6
1784	Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 457-471.	1.1	79
1785	Cumulative patient-based disease activity monitoring in rheumatoid arthritis “ predicts sustained remission, flare and treatment escalation. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 749-758.	1.6	1
1786	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. <i>BMC Rheumatology</i> , 2020, 4, 42.	0.6	10
1787	Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1890.	1.0	17
1788	Does methotrexate cause interstitial lung disease in rheumatoid arthritis: What is the evidence?. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 713-716.	0.9	4
1789	Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1174-1181.	0.5	25
1790	Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 358-365.	0.1	1
1791	Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 674-681.	0.7	39
1793	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 643-644.	1.6	6
1794	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091532.	1.2	6



#	ARTICLE	IF	CITATIONS
1795	Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 142.	1.6	24
1796	Traditional Chinese medicine on treating active rheumatoid arthritis. <i>Medicine (United States)</i> , 2020, 99, e20642.	0.4	8
1797	Methotrexate-loaded multifunctional nanoparticles with near-infrared irradiation for the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 146.	1.6	29
1798	A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. <i>Clinical Rheumatology</i> , 2020, 39, 2797-2802.	1.0	37
1799	Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. <i>Osteoporosis International</i> , 2020, 31, 2131-2139.	1.3	16
1800	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. <i>Arthritis Research and Therapy</i> , 2020, 22, 136.	1.6	16
1802	Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 389-396.	1.3	8
1803	Noninferiority Trials to Evaluate Drug Effects in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1258-1265.	2.9	3
1804	Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial. <i>Rheumatology and Therapy</i> , 2020, 7, 327-344.	1.1	25
1805	Adjunctive Chinese Herbal Products Therapy Reduces the Risk of Ischemic Stroke Among Patients With Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2020, 11, 169.	1.6	3
1806	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096.	1.8	3
1807	Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study. <i>BMC Rheumatology</i> , 2020, 4, 5.	0.6	4
1808	Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 250, 153-159.	0.5	6
1809	Successful abatacept treatment for Felty's syndrome in a patient with rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 168-170.	0.3	5
1810	Immunogenicity of TNF-Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 312.	2.2	94
1811	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.5	43
1812	Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database. <i>PLoS ONE</i> , 2020, 15, e0229998.	1.1	19
1813	Methotrexate and Oral Antirheumatic Drugs. <i>Juntendo Medical Journal</i> , 2020, 66, 27-33.	0.1	0

#	ARTICLE	IF	CITATIONS
1814	A novel indomethacin/methotrexate/MMP-9 siRNA <i>in situ</i> hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis. <i>Nanoscale</i> , 2020, 12, 8546-8562.	2.8	47
1815	Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 499-506.	0.5	66
1816	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 464-471.	0.5	14
1817	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102509.	2.5	13
1818	<p>&lt;p>Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis&lt;p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 43-56.	2.7	72
1819	Mixed methods study of a new model of care for chronic disease: co-design and sustainable implementation of group consultations into clinical practice. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa003.	0.3	6
1820	<p>ADAM17 Genetic Variants and the Response of TNF-̂± Inhibitor in Rheumatoid Arthritis Patients</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 81-88.	0.4	3
1821	Peripheral B Cell Subsets in Autoimmune Diseases: Clinical Implications and Effects of B Cell-Targeted Therapies. <i>Journal of Immunology Research</i> , 2020, 2020, 1-17.	0.9	22
1822	JAK Inhibitors: Prospects in Connective Tissue Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 334-351.	2.9	83
1823	Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 171-175.	0.3	2
1826	Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 556-565.	0.5	17
1827	Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. <i>Clinical Rheumatology</i> , 2020, 39, 2593-2601.	1.0	1
1828	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-. <i>Clinical Rheumatology</i> , 2020, 39, 2563-2572.	1.0	11
1829	Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 285-294.	0.5	3
1830	<p>Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 21-28.	0.8	14
1831	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 41.	1.6	10
1832	Folic acid alleviates side effects of methotrexate in arthritis patients with side effects despite folic acid supplementation: an observational cohort study. <i>Rheumatology</i> , 2020, 59, 3566-3568.	0.9	4
1833	Antitumour necrosis factor-̂± agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000349.	1.1	23

#	ARTICLE	IF	CITATIONS
1834	Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa013.	0.3	21
1835	A need for consensus guideline update: recommend explicit restriction of methotrexate in end-stage renal patients. <i>Rheumatology</i> , 2020, 59, e93-e94.	0.9	0
1836	All-Trans Retinoic Acid Inhibits Migration and Invasiveness of Rheumatoid Fibroblast-Like Synoviocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 372, 185-192.	1.3	6
1837	Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis. <i>Clinical Drug Investigation</i> , 2020, 40, 827-838.	1.1	6
1838	Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study. <i>Chinese Medical Journal</i> , 2020, 133, 1397-1403.	0.9	2
1839	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2017.	1.0	0
1840	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	1.5	35
1841	&lt;p&gt;Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1037-1047.	0.8	8
1842	Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. <i>BMJ</i> , The, 2020, 370, m2288.	3.0	39
1843	Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0235637.	1.1	18
1844	In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1272.	2.2	17
1845	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	2.9	126
1846	Nanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?. <i>Journal of Controlled Release</i> , 2020, 325, 380-393.	4.8	26
1847	Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis. <i>Medicine (United States)</i> , 2020, 99, e20824.	0.4	11
1848	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study. <i>BMC Rheumatology</i> , 2020, 4, 34.	0.6	2
1849	Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. <i>Rheumatology and Therapy</i> , 2020, 7, 517-535.	1.1	12
1850	Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity. <i>Frontiers in Immunology</i> , 2020, 11, 1336.	2.2	8
1851	Progress to Date in Advancing Stratified Medicine in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 619-626.	3.3	9

#	ARTICLE	IF	CITATIONS
1852	<p></p>Rheumatoid Arthritis as a Risk Factor for Coronary Artery Calcification and Obstructive Coronary Artery Disease in Patients with Chest Pain: A Registry Based Cross-Sectional Study</p><p></p>Clinical Epidemiology, 2020, Volume 12, 679-689.	1.5	7
1853	The influence of coffee intake and genetics on adenosine pathway in rheumatoid arthritis. Pharmacogenomics, 2020, 21, 735-749.	0.6	6
1854	JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules, 2020, 10, 1002.	1.8	97
1855	Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations. Annals of the Rheumatic Diseases, 2020, 79, 170-175.	0.5	29
1856	Serial magnetic resonance imaging and ultrasound examinations demonstrate differential inflammatory lesion patterns in soft tissue and bone upon patient-reported flares in rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 19.	1.6	8
1857	<p></p>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</p><p></p>. Patient Preference and Adherence, 2020, Volume 14, 119-131.	0.8	20
1858	Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clinical Rheumatology, 2020, 39, 1813-1822.	1.0	4
1859	A randomized controlled trial of the Effects of a telehealth educational intervention on medication adherence and disease activity in rheumatoid arthritis patients. Journal of Advanced Nursing, 2020, 76, 1172-1181.	1.5	22
1860	Association of a Type 2 "Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2020, 72, 1091-1102.	2.9	8
1861	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 744-759.	0.5	167
1862	Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-to-Target Strategies. Arthritis and Rheumatology, 2020, 72, 1072-1081.	2.9	7
1863	The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2090485.	1.2	9
1864	The occurrence of sacroiliitis in HLA-B*35-positive patients with undifferentiated spondyloarthritis. A cross sectional MRI study. Clinical Rheumatology, 2020, 39, 2299-2306.	1.0	3
1865	Chicken-or-egg question: Which came first, extracellular vesicles or autoimmune diseases?. Journal of Leukocyte Biology, 2020, 108, 601-616.	1.5	14
1866	The future of treatment in systemic sclerosis: can we design better trials?. Lancet Rheumatology, The, 2020, 2, e185-e194.	2.2	10
1867	Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population " the Nord-TrÅndelag Health Study. Scientific Reports, 2020, 10, 3593.	1.6	33
1868	Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis. Medicine (United States), 2020, 99, e19415.	0.4	9
1869	Anti-inflammatory Diet In Rheumatoid Arthritis (ADIRA)" a randomized, controlled crossover trial indicating effects on disease activity. American Journal of Clinical Nutrition, 2020, 111, 1203-1213.	2.2	90

#	ARTICLE	IF	CITATIONS
1871	Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. <i>Value in Health</i> , 2020, 23, 461-470.	0.1	16
1872	Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2020, 16, 116-119.	0.2	1
1873	Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 460-463.	0.5	6
1874	Baricitinib exposure during pregnancy in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X1989929.	1.2	29
1875	Acetabular cup migration after primary cementless total hip arthroplasty in rheumatoid arthritis and its influencing factors: a comparative study with osteoarthritic hip. <i>International Orthopaedics</i> , 2020, 44, 1047-1053.	0.9	7
1876	Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2020, 39, 2139-2150.	1.0	11
1877	Treatment strategies are more important than drugs in the management of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 1363-1368.	1.0	47
1878	Views on glucocorticoid therapy in rheumatology: the age of convergence. <i>Nature Reviews Rheumatology</i> , 2020, 16, 239-246.	3.5	71
1879	New Developments in Transcriptomic Analysis of Synovial Tissue. <i>Frontiers in Medicine</i> , 2020, 7, 21.	1.2	17
1880	What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2020, 37, 1479-1495.	1.3	12
1881	First in man study of [18F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 1047.	1.6	43
1882	Development and formative evaluation of patient research partner involvement in a multi-disciplinary European translational research project. <i>Research Involvement and Engagement</i> , 2020, 6, 6.	1.1	13
1883	Rheumatoid arthritis treatment in Brazil: data from a large real-life multicenter study. <i>Advances in Rheumatology</i> , 2020, 60, 16.	0.8	3
1884	Neuraxial Cytokines in Pain States. <i>Frontiers in Immunology</i> , 2019, 10, 3061.	2.2	88
1885	Moderate Risk of Hepatitis B Virus Reactivation in HBsAg <sup>+</sup> /HBcAb <sup>+</sup> Carriers Receiving Rituximab for Rheumatoid Arthritis. <i>Scientific Reports</i> , 2020, 10, 2456.	1.6	31
1886	Tumour necrosis factor alpha promotes secretion of 14-3-3 $\beta$ by inducing necroptosis in macrophages. <i>Arthritis Research and Therapy</i> , 2020, 22, 24.	1.6	16
1887	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.5	42
1888	Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0228852.	1.1	7

#	ARTICLE	IF	CITATIONS
1890	The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 312-315.	0.5	12
1891	Proportion de r�mission chez les patients atteints de polyarthrite rhumato�de suivis par des rhumatologues en pratique courante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 137-138.	0.0	0
1892	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 277.	1.0	44
1894	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. <i>Trials</i> , 2020, 21, 90.	0.7	14
1895	The Novel Synthetic Peptide AESIS-1 Exerts a Preventive Effect on Collagen-Induced Arthritis Mouse Model via STAT3 Suppression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 378.	1.8	4
1897	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	1.6	24
1898	The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis. <i>Rheumatology</i> , 2020, 59, 2471-2480.	0.9	33
1899	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors� data from a large national quality register. <i>Arthritis Research and Therapy</i> , 2020, 22, 15.	1.6	19
1900	Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2550-2555.	0.9	14
1901	Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies. <i>Clinical Drug Investigation</i> , 2020, 40, 197-209.	1.1	6
1902	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 316-324.	0.9	4
1904	Targets of biologic disease�modifying antirheumatic drugs and risk of multiple myeloma. <i>International Journal of Cancer</i> , 2020, 147, 1300-1305.	2.3	6
1905	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
1906	Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world. <i>PLoS ONE</i> , 2020, 15, e0227960.	1.1	8
1907	Association of High Serum Interleukin�6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1456-1466.	2.9	30
1908	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1227.	1.0	14
1909	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020, 116, 1666-1687.	1.8	1,074
1910	Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 96.	1.6	8

#	ARTICLE	IF	CITATIONS
1911	Quantitative Assessment of Arthritis Activity in Rheumatoid Arthritis Patients Using [11C]DPA-713 Positron Emission Tomography. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3137.	1.8	4
1912	Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. <i>Arthritis Research and Therapy</i> , 2020, 22, 97.	1.6	22
1913	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). <i>Journal of Rheumatology</i> , 2020, 47, 658-667.	1.0	7
1914	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1021-1028.	1.5	3
1916	Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey. <i>Rheumatology International</i> , 2020, 40, 1037-1044.	1.5	1
1917	Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. <i>Rheumatology and Therapy</i> , 2020, 7, 357-369.	1.1	4
1918	Precision medicine and management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 110, 102405.	3.0	56
1919	The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 423-431.	1.6	12
1920	Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 475-482.	1.9	36
1921	Comparing reactions to written leaflets, online information and real-time Doppler images among South Asian patients with rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa009.	0.3	2
1922	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. <i>Rheumatology</i> , 2020, 59, 3303-3313.	0.9	41
1923	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
1924	The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 472.	2.2	11
1925	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?. <i>Frontiers in Immunology</i> , 2020, 11, 589.	2.2	18
1926	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. <i>Journal of Clinical Medicine</i> , 2020, 9, 1082.	1.0	68
1927	Biosimilars: To switch or not to switch – that is the question. <i>Reumatologia</i> , 2020, 58, 1-3.	0.5	0
1928	Adalimumab-induced myasthenia gravis: case-based review. <i>Rheumatology International</i> , 2020, 40, 1891-1894.	1.5	8
1929	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , 2020, 16, 335-345.	3.5	369

#	ARTICLE	IF	CITATIONS
1930	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020, 6, e000536.	1.8	89
1931	Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 867-873.	0.5	13
1932	Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial. <i>Chinese Medicine</i> , 2020, 15, 36.	1.6	5
1933	Serum Neuropeptide Y Levels Are Associated with TNF- $\alpha$ Levels and Disease Activity in Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	0.9	10
1934	Precision Medicine With Leflunomide: Consideration of the <i>DHODH</i> Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 983-989.	1.5	8
1935	New galaxies in the universe of shared decision-making and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 273-278.	2.0	19
1936	Management issues in rheumatoid arthritis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 255-263.	2.0	39
1937	Synergistic Effects of Erzhi Pill Combined With Methotrexate on Osteoblasts Mediated via the Wnt1/LRP5/ $\beta$ 2-Catenin Signaling Pathway in Collagen-Induced Arthritis Rats. <i>Frontiers in Pharmacology</i> , 2020, 11, 228.	1.6	11
1938	New Therapeutic Targets in Autoimmune Cholangiopathies. <i>Frontiers in Medicine</i> , 2020, 7, 117.	1.2	22
1939	Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. <i>Rheumatology and Therapy</i> , 2020, 7, 371-382.	1.1	7
1940	Reconsidering the Role of Melatonin in Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2877.	1.8	29
1941	Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020, 37, 2356-2372.	1.3	35
1942	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101051.	0.2	4
1943	Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA). <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1414-1420.	1.6	3
1944	Are exercises beneficial for patients with rheumatoid arthritis of the hand? A Cochrane review summary with commentary. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 702-704.	0.9	0
1945	Treat-to-target in PsA: methods and necessity. <i>RMD Open</i> , 2020, 6, e001083.	1.8	27
1946	The risk of coronary artery disease in patients with rheumatoid arthritis using Chinese herbal products and conventional medicine in parallel: a population-based cohort study. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 100.	1.2	5
1947	Efficacy and Safety of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Rheumatoid Arthritis: A Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-15.	0.5	35



#	ARTICLE	IF	CITATIONS
1948	Effectiveness of Tocilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial. <i>Trials</i> , 2020, 21, 313.	0.7	4
1949	Rehabilitation in warm climate for young adults with inflammatory arthritis: A 12-month randomized controlled trial. <i>Journal of Rehabilitation Medicine</i> , 2020, 52, jrm00040.	0.8	2
1950	The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2299.	1.8	48
1951	Severe joint deformity and patient global assessment of disease are associated with discrepancies between sonographic and clinical remission: A cross-sectional study of rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2021, 31, 334-342.	0.9	8
1952	A Population-Based Approach to Reporting System-Level Performance Measures for Rheumatoid Arthritis Care. <i>Arthritis Care and Research</i> , 2021, 73, 640-648.	1.5	12
1953	Biologics in atopic disease in pregnancy: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 71-89.	2.7	41
1954	Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. <i>Arthritis Care and Research</i> , 2021, 73, 873-884.	1.5	4
1955	Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors. <i>Modern Rheumatology</i> , 2021, 31, 80-87.	0.9	0
1956	Comment on: what is the best treatment for early rheumatoid arthritis?. <i>Rheumatology</i> , 2021, 60, e177-e178.	0.9	0
1957	Are Health Care Professionals'™ Implicit and Explicit Attitudes Toward Conventional Disease-Modifying Antirheumatic Drugs Associated With Those of Their Patients?. <i>Arthritis Care and Research</i> , 2021, 73, 364-373.	1.5	3
1958	Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 163-177.	1.1	6
1959	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
1960	Assessment of discordance of treatment satisfaction between patients with rheumatoid arthritis in low disease activity or in remission and their treating physicians: A cross-sectional survey. <i>Modern Rheumatology</i> , 2021, 31, 326-333.	0.9	6
1961	Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 123-132.	1.0	1
1962	Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 17-28.	2.7	14
1963	Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. <i>Clinical Rheumatology</i> , 2021, 40, 85-91.	1.0	20
1964	Efficacy and safety of tacrolimus in patients with rheumatoid arthritis – A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2021, 31, 61-69.	0.9	8
1965	Risk factors for cervical spine instability in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 547-555.	1.0	11

#	ARTICLE	IF	CITATIONS
1966	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021, 60, 125-131.	0.9	6
1967	Methotrexate and rheumatoid arthritis associated interstitial lung disease. <i>European Respiratory Journal</i> , 2021, 57, 2000337.	3.1	114
1968	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. <i>Modern Rheumatology</i> , 2021, 31, 53-60.	0.9	2
1969	Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohort. <i>Rheumatology</i> , 2021, 60, 1863-1870.	0.9	5
1970	A practical guide to interpreting and applying systematic reviews of qualitative studies in rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 28-35.	0.9	3
1971	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021, 60, 73-80.	0.9	3
1972	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
1973	Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. <i>Rheumatology</i> , 2021, 60, 346-352.	0.9	45
1974	Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 495-503.	1.0	7
1975	Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 96-102.	0.5	35
1976	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	0.9	14
1977	Intra-articular injection of etanercept versus glucocorticoids in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2021, 40, 557-564.	1.0	11
1978	Qualitative Research in Rheumatology: An Overview of Methods and Contributions to Practice and Policy. <i>Journal of Rheumatology</i> , 2021, 48, 6-15.	1.0	10
1979	Efficacy and Safety of E6011, an Anti-IL-6 Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 587-595.	2.9	17
1980	Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. <i>Joint Bone Spine</i> , 2021, 88, 105060.	0.8	6
1982	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
1983	Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. <i>Rheumatology</i> , 2021, 60, 1708-1716.	0.9	4
1984	RANKL as a therapeutic target of rheumatoid arthritis. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 106-112.	1.3	30

#	ARTICLE	IF	CITATIONS
1985	Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China. <i>Clinical Rheumatology</i> , 2021, 40, 1789-1798.	1.0	7
1986	Challenges for biosimilars: focus on rheumatoid arthritis. <i>Critical Reviews in Biotechnology</i> , 2021, 41, 121-153.	5.1	14
1987	Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2021, 48, 804-812.	1.0	12
1988	A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 1659-1668.	0.9	27
1989	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 286-292.	0.5	35
1990	Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait. <i>Clinical Rheumatology</i> , 2021, 40, 1759-1765.	1.0	5
1991	Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients. <i>Joint Bone Spine</i> , 2021, 88, 105057.	0.8	4
1992	Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: results of a pilot study. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 20-27.	0.6	54
1993	Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature. <i>Clinical Rheumatology</i> , 2021, 40, 1881-1887.	1.0	14
1994	A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 167-181.	1.1	6
1995	Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. <i>Rheumatology</i> , 2021, 60, 2375-2382.	0.9	19
1996	Impact of a risk-sharing agreement in rheumatoid arthritis in Spain. <i>Health Policy</i> , 2021, 125, 335-340.	1.4	5
1997	A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East. <i>Rheumatology and Therapy</i> , 2021, 8, 1-16.	1.1	35
1998	Effect of radiographic disease severity in high-resolution quantitative computed tomography assessment of metacarpophalangeal joint erosion and cysts. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 112-119.	0.9	2
1999	Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. <i>Rheumatology and Therapy</i> , 2021, 8, 41-61.	1.1	35
2000	The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 931-942.	2.9	78
2001	What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. <i>Patient</i> , 2021, 14, 505-532.	1.1	2
2002	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102735.	2.5	135

#	ARTICLE	IF	CITATIONS
2003	Le risque d'admission hospitalisation évitable avant et après le diagnostic chez des patients atteints de polyarthrite rhumatoïde comparativement à des témoins sans polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 40-48.	0.0	0
2004	Feasibility and estimated efficacy of blood flow restricted training in female patients with rheumatoid arthritis: a randomized controlled pilot study. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 169-177.	0.6	7
2005	Fluorescence optical imaging in patients with active rheumatoid arthritis: a comparison with ultrasound and an association with biomarkers. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 95-103.	0.6	6
2006	Screening of dental and sinus infections in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13437.	1.7	1
2007	The patient perspective of nurse-led care in early rheumatoid arthritis: A systematic review of qualitative studies with thematic analysis. <i>Journal of Clinical Nursing</i> , 2021, 30, 145-160.	1.4	12
2008	Methotrexate reduces keratinocyte proliferation, migration and induces apoptosis in HaCaT keratinocytes in vitro and reduces wound closure in Skh1 mice in vivo. <i>Journal of Tissue Viability</i> , 2021, 30, 51-58.	0.9	4
2009	Post-marketing surveillance of high-dose methotrexate (>8mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use. <i>Modern Rheumatology</i> , 2021, 31, 575-586.	0.9	3
2010	Methotrexate osteopathy: five cases and systematic literature review. <i>Osteoporosis International</i> , 2021, 32, 225-232.	1.3	16
2011	Gaps between research and recommendations in rheumatoid arthritis. <i>Rheumatology International</i> , 2021, 41, 57-66.	1.5	0
2012	Dose tapering of biologic agents in patients with rheumatoid arthritis—results from a cohort study in Germany. <i>Clinical Rheumatology</i> , 2021, 40, 887-893.	1.0	1
2013	Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2021, 40, 877-886.	1.0	7
2014	Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corona registry data. <i>Rheumatology International</i> , 2021, 41, 381-390.	1.5	10
2015	Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report. <i>Modern Rheumatology</i> , 2021, 31, 514-517.	0.9	0
2017	Adherence with methotrexate in polish patients—Survey research results. <i>International Journal of Clinical Practice</i> , 2021, 75, e13677.	0.8	0
2018	Model-Based Meta-Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 517-527.	2.3	6
2019	High Levels of Polypharmacy in Rheumatoid Arthritis—A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study. <i>Journal of Pharmacy Practice</i> , 2021, 34, 365-371.	0.5	15
2021	LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1-8.	1.4	1
2022	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. <i>Modern Rheumatology</i> , 2021, 31, 42-52.	0.9	6

#	ARTICLE	IF	CITATIONS
2023	Update of the Mexican College of Rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 215-228.	0.2	2
2025	Measuring inflammatory arthritis in patients with systemic lupus erythematosus using clinical disease activity index. <i>Indian Journal of Rheumatology</i> , 2021, 16, 9.	0.2	0
2026	Cycling of tumor necrosis factor inhibitors <i>versus</i> switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110026.	1.2	14
2028	Romatoid artrit tedavi prensipleri: Neye geĀsiĀy yapalĀm?. <i>Ege TĀp Dergisi</i> , 0, , 42-43.	0.1	1
2029	Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110118.	1.2	9
2030	Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 21.	0.8	5
2031	Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-Ā, IL-1Ā, IL-10 and IL-17A. <i>PLoS ONE</i> , 2021, 16, e0246111.	1.1	15
2032	Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. <i>Drugs</i> , 2021, 81, 349-366.	4.9	20
2033	A new approach for identifying positional isomers of glycans cleaved from monoclonal antibodies. <i>Analyst</i> , The, 2021, 146, 4789-4795.	1.7	15
2034	Development of an Educational Video for Self-Assessment of Patients with RA: Steps, Challenges, and Responses. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 66.	0.3	6
2035	Rheumatologic Rehabilitation. , 2021, , 606-626.e1.		3
2036	Romatoid Artrit HastalarĀn Metotreksat KullanĀmĀ ile Ālgili FarkĀndalĀklarĀ. <i>UludaĀ Āeniversitesi TĀp FakĀltesi Dergisi</i> , 0, , .	0.2	0
2037	Rheumatoide Arthritis Ā PrĀvalenz, Bedeutung und Implikationen fĀr die PrĀvention und GesundheitsfĀrderung. <i>The Springer Reference Pflēgerapie, Gesundheit</i> , 2021, , 831-840.	0.2	0
2038	<i>Guizhi-Shaoyao-Zhimu</i> decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NFĀB signalling to suppress osteoclastogenesis. <i>Pharmaceutical Biology</i> , 2021, 59, 260-272.	1.3	8
2039	Selected psychological factors and medication adherence in patients with rheumatoid arthritis. <i>Reumatologia</i> , 2021, 59, 90-97.	0.5	8
2040	Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 401-413.	2.9	11
2041	Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. <i>Rheumatology</i> , 2021, 60, vi12-vi20.	0.9	26
2042	Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225.	1.2	11

#	ARTICLE	IF	CITATIONS
2043	Head-to-head trials in inflammatory arthritis. <i>Joint Bone Spine</i> , 2021, 88, 105004.	0.8	0
2044	Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 111-117.	0.8	12
2045	Remisyonda olan romatoid artritli hastada tedavi kararları. <i>Ege Tıp Dergisi</i> , 0, , 44-48.	0.1	0
2046	Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab004.	0.3	2
2047	Formulation and Characterization of Alginate-Based Membranes for the Potential Transdermal Delivery of Methotrexate. <i>Polymers</i> , 2021, 13, 161.	2.0	29
2048	Treatment expectations as a possible prognostic factor for DMARD response in rheumatoid arthritis: a prospective cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110158.	1.2	1
2049	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis: an international survey within the GLORIA study. <i>Rheumatology</i> , 2021, 60, 3334-3342.	0.9	13
2050	Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110248.	1.2	4
2051	OUP accepted manuscript. <i>Rheumatology</i> , 2021, , .	0.9	0
2052	Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. <i>Rheumatology</i> , 2022, 61, 2307-2315.	0.9	14
2053	Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. <i>Clinical Rheumatology</i> , 2021, 40, 2779-2789.	1.0	10
2054	Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199956.	1.2	15
2055	Quality Indicators for Evaluating the Health Care of Patients with Rheumatoid Arthritis: a Korean Expert Consensus. <i>Journal of Korean Medical Science</i> , 2021, 36, e109.	1.1	3
2056	Frequency of anergy in a group of patients with rheumatoid arthritis on immunosuppressive therapy. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2021, 28, 16-27.	0.1	0
2057	Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 838-854.	0.3	8
2058	The number of risk factors for persistent disease determines the clinical course of early arthritis. <i>Rheumatology</i> , 2021, 60, 3617-3627.	0.9	3
2059	SPECT imaging and highly efficient therapy of rheumatoid arthritis based on hyperbranched semiconducting polymer nanoparticles. <i>Biomaterials Science</i> , 2021, 9, 1845-1854.	2.6	10
2060	Biosimilars in der pädiatrischen Rheumatologie. <i>Springer Reference Medizin</i> , 2021, , 1-6.	0.0	0

#	ARTICLE	IF	CITATIONS
2061	Frequency of anergy in a group of patients with rheumatoid arthritis on immunosuppressive therapy. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 16-27.	0.0	0
2062	Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 297-308.	0.4	11
2063	Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study. <i>Rheumatology</i> , 2021, 60, 5567-5575.	0.9	5
2064	Upadacitinib improves patient-reported outcomes <i>vs</i> placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. <i>Rheumatology</i> , 2021, 60, 5583-5594.	0.9	17
2065	Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1485-1488.	0.7	0
2066	Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 640070.	2.2	6
2067	The role of extracellular vesicles in rheumatoid arthritis: a systematic review. <i>Clinical Rheumatology</i> , 2021, 40, 3481-3497.	1.0	15
2068	COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China. <i>MedComm</i> , 2021, 2, 82-90.	3.1	7
2069	Phenotype and treatment of elderly onset compared with younger-onset rheumatoid arthritis patients in international daily practice. <i>Rheumatology</i> , 2021, 60, 4801-4810.	0.9	7
2070	Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 639-648.	1.3	3
2071	Review of Wearable Sensor-Based Health Monitoring Glove Devices for Rheumatoid Arthritis. <i>Sensors</i> , 2021, 21, 1576.	2.1	44
2072	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2021, 31, 783-789.	0.9	11
2073	Musculoskeletal ultrasound using superb microvascular imaging documents treatment response to biosimilar infliximab in rheumatoid arthritis. <i>BMJ Case Reports</i> , 2021, 14, e239112.	0.2	1
2074	Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina. <i>Reumatología Clínica</i> , 2021, , .	0.2	0
2075	Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e381-e383.	1.3	4
2076	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	1.6	18
2077	Predictors of joint damage in patients with rheumatoid arthritis: focus on short- and long-term effects of intra-articular glucocorticoid injections. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1515-1526.	0.7	1
2078	Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial. <i>International Immunopharmacology</i> , 2021, 91, 107263.	1.7	0

#	ARTICLE	IF	CITATIONS
2079	Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 145-153.	0.7	9
2080	Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Patient Preference and Adherence, 2021, Volume 15, 359-373.	0.8	24
2081	Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study. Modern Rheumatology, 2021, 31, 796-802.	0.9	1
2082	Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use. Journal of Rheumatology, 2021, 48, 1504-1507.	1.0	11
2083	Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Research and Therapy, 2021, 23, 67.	1.6	29
2084	Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. Drug Safety, 2021, 44, 515-530.	1.4	28
2085	Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort. Rheumatology, 2021, 60, 5576-5582.	0.9	4
2086	Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporosis International, 2021, 32, 1621-1629.	1.3	26
2087	Evaluation of Rheumatology Workforce Supply Changes in Ontario, Canada, from 2000 to 2030. Healthcare Policy, 2021, 16, 119-135.	0.3	11
2088	Disease activity and its predictors in early inflammatory arthritis: findings from a national cohort. Rheumatology, 2021, 60, 4811-4820.	0.9	8
2089	The Story Behind the Use of Glucocorticoids in the Treatment of Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 15-19.	1.6	12
2090	Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Research and Therapy, 2021, 23, 96.	1.6	12
2092	Tofacitinib-induced Ramsay-Hunt Syndrome in a Patient with Rheumatoid Arthritis. Current Drug Safety, 2021, 16, 107-109.	0.3	3
2093	Systemic diseases and the cornea. Experimental Eye Research, 2021, 204, 108455.	1.2	46
2094	Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients. Rheumatology, 2021, 60, 5765-5774.	0.9	4
2095	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. Pain and Therapy, 2021, 10, 287-314.	1.5	37
2096	Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure. Rheumatology and Therapy, 2021, 8, 775-791.	1.1	5
2097	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. Scientific Reports, 2021, 11, 7266.	1.6	21



#	ARTICLE	IF	CITATIONS
2099	Prognostic Factors for Radiographic Progression in Patients with Seronegative Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2021, 11, 184.	1.1	5
2100	Performance of ultrasound to assess erosion progression in rheumatoid arthritis. <i>European Journal of Radiology</i> , 2021, 136, 109536.	1.2	1
2101	Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-42.	0.9	0
2102	The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. <i>Advances in Therapy</i> , 2021, 38, 2077-2093.	1.3	16
2103	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. <i>Pharmaceuticals</i> , 2021, 14, 251.	1.7	2
2104	A Review on Rheumatoid Arthritis Interventions and Current Developments. <i>Current Drug Targets</i> , 2021, 22, 463-483.	1.0	8
2105	Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1090-1099.	1.0	5
2106	Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECORD-linkage On Rheumatic Disease study on administrative healthcare databases. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 333-342.	0.6	4
2107	Acid Sphingomyelinase and Acid Î²-Glucosidase 1 Exert Opposite Effects on Interleukin-1Î²-Induced Interleukin 6 Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. <i>Inflammation</i> , 2021, 44, 1592-1606.	1.7	5
2108	The role of imaging in predicting the development of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 27-33.	0.2	3
2109	Effectiveness of a Second Biologic After Failure of a Non-“tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1512-1518.	1.0	5
2110	“Lost time”™. Patients with early inflammatory/rheumatoid arthritis and their experiences of delays in Primary Care. <i>Musculoskeletal Care</i> , 2021, 19, 495-503.	0.6	2
2111	MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE. <i>Rheumatology</i> , 2021, 61, 270-280.	0.9	5
2112	Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 445-454.	0.6	8
2113	Bone Erosions Detected by Ultrasound Are Prognostic for Clinical Arthritis Development in Patients With ACPA and Musculoskeletal Pain. <i>Frontiers in Medicine</i> , 2021, 8, 653994.	1.2	4
2114	Efficacy and safety of Guizhi-Shaoyao-Zhimu decoction in the treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e24416.	0.4	2
2115	Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: A Review. <i>Drug, Healthcare and Patient Safety</i> , 2021, Volume 13, 81-94.	1.0	11
2116	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. <i>Autoimmunity Reviews</i> , 2021, 20, 102750.	2.5	36

#	ARTICLE	IF	CITATIONS
2117	Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 729-750.	1.1	6
2118	Carbon Nanotubes as Potent Carriers for Targeted Drug Delivery in Rheumatoid Arthritis. <i>Pharmaceutics</i> , 2021, 13, 453.	2.0	23
2119	Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , 2021, 23, 171-182.	1.3	7
2120	Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including HandScan (Optical Spectral Transmission) Scores. <i>Arthritis Care and Research</i> , 2022, 74, 1493-1499.	1.5	3
2121	2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 1-14.	0.2	9
2122	Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 751-760.	0.8	9
2124	Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2021, 40, 4007-4017.	1.0	2
2125	Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. <i>Rheumatology</i> , 2021, 61, 131-138.	0.9	8
2126	Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00744.	1.1	0
2127	Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 57-62.	0.8	1
2128	Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China. <i>Rheumatology and Therapy</i> , 2021, 8, 863-876.	1.1	3
2129	Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial. <i>ELife</i> , 2021, 10, .	2.8	22
2130	Operationalizing Treat-to-Target for Osteoporosis. <i>Endocrinology and Metabolism</i> , 2021, 36, 270-278.	1.3	5
2131	Diagnostic and therapeutic delay in Rheumatoid Arthritis patients: Impact on disease outcome. <i>Pakistan Journal of Medical Sciences</i> , 2021, 37, 1001-1007.	0.3	9
2132	Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0248866.	1.1	21
2133	On- and off-label use of rituximab in rheumatic diseases. <i>Beyond Rheumatology</i> , 2021, 3, .	0.3	0
2134	Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2021, 17, 101-108.	0.4	0
2135	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	1.0	3

#	ARTICLE	IF	CITATIONS
2136	Treat-to-target strategy in patients with rheumatoid arthritis: Audit of adherence from real world clinical data. <i>ReumatologĀa ClĀnica</i> , 2021, 17, 212-214.	0.2	5
2137	Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs. <i>Reumatismo</i> , 2021, 73, 5-14.	0.4	1
2138	Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 372.	0.8	4
2139	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. <i>Rheumatology International</i> , 2021, 41, 1189-1202.	1.5	20
2140	Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 997-1003.	0.5	15
2141	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	3.5	57
2142	Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e563-e567.	0.5	4
2143	Artritis reumatoide: Tratamiento. <i>Medicine</i> , 2021, 13, 1681-1693.	0.0	1
2144	Treat-to-target strategy in patients with rheumatoid arthritis: Audit of adherence from real world clinical data. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 212-214.	0.2	0
2145	Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naĀve to DMARDs. <i>Medicine (United States)</i> , 2021, 100, e25481.	0.4	7
2146	Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , 2021, 60, 4001-4017.	0.9	17
2147	Adiponectin Deregulation in Systemic Autoimmune Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4095.	1.8	11
2148	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. <i>Minerva Medica</i> , 2021, 112, 246-254.	0.3	2
2150	Rheumatoid arthritis related interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 485-497.	1.3	18
2151	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. <i>Current Medical Research and Opinion</i> , 2021, 37, 929-938.	0.9	9
2152	TGFB1 (rs1800470 and rs1800469) variants are independently associated with disease activity and autoantibodies in rheumatoid arthritis patients. <i>Clinical and Experimental Medicine</i> , 2022, 22, 37-45.	1.9	4
2153	Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1107-1119.	0.8	4
2154	COVIDĀ€19 in DMARDĀ€treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 199-209.	1.0	9

#	ARTICLE	IF	CITATIONS
2155	Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 313-322.	0.9	7
2156	The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume. <i>Rheumatology</i> , 2022, 61, 787-793.	0.9	3
2157	Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2021, 40, 3989-4005.	1.0	2
2158	LncRNA FOXD2-AS1 promotes cell proliferation and invasion of fibroblast-like synoviocytes by regulation of miR-331-3p/PIAS3 pathway in rheumatoid arthritis. <i>Autoimmunity</i> , 2021, 54, 254-263.	1.2	19
2159	Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting. <i>Rheumatology International</i> , 2021, 41, 1253-1261.	1.5	31
2160	Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1135-1144.	2.9	6
2161	Bisphosphonates in inflammatory rheumatic diseases. <i>Bone</i> , 2021, 146, 115887.	1.4	9
2162	Diagnostic accuracy of high-resolution peripheral quantitative computed tomography and X-ray for classifying erosive rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 963-973.	0.9	6
2163	Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis. <i>Internal Medicine</i> , 2021, 60, 1359-1367.	0.3	3
2164	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CTâ€P17 (40â€mg/0.4â€mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4323-4333.	1.1	7
2167	Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 669382.	2.2	33
2168	The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. <i>Frontiers in Pharmacology</i> , 2021, 12, 680043.	1.6	62
2169	A Critical Look at Raceâ€Based Practices in Rheumatology Guidelines. <i>Arthritis Care and Research</i> , 2022, 74, 1602-1607.	1.5	3
2170	Natural medicine delivery from biomedical devices to treat bone disorders: A review. <i>Acta Biomaterialia</i> , 2021, 126, 63-91.	4.1	37
2171	Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Current Rheumatology Reviews</i> , 2021, 17, 184-192.	0.4	3
2172	Therapeutic effect of various ginsenosides on rheumatoid arthritis. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 149.	1.2	12
2173	Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 349-358.	0.7	4
2174	Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice. <i>Clinical and Experimental Immunology</i> , 2021, 205, 169-181.	1.1	0

#	ARTICLE	IF	CITATIONS
2175	Systematic Review and Metaanalysis of the Reproducibility of Patient Self-reported Joint Counts in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201439.	1.0	5
2176	Intermetatarsal Bursitis, a Novel Feature of Juxtaarticular Inflammation in Early Rheumatoid Arthritis Related to Clinical Signs: Results of a Longitudinal Magnetic Resonance Imaging Study. <i>Arthritis Care and Research</i> , 2022, 74, 1713-1722.	1.5	9
2177	Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2021, 8, 67-72.	1.3	4
2178	Clinical management and discontinuation of treatment in patients with recent onset rheumatoid arthritis in a rheumatology consultation. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 18, 77-83.	0.2	1
2179	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1744.	3.8	83
2180	A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 4450-4462.	0.9	6
2181	Dairy Consumption: Does It Make an Impact on Self-Reported Disease Activity of Inflammatory Arthritis?. <i>Cureus</i> , 2021, 13, e15010.	0.2	0
2182	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1493-1508.	1.3	27
2183	EULAR recommendations for intra-articular therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1299-1305.	0.5	42
2184	Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2021, 88, 105124.	0.8	6
2185	Determinants of first-line biological treatment in patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e25943.	0.4	2
2186	POS1423Ā€ĀLIFESTYLE HABITS IN PATIENTS WITH RHEUMATOID ARTHRITIS Ā€Ā A CROSS SECTIONAL STUDY ON TWO SCANDINAVIAN COHORTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 994.1-995.	0.5	0
2187	Influence of Age and Sex on Disease Course and Treatment in Rheumatoid Arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 123-138.	0.8	27
2188	Effectiveness of intravenous tocilizumab in routine clinical practice in a cohort of Costa Rican patients with rheumatoid arthritis. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 329-334.	0.2	0
2189	Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis. <i>Clinical Rheumatology</i> , 2021, 40, 3143-3151.	1.0	6
2190	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	1.8	12
2191	Adverse effects of biologic anti-inflammatory agents on the respiratory system: A review. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 27, 54.	0.3	2
2192	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. <i>Trials</i> , 2021, 22, 406.	0.7	1

#	ARTICLE	IF	CITATIONS
2193	Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. <i>Rheumatology</i> , 2021, 60, 4972-4981.	0.9	7
2194	Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea. <i>Archives of Rheumatology</i> , 2021, 36, 499-509.	0.3	3
2195	Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. <i>ReumatologĀa ClĀnica</i> , 2021, 17, 335-342.	0.2	3
2196	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. <i>CJC Open</i> , 2021, 3, 1257-1272.	0.7	18
2197	Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network. <i>PLoS ONE</i> , 2021, 16, e0252289.	1.1	18
2198	Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 335-342.	0.2	0
2199	Impact of sustained remission on quality of life among women with rheumatoid arthritis and systemic lupus erythematosus: a prospective observational study. <i>Egyptian Rheumatology and Rehabilitation</i> , 2021, 48, .	0.2	1
2200	Novel Compound Q-1 Alleviates Type II Collagen-Induced Arthritis in Rats through the NF-ĤB Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-7.	0.5	1
2201	Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1636-1643.	0.6	34
2202	Cross-Cultural Validation of the 5-Item Compliance Questionnaire for Rheumatology to the Arabic Language in Patients with Rheumatoid Arthritis. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1461-1467.	0.8	3
2203	Factors associated with rs1801394 of the methionine synthase reductase gene polymorphism in patients with rheumatoid arthritis. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 15-19.	0.1	1
2204	RecomendaĀo e seguranĀa da vacinaĀo em pacientes com artrite reumatoide utilizando tratamento imunossupressor. <i>Research, Society and Development</i> , 2021, 10, e23910716440.	0.0	0
2205	Quantifying Potential Cost-Savings Through an Alternative Imaging-Based Diagnostic Process in Presumptive Seronegative Rheumatoid Arthritis. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 519-529.	0.7	3
2206	Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1680-1689.	0.9	22
2207	Treat-to-target in axial spondyloarthritis: an observational study in daily practice. <i>Rheumatology</i> , 2022, 61, 1396-1407.	0.9	5
2208	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 607-617.	1.6	3
2209	Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral NaĤve B Cells in Patients With Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 683990.	1.2	1
2210	Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. <i>European Respiratory Review</i> , 2021, 30, 210011.	3.0	104

#	ARTICLE	IF	CITATIONS
2211	The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28). <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021, 32, 675-680.	0.7	0
2212	Resultados de gesti3n en una cohorte de pacientes con artritis reumatoide en una instituci3n de atenci3n integral especializada en Colombia. <i>Revista Colombiana De ReumatologAa</i> , 2021, , .	0.0	0
2213	An Efficient CNN for Hand X-Ray Classification of Rheumatoid Arthritis. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.1	9
2214	Efectividad del tocilizumab intravenoso en la pr3ctica cl3nica usual de una cohorte de pacientes costarricenses con artritis reumatoide. <i>ReumatologAa Cl3nica</i> , 2021, 17, 329-334.	0.2	0
2215	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. <i>Scientific Reports</i> , 2021, 11, 11525.	1.6	10
2216	Sustained Remission in Rheumatoid Arthritis: Time to Withdraw Treatment?. <i>ACR Open Rheumatology</i> , 2021, 3, 578-580.	0.9	0
2217	Korean Domestic Trends in Clinical Research on Rheumatoid Arthritis since 2008. <i>Journal of Korean Medicine Rehabilitation</i> , 2021, 31, 18-29.	0.2	0
2218	Recommendations for the pragmatic use of ultrasound in rheumatoid arthritis by the GEISPER French group. <i>Joint Bone Spine</i> , 2021, 88, 105187.	0.8	9
2219	Switching from TNF± inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNF± inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial. <i>Arthritis Research and Therapy</i> , 2021, 23, 182.	1.6	1
2221	Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China. <i>Annals of Translational Medicine</i> , 2021, 9, 1165-1165.	0.7	3
2222	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 2033-2041.	1.5	6
2223	Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021, 10, 205.	2.5	2
2224	Neutrophil count reduction 1Âmonth after initiating tocilizumab can predict clinical remission within 1Âyear in rheumatoid arthritis patients. <i>Rheumatology International</i> , 2022, 42, 1983-1991.	1.5	4
2225	Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1371-1382.	1.1	8
2226	Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan. <i>Frontiers in Pharmacology</i> , 2021, 12, 628548.	1.6	4
2227	The Development of the Rheumatology Informatics System for Effectiveness Learning Collaborative for Improving Patientâ€Reported Outcome Collection and Patientâ€Centered Communication in Adult Rheumatology. <i>ACR Open Rheumatology</i> , 2021, 3, 690-698.	0.9	5
2228	Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. <i>Pharmacological Research</i> , 2021, 169, 105618.	3.1	23
2229	Predictive analytics for step-up therapy: Supervised or semi-supervised learning?. <i>Journal of Biomedical Informatics</i> , 2021, 119, 103842.	2.5	7

#	ARTICLE	IF	CITATIONS
2230	Association of health-related quality of life with self-management and satisfaction of relationship with healthcare professionals in female patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 114-120.	0.9	1
2231	Clinical, Radiologic, and Functional Outcomes Following Methotrexate Withdrawal in Etanercept-Treated Patients with Active Early Rheumatoid Arthritis: A Subanalysis of COMET Year 2 by Week 52 DAS28 Status. <i>Open Rheumatology Journal</i> , 2021, 15, 31-38.	0.1	0
2232	Frailty as a novel predictor of achieving comprehensive disease control (CDC) in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4869-4877.	1.0	5
2233	The Importance of Outcome Measures in the Management of Inflammatory Rheumatic Diseases. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 191-200.	0.8	2
2234	Small intestinal follicular lymphoma induced by methotrexate: a case report. <i>BMC Gastroenterology</i> , 2021, 21, 280.	0.8	2
2235	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1522-1529.	0.5	46
2236	“œIt is as if you were taking a shot in the dark” Experiencing ambiguity in the pharmacological treatment of rheumatoid arthritis. <i>Research, Society and Development</i> , 2021, 10, e0110917071.	0.0	0
2237	Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. <i>Global &amp; Regional Health Technology Assessment</i> , 0, 8, 69-79.	0.2	1
2238	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. <i>BMC Rheumatology</i> , 2021, 5, 22.	0.6	4
2239	Association of Leptin Levels and Disease Activity in Patients with Early Rheumatoid Arthritis. <i>Archives of Medical Research</i> , 2021, 52, 544-553.	1.5	7
2240	Switching TNF± inhibitors: Patterns and determinants. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00843.	1.1	3
2241	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. <i>Rheumatology International</i> , 2021, 41, 1915-1924.	1.5	1
2242	Efectividad y seguridad en el manejo de enfermedades inflamatorias crÃ³nicas con medicamentos biosimilares de etanercept e infliximab en pacientes colombianos. <i>Revista Colombiana De ReumatologÃa</i> , 2021, , .	0.0	0
2243	Filgotinib in Rheumatoid Arthritis: A Profile of Its Use. <i>Clinical Drug Investigation</i> , 2021, 41, 741-749.	1.1	10
2244	CS-semi5 Inhibits NF-Î²B Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis. <i>Frontiers in Pharmacology</i> , 2021, 12, 655101.	1.6	5
2246	Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2022, 61, 1448-1458.	0.9	12
2247	Corticosteroid injections in the temporomandibular joint temporarily alleviate pain and improve function in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4853-4860.	1.0	3
2248	Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13Âyears. <i>Scientific Reports</i> , 2021, 11, 15051.	1.6	13



#	ARTICLE	IF	CITATIONS
2249	Patient's experiences of the barriers and facilitators to Methotrexate. <i>Musculoskeletal Care</i> , 2022, 20, 158-166.	0.6	6
2251	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021, 42, 4389-4400.	1.0	61
2252	Guideline for the evaluation of prescription appropriateness. <i>Annals of Translational Medicine</i> , 2021, 9, 1352-1352.	0.7	1
2253	Immunopathogenic mechanisms of rheumatoid arthritis and the use of anti-inflammatory drugs. <i>Intractable and Rare Diseases Research</i> , 2021, 10, 154-164.	0.3	7
2254	Interleukin-6 and Serum/Fecal Calprotectin as Useful Specific Markers for Monitoring Rheumatic Diseases: A Pilot Study. <i>Laboratory Medicine</i> , 2021, , .	0.8	1
2255	Increased Levels of Omega-3 Fatty Acids and DHA Are Linked to Pain Reduction in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors. <i>Nutrients</i> , 2021, 13, 3050.	1.7	11
2256	Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2021-220750.	0.5	12
2257	The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis. <i>Rheumatology</i> , 2022, 61, 531-541.	0.9	2
2258	Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8490.	1.2	3
2259	Protein based nanomedicine: Promising therapeutic modalities against inflammatory disorders. <i>Nano Select</i> , 2022, 3, 733-750.	1.9	2
2260	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
2261	Targeted and activatable nanosystem for fluorescent and optoacoustic imaging of immune-mediated inflammatory diseases and therapy via inhibiting NF- $\kappa$ B/NLRP3 pathways. <i>Bioactive Materials</i> , 2022, 10, 79-92.	8.6	8
2262	Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1585-1601.	1.1	5
2263	Exploring the role of monocyte chemoattractant protein-1 in fibroblast-like synovial cells in rheumatoid arthritis. <i>PeerJ</i> , 2021, 9, e11973.	0.9	1
2264	Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia. <i>Clinical Rheumatology</i> , 2022, 41, 53-62.	1.0	7
2265	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	1.6	25
2266	Patterns of Response to Different Treatment Strategies in Seropositive Rheumatoid Arthritis Patients in a Tertiary Hospital in South-Western Saudi Arabia: A Retrospective Study. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 239-246.	0.8	1
2267	Effects of hydroalcoholic extract of <i>Berberis integerrima</i> on the clinical signs, hs-CRP, TNF $\alpha$ , and ESR in active rheumatoid arthritis patients. <i>Journal of Herbal Medicine</i> , 2021, 28, 100444.	1.0	2

#	ARTICLE	IF	CITATIONS
2268	Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical Evaluation of Novel Targets in RA (PREVeNT-RA) Cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 210.	1.6	5
2269	The use of biosimilars as a new approach to the treatment of rheumatoid arthritis. <i>Meditinskiy Sovet</i> , 2021, , 112-121.	0.1	0
2270	Is the fluorescence optical imaging (FOI) able to discriminate between rheumatoid arthritis patients with and without need of rituximab retherapy? A cohort study. <i>BMJ Open</i> , 2021, 11, e047713.	0.8	1
2271	Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 69.	0.9	2
2272	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-186.	0.4	1
2273	Macrophages: The Good, the Bad, and the Gluttony. <i>Frontiers in Immunology</i> , 2021, 12, 708186.	2.2	178
2274	Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 735-745.	1.0	5
2275	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. <i>Arthritis Care and Research</i> , 2023, 75, 231-239.	1.5	6
2277	Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. <i>Clinical Rheumatology</i> , 2022, 41, 63-73.	1.0	4
2278	The efficacy of low dose short-term prednisone therapy for remission induction in newly diagnosed rheumatoid arthritis patients. <i>Advances in Rheumatology</i> , 2021, 61, 50.	0.8	4
2279	Therapy of antigen-induced arthritis of the temporomandibular joint via platelet-rich plasma injections in domestic pigs. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2021, 49, 726-731.	0.7	7
2280	Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021, 7, e001621.	1.8	10
2281	Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2371-2393.	3.0	7
2282	Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 469-479.	0.5	30
2283	Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men. <i>Cell Reports Medicine</i> , 2021, 2, 100396.	3.3	15
2284	Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-11.	0.6	0
2285	PROTECTIVE EFFECT OF THE RAMELTEON, A MELATONIN AGONIST, AGAINST METHOTREXATE-INDUCED BONE-TOXICITY. <i>SÄleyman Demirel Üniversitesi Tıp Fakültesi Dergisi</i> , 0, , .	0.0	0
2286	Safety of Long-Term Use of Four Common Conventional Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2021, 51, 237-245.	0.2	6

#	ARTICLE	IF	CITATIONS
2287	Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers. <i>Rheumatology and Therapy</i> , 2021, 8, 1493-1517.	1.1	13
2289	Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Epidemiology</i> , 2022, 33, 65-74.	1.2	5
2290	Critical Role of Synovial Tissueâ€œResident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 715894.	2.2	44
2291	Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. <i>Journal of Autoimmunity</i> , 2021, 123, 102707.	3.0	27
2292	Comparison between leflunomide and sulfasalazine-based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. <i>Rheumatology International</i> , 2022, 42, 771-782.	1.5	4
2293	Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 236.	1.6	10
2294	WTD Attenuating Rheumatoid Arthritis via Suppressing Angiogenesis and Modulating the PI3K/AKT/mTOR/HIF-1 $\beta$ Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 696802.	1.6	20
2295	Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. <i>Rheumatology</i> , 2021, 60, 5042-5051.	0.9	6
2296	The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients. <i>Rheumatology International</i> , 2022, 42, 2027-2037.	1.5	6
2297	HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA. <i>Arthritis Research and Therapy</i> , 2021, 23, 245.	1.6	16
2298	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021, 8, 1661-1675.	1.1	10
2299	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2596-2602.	0.9	4
2300	Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 817.	0.8	3
2301	Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. <i>British Journal of Clinical Pharmacology</i> , 2021, . .	1.1	1
2302	Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists. <i>Pharmacy Practice</i> , 2021, 19, 2377.	0.8	0
2303	Musculoskeletal Ultrasound of Rheumatologic Conditions. <i>Advances in Clinical Radiology</i> , 2021, 3, 169-182.	0.1	1
2304	Pancytopenia after Low-Dose Methotrexate Therapy in Two Hemodialysis Patients with Rheumatoid Arthritis. <i>American Journal of the Medical Sciences</i> , 2022, 363, 185-190.	0.4	1
2305	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5

#	ARTICLE	IF	CITATIONS
2306	Pain in rheumatoid arthritis: a seven-year follow-up study of pain distribution and factors associated with transition from and to chronic widespread pain. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-10.	0.6	1
2307	Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission. <i>Sultan Qaboos University Medical Journal</i> , 2022, 22, 554-560.	0.3	2
2308	Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study. <i>Rheumatology International</i> , 2021, 41, 1905-1913.	1.5	5
2309	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	0.6	1
2310	Long-Term Results of Anterior-Only Lumbar Interbody Fusions in Rheumatoid Arthritis Patients: Comparative Retrospective Cohort Study. <i>World Neurosurgery</i> , 2021, 154, e109-e117.	0.7	0
2311	IL-6/STAT3 signaling activation exacerbates high fructose-induced podocyte hypertrophy by ketohexokinase-A-mediated tristetraprolin down-regulation. <i>Cellular Signalling</i> , 2021, 86, 110082.	1.7	5
2312	Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4167-4175.	2.0	4
2313	Association Between the Extent of Periodontal Inflammation and the Severity of Rheumatoid Arthritis in Japanese Patients With Rheumatoid Arthritis. <i>International Dental Journal</i> , 2021, 71, 429-437.	1.0	7
2314	Rheumatoid arthritis treatment using hydroxychloroquine and methotrexate co-loaded nanomicelles: In vivo results. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 206, 111952.	2.5	13
2315	Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 15, 100240.	1.3	7
2316	Clinical lipidomics analysis reveals biomarkers of lipid peroxidation in serum from patients with rheumatoid arthritis. <i>Microchemical Journal</i> , 2021, 169, 106607.	2.3	5
2317	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	2.2	40
2319	How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. <i>Joint Bone Spine</i> , 2022, 89, 105285.	0.8	6
2320	Recommandations pour une utilisation pratique de l'arthrographie dans la polyarthrite rhumatoïde par le groupe français GEISPER. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 329-337.	0.0	0
2321	Facteurs prédictifs de poussée de polyarthrite rhumatoïde après arrêt du méthotrexate dans un traitement combiné avec du tocilizumab. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 354-361.	0.0	0
2322	Synthesis and pharmacological evaluation of choroquine derivatives bearing long aminated side chains as antiviral and anti-inflammatory agents. <i>Bioorganic Chemistry</i> , 2021, 116, 105346.	2.0	2
2323	A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , 2021, 173, 105887.	3.1	14
2324	Antiarthritic activity of OA-DHZ; a gastroprotective NF- $\kappa$ B/MAPK/COX inhibitor. <i>Cytokine</i> , 2021, 148, 155688.	1.4	5

#	ARTICLE	IF	CITATIONS
2325	Factors Associated with <i>Pneumocystis jirovecii</i>; Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study. <i>Internal Medicine</i> , 2022, 61, 997-1006.	0.3	9
2326	Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4026-4034.	1.1	19
2327	The sonographic identification of cortical bone interruptions in rheumatoid arthritis: a morphological approach. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110043.	1.2	6
2328	Low-dose rituximab protocol in rheumatoid arthritisâ€”outcome and economic impact. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa077.	0.3	6
2329	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110336.	1.2	6
2330	Nanotechnology for diagnosis and therapy of rheumatoid arthritis: Evolution towards theranostic approaches. <i>Chinese Chemical Letters</i> , 2021, 32, 66-86.	4.8	46
2331	Evaluation of biologicalâ€”diseaseâ€”modifying antirheumatic drugs in a refractory rheumatoid arthritis patient who was on hemodialysis. <i>Nihon Toseki Igakkai Zasshi</i> , 2021, 54, 51-56.	0.2	0
2332	Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2020, 11, 608703.	1.6	32
2333	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritisâ€”a comprehensive review. <i>Arthritis Research and Therapy</i> , 2021, 23, 3.	1.6	18
2334	Synovitis and Tenosynovitis on Ultrasound as Predictors of DMARD Tapering Failure in Patients with Longâ€”Standing Rheumatoid Arthritis in Clinical Remission or Low Disease Activity. <i>Journal of Ultrasound in Medicine</i> , 2021, 40, 2549-2559.	0.8	2
2335	Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e143.	1.1	3
2336	Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease. <i>Internal Medicine</i> , 2021, 60, 3995-3998.	0.3	2
2338	Design of a Glove Controlled by Electromyographic Signals for the Rehabilitation of Patients with Rheumatoid Arthritis. <i>Communications in Computer and Information Science</i> , 2020, , 3-11.	0.4	8
2339	Arzneiverordnungen 2016 im Ãœberblick. , 2017, , 3-32.		7
2340	Experience of musculoskeletal ultrasound scanning improves physiciansâ€™ physical examination skills in assessment of synovitis. <i>Clinical Rheumatology</i> , 2020, 39, 1091-1099.	1.0	3
2341	Established rheumatoid arthritis â€”Redefining the concept. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101476.	1.4	7
2342	Evaluation and monitoring of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101480.	1.4	2
2343	Biosimilars in pediatric rheumatology and their introduction into routine care. <i>Clinical Immunology</i> , 2020, 216, 108447.	1.4	6

#	ARTICLE	IF	CITATIONS
2344	Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. <i>Joint Bone Spine</i> , 2020, 87, 439-443.	0.8	71
2345	Efecto del tratamiento antirresortivo y osteoformador en las erosiones $\tilde{A}^3$ seas en la artritis reumatoide. <i>Medicina Clínica</i> , 2020, 154, 358-365.	0.3	2
2346	The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 583-585.	1.6	18
2347	Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 735-743.	1.6	15
2348	Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. <i>Scientific Reports</i> , 2020, 10, 21907.	1.6	18
2350	Switching to biosimilars in the treatment of rheumatic diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 557-571.	1.3	6
2351	A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 161-167.	0.3	1
2352	OUP accepted manuscript. <i>Rheumatology</i> , 2018, 57, 1135-1144.	0.9	60
2353	A comparative study of the efficacy of Chinese herbal medicine Duhuo Jisheng decoction combined with DMARDs vs isolated DMARDs for rheumatoid arthritis. <i>Medicine (United States)</i> , 2020, 99, e23479.	0.4	3
2355	Tenosynovitis US scoring systems follow synovitis and clinical scoring systems in RA and are responsive to change after biologic therapy. <i>Medical Ultrasonography</i> , 2015, 17, 352.	0.4	14
2356	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.5	36
2357	<i>Pneumocystis jirovecii</i> pneumonia in a patient taking Benepali for rheumatoid arthritis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224764.	0.2	2
2358	The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies. <i>Pan African Medical Journal</i> , 2021, 38, 183.	0.3	2
2359	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096403.	1.2	21
2360	Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature. <i>American Journal of Case Reports</i> , 2018, 19, 582-588.	0.3	7
2361	Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments. <i>F1000Research</i> , 2016, 5, 2019.	0.8	4
2362	Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 4527-4534.	0.3	11
2363	CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0128607.	1.1	19

#	ARTICLE	IF	CITATIONS
2364	Pretreatment Prediction of Individual Rheumatoid Arthritis Patients'™ Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers. PLoS ONE, 2015, 10, e0132055.	1.1	28
2365	Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. PLoS ONE, 2015, 10, e0136982.	1.1	7
2366	Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0138543.	1.1	164
2367	Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach. PLoS ONE, 2016, 11, e0148791.	1.1	11
2368	A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients. PLoS ONE, 2016, 11, e0152362.	1.1	20
2369	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. PLoS ONE, 2016, 11, e0153140.	1.1	19
2370	Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0160225.	1.1	42
2371	Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies. PLoS ONE, 2016, 11, e0161141.	1.1	32
2372	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0161727.	1.1	11
2373	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-̢ Inhibitors in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0163087.	1.1	43
2374	A Nationwide Survey on Patient's™ versus Physician's Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study. PLoS ONE, 2016, 11, e0166607.	1.1	16
2375	Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. PLoS ONE, 2016, 11, e0168369.	1.1	4
2376	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS ONE, 2017, 12, e0170108.	1.1	41
2377	Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?. PLoS ONE, 2017, 12, e0171070.	1.1	30
2378	Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. PLoS ONE, 2017, 12, e0175281.	1.1	24
2379	Factors associated with the risk of gingival disease in patients with rheumatoid arthritis. PLoS ONE, 2017, 12, e0186346.	1.1	7
2380	Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS ONE, 2017, 12, e0188810.	1.1	20
2381	Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-. PLoS ONE, 2018, 13, e0194130.	1.1	65

#	ARTICLE	IF	CITATIONS
2382	Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNF $\pm$ therapy. PLoS ONE, 2018, 13, e0194693.	1.1	17
2383	CLINICAL CHARACTERISTICS OF FRAILITY IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS. Journal of Frailty & Aging, the, 2020, 9, 1-6.	0.8	11
2384	PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS. Nauchno-Prakticheskaya Revmatologiya, 2014, .	0.2	3
2385	PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS. Nauchno-Prakticheskaya Revmatologiya, 2017, 55, 409-419.	0.2	40
2386	RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 263-271.	0.2	38
2387	PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Nauchno-Prakticheskaya Revmatologiya, 0, 57, 1-40.	0.2	23
2388	The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 564-577.	0.2	10
2389	Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 8-16.	0.2	45
2390	EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 268-275.	0.2	6
2391	Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 62-79.	0.2	17
2392	Rheumatoid arthritis: problems of treatment at the present stage. Sovremennaya Revmatologiya, 2018, 12, 65-70.	0.1	3
2393	Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats. Advanced Pharmaceutical Bulletin, 2016, 6, 617-625.	0.6	13
2394	Prevalence of Malignancy Among Urban Black Rheumatoid Arthritis Patients. International Journal of Clinical Research & Trials, 2020, 5, .	1.6	2
2395	Do ankle, hindfoot, and heel ultrasound findings predict the symptomatology and quality of life in rheumatoid arthritis patients?. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ„-SzopiÅ„ska, 2020, 20, e70-e82.	0.7	9
2396	New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab. AlĖmanah KliniĖskoj Mediciny, 2019, 47, 461-469.	0.2	1
2397	Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study. Nagoya Journal of Medical Science, 2019, 81, 571-585.	0.6	4
2398	Leflunomide in monotherapy of rheumatoid arthritis: metaĖanalysis of randomized trials. Polish Archives of Internal Medicine, 2012, 122, 22-32.	0.3	20
2400	<p>Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World</p>. Journal of Inflammation Research, 2020, Volume 13, 1141-1150.	1.6	6



#	ARTICLE	IF	CITATIONS
2401	The role of targeted synthetic drugs in the treatment of rheumatic diseases: focus on tofacitinib. Meditsinskiy Sovet, 2020, , 83-94.	0.1	1
2402	Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Current Medicinal Chemistry, 2019, 26, 2823-2843.	1.2	20
2403	Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment. Current Pharmaceutical Design, 2019, 25, 969-986.	0.9	24
2404	Biosimilars in Rheumatic Diseases: Regulatory Guidelines, Efficacy and Safety Implications in Saudi Arabia. Open Rheumatology Journal, 2018, 12, 313-322.	0.1	5
2405	Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results. Open Rheumatology Journal, 2018, 12, 323-331.	0.1	2
2406	Design, Delivery, Maintenance, and Outcomes of Peer-to-Peer Online Support Groups for People With Chronic Musculoskeletal Disorders: Systematic Review. Journal of Medical Internet Research, 2020, 22, e15822.	2.1	15
2407	Meta-Analysis of the Clinical Efficacy of the Placebo Effect from Tumour-Necrosis-Factor Inhibitors to Treat Rheumatoid Arthritis after Methotrexate Failure. Journal of Rheumatic Diseases and Treatment, 2016, 2, .	0.1	2
2408	Treatment Update on Rheumatoid Arthritis. The Japanese Journal of Rehabilitation Medicine, 2018, 55, 334-339.	0.0	1
2410	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterranean Journal of Rheumatology, 2018, 29, 27-37.	0.3	13
2411	Orf disease in a patient with rheumatoid arthritis. Mediterranean Journal of Rheumatology, 2018, 29, 89-91.	0.3	4
2412	<i>Pneumocystis Jirovecii</i> Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review. Mediterranean Journal of Rheumatology, 2019, 30, 167.	0.3	6
2413	Changing Patterns of Medical Visits and Factors Associated with No-show in Patients with Rheumatoid Arthritis during COVID-19 Pandemic. Journal of Korean Medical Science, 2020, 35, e423.	1.1	19
2415	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Frontiers in Pharmacology, 2020, 11, 598308.	1.6	29
2416	Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. International Journal of Molecular Sciences, 2020, 21, 865.	1.8	21
2417	Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network. Journal of Clinical Medicine, 2020, 9, 1528.	1.0	5
2418	New guidelines for treatment of rheumatoid arthritis. Interni Medicina Pro Praxi, 2018, 20, 62-67.	0.0	1
2419	DMARDs-treated patient in the care of a General Practitioner. MedicĀna Pro Praxi, 2019, 16, 143-147.	0.0	1
2421	A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate. Journal of Health Economics and Outcomes Research, 2020, 7, 10-23.	0.6	1

#	ARTICLE	IF	CITATIONS
2422	Development of a Patient-centered Quality Measurement Framework for Measuring, Monitoring, and Optimizing Rheumatoid Arthritis Care in Canada. <i>Journal of Rheumatology</i> , 2021, 48, 326-334.	1.0	7
2423	Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 669-677.	0.7	13
2424	Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 917-931.	0.7	20
2425	Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 465-473.	0.7	8
2426	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 41-59.	0.7	20
2427	The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. <i>Journal of Rheumatic Diseases</i> , 2020, 27, 4.	0.4	17
2428	The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor- $\alpha$ Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2020, 27, 159-167.	0.4	5
2429	Biosimilars: New guns for the treatment of rheumatologic patients?. <i>Beyond Rheumatology</i> , 2019, 1, 15-21.	0.3	2
2430	Importance of patient education in management of patients with rheumatoid arthritis: an intervention study. <i>Egyptian Rheumatology and Rehabilitation</i> , 2019, 46, 42-47.	0.2	2
2431	Real-life efficacy and safety of secukinumab: A single-center, retrospective observational study with 52-week follow-up. <i>Indian Journal of Drugs in Dermatology</i> , 2019, 5, 14.	0.0	3
2432	Potential of neutrophil to lymphocyte ratio in predicting sustained remission in rheumatoid arthritis compared to other immune activation markers. <i>Indian Journal of Medical Research</i> , 2020, 152, 234.	0.4	4
2433	Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Indian Journal of Rheumatology</i> , 2017, 12, 104.	0.2	2
2434	Comorbidity in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2016, 146, w14290.	0.8	29
2435	Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?. <i>Annals of Dermatology</i> , 2019, 31, 495.	0.3	5
2436	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms. <i>Reumatologia</i> , 2020, 58, 390-400.	0.5	8
2437	Treatment strategy for patients with rheumatoid arthritis. <i>Journal of the Korean Medical Association</i> , 2020, 63, 422-430.	0.1	6
2438	Effects of Conventional and Biological Drugs Used for the Treatment of Rheumatoid Arthritis on the Quality of Life and Depression. <i>Eurasian Journal of Medicine</i> , 2019, 51, 12-16.	0.2	11
2439	Relationship between bone mineral density and anti-citrullinated protein antibody and rheumatoid factor in patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2019, 6, 29-32.	1.3	11

#	ARTICLE	IF	CITATIONS
2440	Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain. <i>European Journal of Rheumatology</i> , 2020, 7, 149-157.	1.3	4
2441	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. <i>World Journal of Experimental Medicine</i> , 2015, 5, 225.	0.9	21
2442	Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis. <i>Canadian Geriatrics Journal</i> , 2020, 23, 184-189.	0.7	2
2443	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	6
2444	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019, 8, 1-12.	1.0	55
2445	Update on the diagnosis and management of early rheumatoid arthritis. <i>Clinical Medicine</i> , 2020, 20, 561-564.	0.8	13
2446	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. <i>Rheumatology</i> , 2022, 61, 2783-2791.	0.9	4
2447	Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device. <i>Rheumatology International</i> , 2022, 42, 1565-1572.	1.5	2
2448	Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death. <i>Scientific Reports</i> , 2021, 11, 20766.	1.6	8
2449	Non-invasive monitoring of arthritis treatment response via targeting of tyrosine-phosphorylated annexin A2 in chondrocytes. <i>Arthritis Research and Therapy</i> , 2021, 23, 265.	1.6	0
2450	Features of inflammatory rheumatic diseases treatment in older people. <i>Russian Journal of Geriatric Medicine</i> , 2021, , 327-339.	0.3	0
2451	Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital. <i>Farmakoekonomika</i> , 2021, 14, 334-341.	0.4	0
2452	Management of Rheumatoid Arthritis: An Overview. <i>Cells</i> , 2021, 10, 2857.	1.8	228
2453	Pain catastrophizing hinders Disease Activity Score 28 " erythrocyte sedimentation rate remission of rheumatoid arthritis in patients with normal C-reactive protein levels. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1520-1529.	0.9	5
2454	Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 695-704.	1.0	5
2455	Inhibidores de receptores JAK quinasa e infecci3n por virus varicela zoster en pacientes con artritis reumatoide. Revisi3n sistem4tica de la literatura. <i>Reumatolog4a Cl4nica</i> , 2021, , .	0.2	0
2456	Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 433-440.	3.0	1
2457	Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study). <i>Modern Rheumatology</i> , 2022, 32, 846-856.	0.9	6

#	ARTICLE	IF	CITATIONS
2458	Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 398-401.	0.5	8
2459	Effective factors on Sharp Score in patients with rheumatoid arthritis: a retrospective study. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 865.	0.8	3
2461	Molecular Effects of Exercise in Rheumatoid Arthritis. , 0, , .		0
2464	Cancer Risk in Rheumatic Diseases. , 2013, , 515-527.		0
2465	Hospital and clinic cooperation for the treatment of rheumatoid arthritis in Okayama Prefecture, Japan. <i>Okayama Igakkai Zasshi</i> , 2014, 126, 209-215.	0.0	0
2466	Comparing the Progression of Hip Joint Destruction in Patients with Rheumatoid Arthritis before and after Intervention with Methotrexate and Biologics DMARDs. <i>The Showa University Journal of Medical Sciences</i> , 2014, 26, 57-61.	0.1	0
2467	NEW RECOMMENDATIONS FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE ROLE OF METHOTREXATE. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2014, 52, 8.	0.2	12
2468	Efectividad del Rituximab en la Artritis Reumatoide. <i>Revista Médica Del Hospital JosÃ© Carrasco Arteaga</i> , 2014, 6, 35-38.	0.0	0
2469	NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2014, 52, 209.	0.2	17
2470	The tumor necrosis factor- $\alpha$ inhibitor golimumab in the treatment of rheumatoid arthritis. <i>Sovremennaya Revmatologiya</i> , 2014, , 76.	0.1	0
2471	Application of Japanese Oriental Medicine for the Treatment of Rheumatoid Arthritis Complicated with Other Serious Diseases. <i>Alternative &amp; Integrative Medicine</i> , 2015, 04, .	0.1	0
2473	Current Status of and Future Perspectives on Biologics in Rheumatic Diseases. <i>Juntendo Medical Journal</i> , 2015, 61, 573-579.	0.1	0
2475	Significant muscle loss following intramuscular corticosteroid injection used to treat active rheumatoid arthritis: a case report. <i>Journal of Rheumatology and Orthopedics</i> , 2015, 2, 2.	0.2	0
2476	Effects of Concomitant Conventional and Previous Biological Disease Modifying Anti-Rheumatic Drugs Treatment on the Efficacy of Tocilizumab to Induce Remission in Patients with Rheumatoid Arthritis - An Observational Real-Life Study. <i>Rheumatology (Sunnyvale, Calif)</i> , 2015, 05, .	0.3	0
2477	METHOTREXATE IN RHEUMATOID ARTHRITIS - 2015: NEW FACTS AND IDEAS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2015, 53, 64-76.	0.2	5
2478	ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2015, 53, 522-541.	0.2	7
2479	Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2015, 05, 104-112.	0.1	0
2481	Safety and efficacy of Methotrexate Monotherapy Vs Methotrexate Plus Leflunomide Combination Therapy in Early Active Rheumatoid Arthritis Patients. <i>Medicine Science</i> , 2016, 5, 117.	0.0	1

#	ARTICLE	IF	CITATIONS
2482	USE OF SUBCUTANEOUS METHOTREXATE FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: THE REMARCA TRIAL. Nauchno-Prakticheskaya Revmatologiya, 2016, 54, 138-144.	0.2	5
2483	Mechanism and Clinical Significance of IL-6 Combined with TNF-Î± or IL-1 for the Induction of Acute Phase Proteins SAA and CRP in Chronic Inflammatory Diseases. Journal of Alcoholism and Drug Dependence, 2016, 4, .	0.2	0
2484	Antirheumatika und Antiphlogistika. , 2017, , 373-384.		0
2485	Regulation of Regulatory T Cell and B Cell Target Therapies. Journal of the Nihon University Medical Association, 2017, 76, 11-14.	0.0	0
2486	Clinical Evaluation of Classical Ayurvedic Formulations Simhanada Guggulu and Brihat Saindhavadi Taila in the Management of Rheumatoid Arthritis (Amavata): A Multicentric Open Label Prospective Study. Journal of Research in Ayurvedic Sciences, 2017, 1, 238-246.	0.1	1
2487	Rehabilitation Medicine and Treatment for the Patient with Rheumatoid Arthritis. The Japanese Journal of Rehabilitation Medicine, 2017, 54, 980-985.	0.0	0
2489	THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIAÂ®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL. Nauchno-Prakticheskaya Revmatologiya, 2017, 55, 351-359.	0.2	7
2490	Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report. Mediterranean Journal of Rheumatology, 2017, 28, 217-220.	0.3	2
2491	Patientenpräferenzen bei der Auswahl von Antirheumatika: Eine wahlbasierte Conjoint-Analyse bei Patienten mit rheumatoider Arthritis. Gesundheitsökonomie Und Qualitätsmanagement, 2018, 23, 307-319.	0.0	0
2493	Corticosteroide. , 2018, , 475-480.		0
2494	Biological therapy of rheumatoid arthritis: is it a real prediction of efficacy?. Medical News of North Caucasus, 2018, 13, .	0.0	0
2495	INNOVATIVE THERAPY OF RHEUMATOID ARTHRITIS: ALGORITHMS AND TARGETS OF TREATMENT. , 2018, 66, 3-9.		1
2496	Visceral Leishmaniasis in the Mediterranean area. European Journal of Rheumatology, 2018, 5, 78-80.	1.3	0
2497	Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug. Mediterranean Journal of Rheumatology, 2018, 29, 13-16.	0.3	3
2498	A Quick and Painless Reminder: The Pharmacotherapy of Rheumatoid Arthritis in Primary Practice. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2018, 60, 38-42.	0.2	0
2499	SAT0194â€¦Significant overtreatment with biological drugs is common in routine care for patients where serum drug levels are monitored. , 2018, , .		1
2500	LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124). Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 280-285.	0.2	1
2501	The impact of anti-cyclic citrullinated peptide antibody status on the management of patients with early rheumatoid arthritis: observational study results from Lithuania. Acta Medica Lituanica, 2018, 25, 112-123.	0.2	2

#	ARTICLE	IF	CITATIONS
2502	Optical noninvasive diagnostics of the functional state of microcirculatory bed in patients with disorders of peripheral haemodynamics. <i>Regional Blood Circulation and Microcirculation</i> , 2018, 17, 23-32.	0.1	9
2503	Influence of therapy on the development of long-term articular and extra-articular damages in adult patients with juvenile idiopathic arthritis. <i>ScienceRise: Medical Science</i> , 2018, .	0.0	0
2504	Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study. <i>Open Rheumatology Journal</i> , 2018, 12, 179-188.	0.1	1
2506	Piggybacked by PEGylation?. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1081-1083.	0.7	0
2507	A 16-week multicenter observational study of the efficiency and safety of rheumatoid arthritis therapy with methotrexate. <i>Sovremennaya Revmatologiya</i> , 2018, 12, 106-111.	0.1	0
2508	The survival rate of therapy with tumor necrosis factor- $\alpha$ inhibitors: main causes and drug substitution tactics. <i>Sovremennaya Revmatologiya</i> , 2018, 12, 23-31.	0.1	0
2509	Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis. <i>Sovremennaya Revmatologiya</i> , 2018, 12, 101-105.	0.1	2
2510	Clinical efficacy of the rituximab biosimilar Acellbia <sup>®</sup> 600 mg in patients with active rheumatoid arthritis in clinical practice. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 56, 703-708.	0.2	1
2511	CLINICAL AND PHARMACOECONOMIC ASPECTS OF ACTIVE CONTROLLED ANTI-INFLAMMATORY THERAPY OF RHEUMATOID ARTHRITIS, BASED ON THE PRINCIPLES OF THE «TREAT-TO-TARGET» STRATEGY: CURRENT STATE OF THE ISSUE. <i>Avicenna Bulletin</i> , 2019, 21, 141-146.	0.0	0
2512	A IL-6 Receptor Blocker for Rheumatoid Arthritis – Sarilumab. <i>Pharmacy Information</i> , 2019, 08, 1-8.	0.1	0
2513	Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2019, 17, 449-457.	0.1	0
2515	Rheumatoide Arthritis – Internistische Aspekte. , 2019, , 455-466.		0
2516	Methotrexate Plus Leflunomide Step-Up Therapy in Early Rheumatoid Arthritis Patients with Non-Response to Initial Methotrexate Monotherapy. , 0, , .		0
2518	Corticosteroide. , 2019, , 623-630.		0
2519	Usability Evaluation of an Image-based Pill Identification Application. <i>Journal of Rheumatic Diseases</i> , 2019, 26, 111.	0.4	3
2520	UTILIZATION PATTERNS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES. <i>Farmacia</i> , 2019, 67, 184-192.	0.1	0
2522	Assessment of pain in rheumatoid arthritis. Practical significance. <i>Sovremennaya Revmatologiya</i> , 2019, 13, 121-128.	0.1	6
2523	Tofacitinib: efficiency and safety in long-term use. <i>Meditinskiy Sovet</i> , 2019, , 64-71.	0.1	0

#	ARTICLE	IF	CITATIONS
2524	Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy. Pakistan Journal of Medical Sciences, 2019, 35, 802-806.	0.3	1
2525	Allelic polymorphisms of thymidylate synthase gene and their haplotypes as predictors of the therapeutic response to methotrexate in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 149-153.	0.2	2
2526	Pancitopenia inducida por bajas dosis de metotrexato. CES Medicina, 2019, 33, 119-125.	0.1	0
2528	Treatment of inflammatory pain “ an interdisciplinary problem from the perspective of a rheumatologist, neurologist, physiotherapist, pain specialist and clinical pharmacologist. BÃ³l, 2019, 19, 11-26.	0.1	1

2529

#	ARTICLE	IF	CITATIONS
2548	4. Rheumatic and Collagen-vascular Diseases: Updates on Diagnosis and Treatment. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 486-495.	0.0	0
2549	é-Çç-€ãfªã,  ãfžãfæ, £è€...ã®Janus kinase1/4~JAK1¼%œ~»ã®3è-~æ²»ç™,æ™,ã®Bãž<è,ç,Žã†æ´»æ€ŠãCE-ã«JAKé,æŠãæ€Šã-é-øã,Žã™ã		
2550	Biological therapy safety in chronic inflammatory arthropathy patients. European Journal of Rheumatology, 2020, 7, 53-59.	1.3	0
2552	Respuesta a medicamentos biolÃ³gicos en pacientes con artritis reumatoide segÃºn nivel de actividad al inicio. Ars Medica, 2020, 45, 14-18.	0.1	0
2553	Change of ARASHI Scores for Large Joints in Rheumatoid Arthritis Patients Treated With Abatacept for Three Years: A Clinical Observational Study. Archives of Rheumatology, 2021, 36, 10-18.	0.3	0
2554	AB0284â€¦RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL TREATMENT. Annals of the Rheumatic Diseases, 2020, 79, 1441.1-1441.	0.5	0
2555	FRI0022â€¦THE ANALYSIS OF THE INVOLVEMENT OF TRANSFORMING-GROWTH INTERACTING FACTOR POLYMORPHISMS IN THE BONE METABOLISM OF RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 583.1-583.	0.5	0
2556	AB0280â€¦SURVIVAL ANALYSIS ON SECOND BIOLOGIC THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS OLDER THAN 65 YEARS. Annals of the Rheumatic Diseases, 2020, 79, 1439.2-1439.	0.5	0
2559	ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 262-267.	0.2	7
2560	Simple Simultaneous Assay of Methotrexate and Non-Steroidal Anti-Inflammatory Drugs by HPLC. Chromatography, 2020, 41, 79-84.	0.8	3
2561	Ultrasonography Reliability in the Detection of Inflammatory and Structural Abnormalities. Journal of Clinical Rheumatology, 2021, 27, e367-e370.	0.5	0
2562	NT-proBNP in Rheumatoid Arthritis Patients: Interaction of Immuno-inflammatory Process and Cardiovascular System. Family Medicine, 2020, .	0.1	0
2563	COVID-19 driven care changes in high risk patients from an outpatient to a community setting. Pflege, 2020, 33, 219-227.	0.8	0
2564	Polymorphisms of methotrexate metabolism genesâ€”as predictors of its hepatotoxicity in rheumatoid arthritis. Eksperimental'naya i Klinicheskaya Gastroenterologiya, 2020, , 106-111.	0.1	0
2565	Fibroblast growth factor and hepatocyte growth factor in adolescents with juvenile idiopathic arthritis treated with methotrexate. ScienceRise: Medical Science, 2020, .	0.0	1
2566	The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project â€œRACURSâ€). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 571-577.	0.2	2
2568	Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. International Journal of Molecular Sciences, 2021, 22, 11592.	1.8	36
2569	Effectiveness and safety study of oral triamcinolone in patients with rheumatoid arthritis in India. International Journal of Health & Allied Sciences, 2020, 9, 14.	0.0	0



#	ARTICLE	IF	CITATIONS
2570	Drug Therapy. Perspectives in Nursing Management and Care for Older Adults, 2020, , 129-147.	0.1	0
2571	Extra-articular Manifestations of Rheumatoid Arthritis. Juntendo Medical Journal, 2020, 66, 21-26.	0.1	2
2572	Rheumatoide Arthritis â€“ Pravalenz, Bedeutung und Implikationen fur die Pravention und Gesundheitsforderung. The Springer Reference Pflege, Gesundheit, 2020, , 1-10.	0.2	0
2573	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Molecular Biomedicine, 2020, 1, 16.	1.7	4
2574	ATIC as a link between antirheumatic drugs and regulation of energy metabolism in skeletal muscle. Periodicum Biologorum, 2020, 121-122, 129-145.	0.1	0
2575	Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab. PLoS ONE, 2020, 15, e0241189.	1.1	5
2576	A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review. Mediterranean Journal of Rheumatology, 2021, 32, 256.	0.3	1
2577	Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab. Internal Medicine, 2022, , .	0.3	5
2578	Antirheumatika und Antiphlogistika. , 2020, , 421-436.		2
2579	Rheumatoid Arthritis Interstitial Lung Disease: Measuring and Predictive Factors Among Patients Treated in Rehabilitation Clinics at Royal Medical Services. Medicinski Arhiv = Medical Archives = Archives De Medecine, 2020, 74, 450.	0.4	2
2580	Hastalıy modifye eden antiromatizmal ilalarla etkilyimler bakmndan analjezik ilaların arlc kullanm. Ege Tp Dergisi, 0, , 27-33.	0.1	0
2582	Corticosteroide. , 2020, , 481-486.		0
2583	Beyond Methotrexate and Biologics in RA â€“ Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium. Mediterranean Journal of Rheumatology, 2020, 31, 120.	0.3	5
2584	Rheumatoid Arthritis: Defining Clinical and Ultrasound Deep Remission. Mediterranean Journal of Rheumatology, 2020, 31, 384.	0.3	2
2585	Advantage of the Use of Articular Ultrasonography in Routine Medical Care. Juntendo Medical Journal, 2020, 66, 15-20.	0.1	0
2587	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 163.	0.3	1
2588	Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland. Rheumatology Advances in Practice, 2020, 4, rkaa059.	0.3	0
2589	Does biologic survival depend on co-prescribed methotrexate dose in established rheumatoid arthritis? A real-world study. European Journal of Rheumatology, 2020, 7, 21-25.	1.3	0

#	ARTICLE	IF	CITATIONS
2590	Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. <i>Translational and Clinical Pharmacology</i> , 2020, 28, 160.	0.3	2
2591	A primary care approach to the management of Arthritis. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2020, 62, e1-e7.	0.2	1
2592	A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping. <i>JMIR Serious Games</i> , 2022, 10, e31570.	1.7	2
2594	é–Çç~€ãfã,  ãfžãfãã,,ãã,,é«~é½Çè€...ã@ç–¾æ,£ã•¼ÿ. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2020, 16, 117-118.	0.0	0
2595	Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. <i>Cells</i> , 2021, 10, 3017.	1.8	63
2596	The impact of diabetes mellitus on treatment and outcomes of rheumatoid arthritis at 5-year follow-up: results from a multi-ethnic Asian cohort. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab077.	0.3	1
2597	The Macrophage Reprogramming Ability of Antifolates Reveals Soluble CD14 as a Potential Biomarker for Methotrexate Response in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 776879.	2.2	7
2598	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy. <i>BMC Nephrology</i> , 2021, 22, 364.	0.8	2
2599	High-dose dexamethasone injection disordered metabolism and multiple protein kinases expression in the mouse kidney. <i>Bioscience Reports</i> , 2021, 41, .	1.1	1
2600	Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 703279.	1.6	1
2601	The perception of stakeholders on the applicability of nurse-led clinics in the management of rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, ii45-ii52.	0.3	5
2602	Development of pancytopenia after single low-dose methotrexate therapy in patients with chronic kidney disease: a review of the literature. <i>Turkish Journal of Internal Medicine</i> , 2020, 2, 83-90.	0.3	2
2603	Joint Destruction Is Associated With All Types of Cardiovascular Events in French Rheumatoid Patients: A Real-Life Study With Very Long Follow-Up. <i>Frontiers in Medicine</i> , 2020, 7, 556086.	1.2	1
2604	Are down-titration and discontinuation strategies of tumour necrosis factor “blocking agents for rheumatoid arthritis in patients with low disease activity possible? A Cochrane Review summary with commentary. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 278-280.	0.9	0
2605	Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. <i>Clinical Medicine</i> , 2020, 20, 551-559.	0.8	7
2606	è†ã±ã...ç–¾æ,£æ²»ç™,ã@ç™ã±•ã¨è²é¡£. <i>Drug Delivery System</i> , 2020, 35, 376-383.	0.0	1
2609	Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corona Registry. <i>American Health and Drug Benefits</i> , 2018, 11, 148-158.	0.5	7
2610	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. <i>American Health and Drug Benefits</i> , 2018, 11, 192-202.	0.5	9

#	ARTICLE	IF	CITATIONS
2611	Correlations between the polymorphism of +869T/C in TGF- $\beta$ 1 and rheumatoid arthritis. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019, 19, 127-132.	0.1	3
2612	Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis. <i>American Health and Drug Benefits</i> , 2019, 12, 400-409.	0.5	2
2614	Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1023-1030.	0.5	8
2615	High incidence of serious infections requiring hospitalisation in human T-cell leukaemia virus type 1-positive rheumatoid arthritis: A case-controlled observational study. <i>Modern Rheumatology</i> , 2021, , .	0.9	2
2616	Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. <i>International Ophthalmology</i> , 2022, 42, 689-711.	0.6	9
2617	Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies—results from a 25-year longitudinal inception cohort. <i>Rheumatology</i> , 2022, 61, 3212-3222.	0.9	10
2618	Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab087.	0.3	4
2619	Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1530-1539.	0.9	8
2620	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <i>Journal of Clinical Pharmacology</i> , 2021, , .	1.0	9
2621	Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 835-844.	0.6	22
2622	Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2815-2825.	0.9	12
2623	Advances in Use of Nanomaterials for Musculoskeletal Regeneration. <i>Pharmaceutics</i> , 2021, 13, 1994.	2.0	4
2624	Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review. <i>Advances in Therapy</i> , 2022, 39, 75-93.	1.3	4
2625	Surgical treatment of wrist joint dysfunction in rheumatoid arthritis: A report of two cases. <i>Modern Rheumatology Case Reports</i> , 2021, , .	0.3	1
2626	Simultaneous measurement of upadacitinib and methotrexate by UPLC-MS/MS and its pharmacokinetic application in rats. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1188, 123071.	1.2	1
2627	Pregnancy outcomes in patients with rheumatoid arthritis who discontinue methotrexate treatment to conceive. <i>Clinical Rheumatology</i> , 2022, 41, 669-675.	1.0	1
2628	Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 327-334.	0.5	15
2629	<sc>SARS</sc> and <sc>CoV</sc> 2 Infection and <sc>COVID</sc> 19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	2.9	117

#	ARTICLE	IF	CITATIONS
2630	Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. <i>Rheumatology and Therapy</i> , 2022, 9, 175-189.	1.1	2
2631	MicroRNA-106b overexpression suppresses synovial inflammation and alleviates synovial damage in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 1054-1063.	0.9	6
2632	Increased Ratio of CD14++CD80+ Cells/CD14++CD163+ Cells in the Infrapatellar Fat Pad of End-Stage Arthropathy Patients. <i>Frontiers in Immunology</i> , 2021, 12, 774177.	2.2	2
2633	Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 573-580.	1.0	3
2634	A Serum Biomarker Panel of exomiR-451a, exomiR-25-3p and Soluble TWEAK for Early Diagnosis of Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 790880.	2.2	11
2635	Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. <i>RMD Open</i> , 2021, 7, e001882.	1.8	10
2636	Hematological parameters as a predictor of disease remission in patients with rheumatoid arthritis. <i>Annals of Medicine and Surgery</i> , 2021, 72, 103085.	0.5	4
2637	Classification criteria for seronegative rheumatoid arthritis based on rheumatologist's practice and experience. <i>Current Medical Issues</i> , 2021, 19, 236.	0.1	0
2640	Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab099.	0.3	5
2641	Use of protocol-driven medication refills by pharmacists decreases rheumatologist in-basket work and improves rheumatologist satisfaction. <i>BMJ Open Quality</i> , 2022, 11, e001566.	0.4	3
2642	Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). <i>Clinical Rheumatology</i> , 2022, 41, 1045-1055.	1.0	3
2643	Association of tumor necrosis factor inhibitors and liver cirrhosis in patients with rheumatoid arthritis: A nationwide population-based nested case-control study. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 327-334.	0.9	3
2645	INFLUENCE OF MEDICATION ON FLARE UP AND INFECTION AFTER ELECTIVE ORTHOPEDIC SURGERY IN RHEUMATOID ARTHRITIS PATIENT - A NARRATIVE REVIEW. <i>Journal Orthopaedi and Traumatology Surabaya (JOINTS)</i> , 2020, 9, 77.	0.0	0
2647	Ultrasound remission in patients with rheumatoid arthritis in clinical remission. <i>Reumatologia</i> , 2022, 59, 378-385.	0.5	1
2648	Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment. <i>Archives of Rheumatology</i> , 0, , .	0.3	0
2649	Clinical Inertia in Rheumatology Practice. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2021, 51, 402-406.	0.2	3
2650	Importance of baseline musculoskeletal ultrasound findings in the prognosis of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 847.	1.0	2
2651	miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis. <i>Cells</i> , 2022, 11, 452.	1.8	28

#	ARTICLE	IF	CITATIONS
2652	Persistently normal blood tests in patients taking methotrexate for RA or azathioprine for IBD: a retrospective cohort study. <i>British Journal of General Practice</i> , 2022, 72, e528-e537.	0.7	6
2653	Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. <i>Rheumatology</i> , 2022, 61, 4286-4296.	0.9	2
2654	Functional coding haplotypes and machine-learning feature elimination identifies predictors of Methotrexate Response in Rheumatoid Arthritis patients. <i>EBioMedicine</i> , 2022, 75, 103800.	2.7	8
2655	Automated Classification of Rheumatoid Arthritis, Osteoarthritis, and Normal Hand Radiographs with Deep Learning Methods. <i>Journal of Digital Imaging</i> , 2022, 35, 193-199.	1.6	18
2656	Pre-RA: Can early diagnosis lead to prevention?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101737.	1.4	9
2657	Folate-Targeted Liposomal Formulations Improve Effects of Methotrexate in Murine Collagen-Induced Arthritis. <i>Biomedicines</i> , 2022, 10, 229.	1.4	3
2659	JAK inhibition and the holy grail for pain control in early RA. <i>RMD Open</i> , 2022, 8, e002068.	1.8	1
2660	The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study. <i>Rheumatology International</i> , 2022, 42, 639-650.	1.5	0
2661	Can we predict unresponsiveness to methotrexate in rheumatoid arthritis? A pharmacogenetic study. <i>Inflammopharmacology</i> , 2022, 30, 193-197.	1.9	3
2662	Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 764067.	1.2	5
2663	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 133-145.	3.5	193
2664	Musculoskeletal ultrasound as a screening-tool for rheumatoid arthritis: results of the "Rheuma-Truck" screening and awareness initiative. <i>Advances in Rheumatology</i> , 2022, 62, 1.	0.8	2
2665	The Effect and Safety of Igaratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 780154.	1.6	4
2666	Clinical-like cryotherapy in acute knee arthritis of the knee improves inflammation signs, pain, joint swelling, and motor performance in mice. <i>PLoS ONE</i> , 2022, 17, e0261667.	1.1	0
2667	Clinical-Like Cryotherapy in Acute Knee Arthritis Protects Neuromuscular Junctions of Quadriceps and Reduces Joint Inflammation in Mice. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	2
2668	Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. <i>Clinical Rheumatology</i> , 2022, 41, 1247-1254.	1.0	6
2670	Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1246.	1.8	20
2671	Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. <i>Chinese Medical Journal</i> , 2022, 135, 409-415.	0.9	6

#	ARTICLE	IF	CITATIONS
2672	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. <i>Scientific Reports</i> , 2022, 12, 134.	1.6	18
2673	Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 146-157.	3.5	55
2674	Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution. <i>Arthritis Research and Therapy</i> , 2022, 24, 4.	1.6	10
2675	New Association Between Diabetes Mellitus and Pancreatic Cancer. <i>Current Diabetes Reviews</i> , 2022, 18, .	0.6	0
2676	Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients. <i>Frontiers in Medicine</i> , 2021, 8, 785744.	1.2	5
2677	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. <i>Rheumatology</i> , 2022, 61, 4273-4285.	0.9	3
2678	Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1373-1378.	1.4	6
2679	The Expression of Inflammasomes NLRP1 and NLRP3, Toll-Like Receptors, and Vitamin D Receptor in Synovial Fibroblasts From Patients With Different Types of Knee Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 767512.	2.2	14
2680	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>Reumatologia Clínica (English Edition)</i> , 2022, 18, 33-41.	0.2	0
2681	Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. <i>Rheumatology</i> , 2022, 61, 3952-3962.	0.9	17
2682	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. <i>Rheumatology</i> , 2022, 61, 3930-3938.	0.9	13
2683	Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac002.	0.3	9
2684	Paradoxical reactions to biologics in chronic inflammatory systemic diseases. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2022, , .	0.6	5
2685	A broad look into the future of rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210762.	1.2	18
2686	Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels. <i>Scientific Reports</i> , 2022, 12, 1877.	1.6	4
2687	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. <i>RMD Open</i> , 2022, 8, e002012.	1.8	50
2688	The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience. <i>Frontiers in Pediatrics</i> , 2022, 10, 820586.	0.9	16
2689	Impact of lifestyle and comorbidities on seropositive rheumatoid arthritis risk from Korean health insurance data. <i>Scientific Reports</i> , 2022, 12, 2201.	1.6	2

#	ARTICLE	IF	CITATIONS
2690	Randomized clinical trials on the efficacy and safety of tocilizumab in subjects with rheumatoid arthritis: a systematic review. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2022, 17, .	0.4	0
2691	A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis. <i>Rheumatology and Therapy</i> , 2022, 9, 771-779.	1.1	4
2692	Co-treatment of Nimbolide augmented the anti-arthritic effects of methotrexate while protecting against organ toxicities. <i>Life Sciences</i> , 2022, 295, 120372.	2.0	8
2693	Identification of Risk Factors for COVID-19 Hospitalization in Patients With Anti-Rheumatic Drugs: Results From a Multicenter Nested Case Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1061-1065.	2.3	2
2694	Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool. <i>Arthritis Research and Therapy</i> , 2022, 24, 36.	1.6	1
2695	The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 839206.	1.2	1
2696	Update on imaging of the cervical spine in rheumatoid arthritis. <i>Skeletal Radiology</i> , 2022, , 1.	1.2	2
2697	Pathogenesis of follicular thymic hyperplasia associated with rheumatoid arthritis. <i>Pathology International</i> , 2022, 72, 252-260.	0.6	3
2698	Cytokines and Inflammation in Meniere Disease. <i>Clinical and Experimental Otorhinolaryngology</i> , 2022, 15, 49-59.	1.1	25
2699	Intraindividual Changes in Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Tests in Korean Patients Visiting Local Clinics and Hospitals. <i>Journal of Clinical Medicine</i> , 2022, 11, 832.	1.0	0
2700	Effectiveness and safety of aerobic exercise for rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2022, 14, 17.	0.7	12
2701	Implementing a <sc>Treat-to-Target</sc> Approach for Rheumatoid Arthritis During the <sc>COVID-19</sc> Pandemic: Results of a Virtual Learning Collaborative Program. <i>Arthritis Care and Research</i> , 2022, 74, 572-578.	1.5	1
2702	Learning from chess engines: how reinforcement learning could redefine clinical decision-making in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1072-1075.	0.5	3
2703	Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 927.	1.0	5
2704	Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET. <i>RMD Open</i> , 2022, 8, e002108.	1.8	3
2705	Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 631-638.	1.5	5
2706	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2375.	3.8	78
2707	Short-term induction glucocorticoids and disease-modifying anti-rheumatic drugs (DMARD) therapy for rheumatoid arthritis. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	2

#	ARTICLE	IF	CITATIONS
2708	Migration, Distribution, and Safety Evaluation of Specific Phenotypic and Functional Mouse Spleen-Derived Invariant Natural Killer T2 Cells after Adoptive Infusion. <i>Mediators of Inflammation</i> , 2021, 2021, 1-11.	1.4	3
2709	CTLA4-Ig treatment induces M1 to M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 306.	1.6	14
2710	Early Undifferentiated Arthritis: A Developing Country Perspective from Nepal. <i>Journal of the Nepal Medical Association</i> , 2018, 56, 983-990.	0.1	0
2711	Infectious Risk of Add-On Leflunomide or Tacrolimus Versus TNF Inhibitors Among Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A Population-Based Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2712	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110730.	1.2	52
2713	The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210744.	1.2	7
2715	Using patient-reported data from a smartphone app to capture and characterize real-time patient-reported flares in rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac021.	0.3	5
2716	Efficacy and Safety of Tripterygium Glycosides (TG) in Treating Rheumatoid Arthritis: An Updated Meta-Analysis of Thirty-Six Randomized Controlled Trials of TG Combined With One Kind of Conventional Disease-Modifying Anti-Rheumatic Drugs. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2717	Ultrasound scoring systems for evaluation of synovitis and tenosynovitis in patients with rheumatoid arthritis. <i>Journal of Medical Ultrasound</i> , 2022, 30, 3.	0.2	1
2718	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 86-96.	0.4	5
2719	Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: results from the multicenter observational cohort study, FRANK Registry. <i>Arthritis Research and Therapy</i> , 2022, 24, 53.	1.6	5
2720	Validity and risk of adopting PGA as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, 2978.	1.6	1
2721	An Integrative Pharmacology Model for Decoding the Underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2022, 13, 801350.	1.6	3
2722	Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis. <i>Experimental and Molecular Medicine</i> , 2022, 54, 143-155.	3.2	20
2723	Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. <i>Arthritis Research and Therapy</i> , 2022, 24, 47.	1.6	7
2725	Editorial: Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era. <i>Frontiers in Medicine</i> , 2022, 9, 858817.	1.2	1
2726	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 353.	1.1	9
2727	Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2366.	1.8	14



#	ARTICLE	IF	CITATIONS
2728	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 861-867.	0.5	35
2729	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 622-631.	0.5	4
2730	Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2022, 49, 447-453.	1.0	1
2731	Yunpi Qufeng Chushi Formula for Pre-Rheumatoid Arthritis: Study Protocol for a Multiple-Center, Double-Blind, Placebo-Controlled Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 793394.	1.6	0
2733	Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis. <i>PLoS ONE</i> , 2022, 17, e0264628.	1.1	4
2734	New Druggable Targets for Rheumatoid Arthritis Based on Insights From Synovial Biology. <i>Frontiers in Immunology</i> , 2022, 13, 834247.	2.2	11
2735	Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study. <i>F1000Research</i> , 2022, 11, 187.	0.8	0
2736	The Risk of Adverse Effects of TNF- $\alpha$ Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 814429.	2.2	7
2737	Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions. <i>Scientific Reports</i> , 2022, 12, 2563.	1.6	2
2738	Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2375-2383.e6.	0.3	19
2739	Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis. <i>Medicine (United States)</i> , 2022, 101, .	0.4	1
2740	Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study. <i>Clinical Rheumatology</i> , 2022, 41, 1989-2000.	1.0	31
2741	Current status of shared decision making for rheumatoid arthritis treatment in Japan: a web-based survey on physicians and patients. <i>Current Medical Research and Opinion</i> , 2022, 38, 853-861.	0.9	2
2742	Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 865267.	2.2	12
2743	The Effects of Patient Education on Psychological Status and Clinical Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2022, 13, 848427.	1.3	2
2744	Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, 13.	0.6	2
2745	Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines. <i>RMD Open</i> , 2022, 8, e002093.	1.8	2
2746	Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2871.	1.8	41

#	ARTICLE	IF	CITATIONS
2747	Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. <i>Rheumatology</i> , 2022, 61, 3552-3566.	0.9	19
2748	Methotrexate Pneumonitis After a Low-Dose Medication Error: A Case Report. <i>Cureus</i> , 2022, 14, e23078.	0.2	0
2749	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	1.1	18
2750	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry. <i>Rheumatology International</i> , 2022, 42, 803-814.	1.5	3
2751	Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland. <i>BMJ Open</i> , 2022, 12, e056352.	0.8	2
2752	Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial. <i>RMD Open</i> , 2022, 8, e001828.	1.8	5
2753	Methotrexate-associated lymphoproliferative disorder affecting the gingiva and intestinal mucosa with intestinal perforation: A case report. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2022, 34, 169-173.	0.2	0
2754	Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2022, 12, 499.	1.1	27
2755	Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 444.	1.1	21
2756	Comparison of Efficacy of Acupuncture-Related Therapy in the Treatment of Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Immunology</i> , 2022, 13, 829409.	2.2	17
2757	Challenges in the management of older patients with inflammatory rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 326-334.	3.5	19
2758	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2022, 9, 781-802.	1.1	9
2759	Unmet Needs in Rheumatoid Arthritis: A Subgroup of Patients With High Levels of Pain, Fatigue, and Psychosocial Distress 3 Years After Diagnosis. <i>ACR Open Rheumatology</i> , 2022, , .	0.9	1
2760	Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). <i>Modern Rheumatology</i> , 2022, , .	0.9	3
2761	Treatment of Giant Cell Arteritis (GCA). <i>Journal of Clinical Medicine</i> , 2022, 11, 1799.	1.0	7
2762	Factors influencing the Sharp score of 1057 patients with rheumatoid arthritis and anemia: a retrospective study. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210885.	0.4	3
2763	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
2764	Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4111.	1.8	5

#	ARTICLE	IF	CITATIONS
2765	Cut microbial dysbiosis in rheumatoid arthritis: a systematic review protocol of case-control studies. <i>BMJ Open</i> , 2022, 12, e052021.	0.8	2
2766	Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 1785-1795.	1.5	4
2767	Targets Exploration of Hydroxychloroquine for Pigmentation and Cell Protection Effect in Melanocytes: The Clue for Vitiligo Treatment. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 1011-1024.	2.0	2
2768	Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study. <i>Journal of Rheumatic Diseases</i> , 2022, 29, 79-88.	0.4	2
2769	Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2022, 21, 103085.	2.5	9
2770	Efficient and automatic synthesis of TSPO PET ligand [18F]-GE-180 and its application in rheumatoid arthritis model. <i>Applied Radiation and Isotopes</i> , 2022, 184, 110213.	0.7	1
2771	Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells. <i>International Immunopharmacology</i> , 2022, 107, 108698.	1.7	23
2772	Management of patients with rheumatoid arthritis by telemedicine: connected monitoring. A randomized controlled trial. <i>Joint Bone Spine</i> , 2022, 89, 105368.	0.8	8
2773	Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review. <i>Rheumatology and Therapy</i> , 2022, 9, 331-378.	1.1	13
2774	JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. <i>Reumatología Clínica (English Edition)</i> , 2021, , .	0.2	0
2775	Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2022, 27, 63-71.	0.3	8
2776	Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review. <i>Healthcare (Switzerland)</i> , 2021, 9, 1726.	1.0	4
2777	Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2021, , .	0.7	0
2778	Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response. <i>Frontiers in Immunology</i> , 2021, 12, 789334.	2.2	23
2779	Toward Overcoming Treatment Failure in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 755844.	2.2	18
2780	Short communication: Differences in clinical outcomes according to the healthcare regime in Colombian patients with rheumatoid arthritis. <i>Revista Colombiana De Reumatología</i> , 2021, , .	0.0	0
2781	Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5743.	1.0	3
2782	Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk. <i>Pharmaceuticals</i> , 2022, 15, 11.	1.7	12

#	ARTICLE	IF	CITATIONS
2783	Jintiange Capsule Alleviates Rheumatoid Arthritis and Reverses Changes of Serum Metabolic Profile in Collagen-Induced Arthritic Rats. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6685-6706.	1.6	5
2784	Clinical Advantage of Attaining Index-Based Remission Prior to Composite Remission in Treating Rheumatoid Arthritis. <i>ReumatologĀa ClĀnica</i> , 2021, , .	0.2	0
2785	Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. <i>Rheumatology and Therapy</i> , 2022, 9, 411-433.	1.1	1
2786	Patients Retransitioning from Biosimilar TNFĀ Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. <i>BioDrugs</i> , 2022, 36, 27-39.	2.2	3
2787	Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. <i>Rheumatology</i> , 2022, 61, 3246-3256.	0.9	3
2789	Evidence-based efficacy of methotrexate in adult CrohnĀ™s disease in different intestinal and extraintestinal indications. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210858.	1.4	4
2790	Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 14.	0.3	1
2791	Cross talks between autoimmunity and cancer. , 2022, , 15-49.		0
2792	Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study. <i>Rheumatology and Immunology Research</i> , 2022, 3, 31-37.	0.2	0
2793	Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions. <i>Arthritis Research and Therapy</i> , 2022, 24, 74.	1.6	6
2794	Protocol for the pilot randomized trial of the CARdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention. <i>Pilot and Feasibility Studies</i> , 2022, 8, 84.	0.5	3
2795	Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study. <i>BMC Rheumatology</i> , 2022, 6, 24.	0.6	1
2796	PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR) Tj ETQq0 0 0 ,rgBT /Overlock 10	0.7	11
2797	Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 327-339.	0.4	3
2798	New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2365-2380.	1.6	23
2799	Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2. <i>Pharmaceutics</i> , 2022, 14, 877.	2.0	5
2800	Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2022, 12, 641.	1.1	3
2801	A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and XeljanzĀ® in Chinese healthy subjects. <i>International Immunopharmacology</i> , 2022, 109, 108780.	1.7	3

#	ARTICLE	IF	CITATIONS
2836	Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	1.6	0
2837	A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis. <i>Case Reports in Rheumatology</i> , 2022, 2022, 1-5.	0.2	1
2839	Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remission in rheumatoid arthritis? Results from a real-life cohort. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ-SzopiÅska</i> , 2022, 22, 21-27.	0.7	1
2843	Real-life experience of tofacitinib in patients with treatment-resistant rheumatoid arthritis: 5 -year follow up: Monocentric experience. <i>Åstanbul Kuzey Klinikleri</i> , 2022, , .	0.1	0
2844	Sensory testing and topical capsaicin can characterize patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 2351-2360.	1.0	5
2845	Multifunctional Nanoparticles Co-Loaded with Perfluoropropane, Indocyanine Green, and Methotrexate for Enhanced Multimodal Imaging of Collagen-Induced Arthritis. <i>Molecular Pharmaceutics</i> , 2022, , .	2.3	1
2846	Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. <i>Medicina (Lithuania)</i> , 2022, 58, 571.	0.8	4
2847	Perspectives of at-Risk Individuals on Preventive Intervention for Rheumatoid Arthritis: A Mini Review. <i>Frontiers in Immunology</i> , 2022, 13, 883287.	2.2	4
2848	Management results of a cohort of rheumatoid arthritis patients in a specialized comprehensive healthcare institution in Colombia. <i>Revista Colombiana De ReumatologÅa (English Edition)</i> , 2022, , .	0.1	0
2849	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	7
2850	Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection. <i>Scientific Reports</i> , 2022, 12, 7843.	1.6	5
2851	The Association of Increase of Human T-Cell Leukemia Virus Type-1 (HTLV-1) Proviral Load (PVL) With Infection in HTLV-1-Positive Patients With Rheumatoid Arthritis: A Longitudinal Analysis of Changes in HTLV-1 PVLs in a Single Center Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
2852	Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina. <i>ReumatologÅa ClÅnica (English Edition)</i> , 2022, 18, 286-292.	0.2	0
2853	Musculoskeletal ultrasound for treating rheumatoid arthritis to targetâ€”a systematic literature review. <i>Rheumatology</i> , 2022, 61, 4590-4602.	0.9	4
2854	Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. <i>RMD Open</i> , 2022, 8, e002040.	1.8	0
2855	Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. <i>PLoS ONE</i> , 2022, 17, e0266816.	1.1	6
2856	Dexamethasone-Loaded Radially Mesoporous Silica Nanoparticles for Sustained Anti-Inflammatory Effects in Rheumatoid Arthritis. <i>Pharmaceutics</i> , 2022, 14, 985.	2.0	12
2857	The Clinical Presentation and Factors Associated with Disease Severity of Rheumatoid Arthritis in Uganda: A Cross-Sectional Study. <i>Open Access Rheumatology: Research and Reviews</i> , 2022, Volume 14, 75-86.	0.8	2

#	ARTICLE	IF	CITATIONS
2858	Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 1365-1381.	2.0	2
2859	The second decade of anti-TNF- $\alpha$ therapy in clinical practice: new lessons and future directions in the COVID-19 era. <i>Rheumatology International</i> , 2022, 42, 1493-1511.	1.5	22
2860	Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24449.	0.9	2
2861	Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152019.	1.6	1
2862	Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	14
2864	Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	1
2865	Implementation of the treat-to-target approach and treatment satisfaction in patients with rheumatoid arthritis: perspectives of Chinese rheumatologists. <i>Clinical Rheumatology</i> , 2022, 41, 2659-2668.	1.0	1
2866	Gamma-glutamyl hydrolase gene polymorphisms "another way to predict methotrexate efficacy in rheumatoid arthritis. <i>Russian Journal of Immunology: RJL: Official Journal of Russian Society of Immunology</i> , 2020, 23, 335-340.	0.2	0
2867	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
2868	Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic. <i>Scientific Reports</i> , 2022, 12, 8283.	1.6	1
2869	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. <i>Rheumatology</i> , 2023, 62, S1170-S1180.	0.9	4
2870	Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210963.	1.2	1
2871	Total-Body <sup>18</sup> F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1579-1585.	2.8	13
2872	Determinantes psicológicos da qualidade-de-vida em pessoas com artrite reumatóide. <i>ACTA Paulista De Enfermagem</i> , 2022, 35, .	0.1	0
2873	Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients "the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response" results from the multicenter observational ACT-POL study. <i>Reumatologia</i> , 2022, 60, 92-100.	0.5	1
2875	Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2955.	1.0	2
2876	Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: New insights and challenges. <i>International Immunopharmacology</i> , 2022, 108, 108858.	1.7	4
2877	The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1628-1637.	2.9	9

#	ARTICLE	IF	CITATIONS
2878	Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States. <i>International Journal of Cancer</i> , 2022, 151, 1216-1227.	2.3	4
2879	Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives. <i>Clinical Ophthalmology</i> , 0, Volume 16, 1665-1673.	0.9	5
2880	Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNF $\pm$ therapy: a placebo-controlled phase II study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1076-1084.	0.5	17
2881	Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	2
2882	Increase of Circulating Monocyte-Platelet Conjugates in Rheumatoid Arthritis Responders to IL-6 Blockage. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5748.	1.8	4
2883	Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 836-845.	2.3	0
2884	Making space for patients' preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis. <i>BMJ Open</i> , 2022, 12, e058303.	0.8	1
2885	Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3259-3267.	1.6	0
2886	Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. <i>Clinical Drug Investigation</i> , 2022, 42, 477-489.	1.1	7
2887	Practices among General Practitioners in Rheumatoid Arthritis (GEPRA-I): results of a region-wide online survey. , 2022, 23, .		1
2888	Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	3
2889	Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	7
2890	Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
2893	How long does it take to translate research findings into routine healthcare practice?—the case of biological drugs for rheumatoid arthritis in Brazil. <i>Annals of Translational Medicine</i> , 2022, 10, 738-738.	0.7	6
2894	Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 269-278.	0.4	4
2897	Oral methotrexate at doses 15–25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 2701-2712.	1.0	4
2898	Impact of a pharmaceutical care service for patients with rheumatoid arthritis using a customised mobile device (the PROUD trial): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e061917.	0.8	0
2899	Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission. <i>Nature Reviews Rheumatology</i> , 2022, 18, 384-397.	3.5	49

#	ARTICLE	IF	CITATIONS
2900	Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 1143-1155.	1.1	3
2901	Trends of adverse events and mortality after DMARDs in patients with rheumatoid arthritis: Interrupted time-series analysis. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	1
2902	Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
2903	The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 113-121.	0.8	0
2904	IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1003.	1.1	1
2905	Vasculitogenic T Cells in Large Vessel Vasculitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2906	Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
2907	Increasing trend of radiographic features of knee osteoarthritis in rheumatoid arthritis patients before total knee arthroplasty. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
2908	Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0270391.	1.1	1
2909	Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	4
2910	Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	7
2911	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454.	1.5	2
2913	Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
2914	Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study. <i>Arthritis Care and Research</i> , 2023, 75, 240-251.	1.5	1
2915	Impact of continuity of care on risk for major osteoporotic fracture in patients with new onset rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2916	Development of an interdisciplinary early rheumatoid arthritis care pathway. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	4
2917	AN IATROGENIC COMPLICATION IN A PATIENT WITH RHEUMATOID ARTHRITIS. , 2021, 2, 25-29.		0
2918	Significance of glucocorticoid dose adjustment in rheumatoid arthritis. , 2022, 1, 81-84.		0



#	ARTICLE	IF	CITATIONS
2919	DYSLIPIDEMIA IN PATIENTS WITH RHEUMATOID ARTHRITIS DEPENDS ON COMORBID PATHOLOGY AND GENETIC PREDICTORS. <i>World of Medicine and Biology</i> , 2022, 18, 29.	0.1	0
2920	Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies. <i>Rheumatology International</i> , 0, , .	1.5	0
2921	Synchronous Investigation of the Mechanism and Substance Basis of Tripterygium Glycosides Tablets on Anti-rheumatoid Arthritis and Hepatotoxicity. <i>Applied Biochemistry and Biotechnology</i> , 2022, 194, 5333-5352.	1.4	6
2922	The Effect of Anti-rheumatic Drugs on the Skeleton. <i>Calcified Tissue International</i> , 2022, 111, 445-456.	1.5	4
2923	11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7334.	1.8	2
2924	Nano-medicine in Treating Reumatoid Arthritics. , 0, 2, 186-199.		0
2925	Ultrasound tenosynovitis: A differential feature of patients with seronegative rheumatoid arthritis. <i>ReumatologĀa ClĀnica</i> , 2022, , .	0.2	0
2926	Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
2927	Serum Amyloid A ProteinĀAssociated Kidney Disease: Presentation, Diagnosis, and Management. <i>Kidney Medicine</i> , 2022, 4, 100504.	1.0	4
2928	Association between Endodontic Infection, Its Treatment and Systemic Health: A Narrative Review. <i>Medicina (Lithuania)</i> , 2022, 58, 931.	0.8	20
2929	The Herbal Combination of Radix astragali, Radix angelicae sinensis, and Caulis Ionicerae Regulates the Functions of Type 2 Innate Lymphocytes and Macrophages Contributing to the Resolution of Collagen-Induced Arthritis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2930	Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human BĀLymphocyte Stimulating Factor ReceptorĀAntibody Fusion Protein, in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 1273-1283.	0.8	7
2931	Effectiveness and Safety of Golimumab for Patients Ā%Ń75 Years Old with Rheumatoid Arthritis. <i>Internal Medicine</i> , 2022, 61, 2117-2125.	0.3	0
2932	Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique. <i>RMD Open</i> , 2022, 8, e002458.	1.8	5
2933	Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? ĀA Cohort Study in a Colombian Population. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 107-117.	3.0	0
2934	The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	9
2935	Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 327-333.	0.2	1
2936	Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss. <i>Bone and Joint Research</i> , 2022, 11, 484-493.	1.3	3

#	ARTICLE	IF	CITATIONS
2937	Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients's offspring. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1367-1373.	0.5	5
2938	Treatment Patterns among Patients with Atopic Dermatitis in Secondary Care: A National, Observational, Non-interventional, Retrospective Study in Sweden. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00774.	0.6	2
2939	Treatment Guidelines in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 679-689.	0.8	21
2940	ACCP-negative rheumatoid arthritis " clinical and immunological features. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 314-326.	0.2	2
2941	Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2942	N-Acetyl-L-cysteine in human rheumatoid arthritis and its effects on nitric oxide (NO) and malondialdehyde (MDA): analytical and clinical considerations. <i>Amino Acids</i> , 2022, 54, 1251-1260.	1.2	15
2943	Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	14
2944	Gut Microbiota Structure and Metabolites, Before and After Treatment in Early Rheumatoid Arthritis Patients: A Pilot Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
2945	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2946	In vivo efficacy & phantom imaging connote the theranostic potential of a drug-loaded lipid nanobubble. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103568.	1.4	0
2947	'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps. <i>RMD Open</i> , 2022, 8, e002387.	1.8	23
2948	Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs. <i>Diagnostics</i> , 2022, 12, 1773.	1.3	0
2949	Effects of anti-SSA antibodies on the response to methotrexate in rheumatoid arthritis: A retrospective multicenter observational study. <i>PLoS ONE</i> , 2022, 17, e0271921.	1.1	1
2950	Real-world use of an etanercept biosimilar including selective versus automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	0
2951	Hit-hard and early versus step-up treatment in severe sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 461-467.	1.2	8
2952	Differential diagnosis of inflammatory arthritis from musculoskeletal ultrasound view. <i>Rheumatology and Immunology Research</i> , 2022, 3, 54-60.	0.2	0
2953	A quantitative assessment of the risk of falls in rheumatoid arthritis patients and determination of the risk factors. <i>Turkish Journal of Physical Medicine and Rehabilitation</i> , 2022, 68, 271-277.	0.3	1
2954	Measuring a grey area in medication deployment reveals delays from invention to clinical use of rheumatoid arthritis medications. <i>Annals of Translational Medicine</i> , 2022, 10, 757-757.	0.7	0

#	ARTICLE	IF	CITATIONS
2955	Treatment resistance of rheumatoid arthritis relates to infection of periodontal pathogenic bacteria: a caseâ€“control cross-sectional study. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
2956	Effectiveness of Golimumab as Second Anti-TNFÎ± Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 4178.	1.0	6
2957	Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	5
2958	Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta-Analysis and Network Metaregression. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	6
2959	Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases. <i>Stem Cells International</i> , 2022, 2022, 1-8.	1.2	7
2960	Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4459.	1.0	3
2961	Probability of Medication Intensifications in Rheumatoid Arthritis Patients With Low Disease Activity Scores on Their Patient-Reported Outcomes. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.5	2
2963	Reprogrammed siTNFÎ±/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 787-803.	5.7	7
2964	ROCK inhibition with Y-27632 reduces joint inflammation and damage in serum-induced arthritis model and decreases in vitro osteoclastogenesis in patients with early arthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
2965	Rheumatoid arthritis â€“ symptoms, diagnosis, treatment. <i>Journal of Education, Health and Sport</i> , 2022, 12, 343-347.	0.0	0
2966	Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy. <i>Rheumatology International</i> , 0, , .	1.5	0
2967	Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2968	Outcomes of coronavirus disease 19 patients with a history of rheumatoid arthritis: A retrospective registryâ€“based study in Iran. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 1196-1199.	0.9	8
2969	Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). <i>Modern Rheumatology</i> , 0, , .	0.9	1
2970	Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. <i>PLoS ONE</i> , 2022, 17, e0272327.	1.1	1
2971	Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
2972	Emerging story of gut dysbiosis in spondyloarthropathy: From gastrointestinal inflammation to spondyloarthritis. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	4
2973	Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2022, 387, 715-726.	13.9	27

#	ARTICLE	IF	CITATIONS
2974	Abatacept downregulates Fc $\gamma$ 3 receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	2
2975	Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. <i>Rheumatology</i> , 2023, 62, 1476-1484.	0.9	1
2976	The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nationwide, population-based real-world study. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 1295-1305.	0.9	3
2977	Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders. <i>Genes and Diseases</i> , 2023, 10, 1291-1317.	1.5	14
2978	Trends in risks of malignancies in Japanese patients with rheumatoid arthritis: Analyses from a 14-year observation of the IORRA cohort. <i>Modern Rheumatology</i> , 2023, 33, 715-722.	0.9	6
2979	Disease mechanisms in preclinical rheumatoid arthritis: A narrative review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
2980	-Omic Approaches and Treatment Response in Rheumatoid Arthritis. <i>Pharmaceutics</i> , 2022, 14, 1648.	2.0	5
2981	Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology. Patient Preference and Adherence, 0, Volume 16, 2149-2158.	0.8	1
2982	Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
2983	A Multicenter, Prospective, Randomized, Parallel-Group Trial on the Effects of Temporary Methotrexate Discontinuation for One Week Versus Two Weeks on Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2023, 75, 171-177.	2.9	7
2984	Development and validation of equations for conversion from DAS28ESR and DAS28CRP to the SDAI in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 3697-3706.	1.0	0
2985	Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 3615-3627.	1.0	10
2986	Efficacy of tripterygium glycosides (TG) in rheumatoid arthritis as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional DMARDs: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2022, 184, 106405.	3.1	5
2987	The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-12.	0.8	0
2988	Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: a post hoc analysis of SELECT-COMPARE. <i>Rheumatology</i> , 2023, 62, 1804-1813.	0.9	4
2989	Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts. <i>RMD Open</i> , 2022, 8, e002442.	1.8	6
2990	A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing $\gamma$ 3c cytokine-related JAK-STAT signal. <i>Science Advances</i> , 2022, 8, .	4.7	19
2991	Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	2

#	ARTICLE	IF	CITATIONS
2992	Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2022, 41, 3707-3714.	1.0	10
2993	The potential role of community pharmacy staff in reducing patient delay in consulting with symptoms of rheumatoid arthritis: a qualitative study. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	1
2994	Secondary Failure of Tocilizumab in Treating Elderly-Onset Rheumatoid Arthritis With Systemic Symptoms Complicated by Diverticulum Perforation. <i>Cureus</i> , 2022, , .	0.2	3
2995	Nano-Based Co-Delivery System for Treatment of Rheumatoid Arthritis. <i>Molecules</i> , 2022, 27, 5973.	1.7	2
2996	Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 5207.	1.0	1
2997	Development and real-life use assessment of a self-management smartphone application for patients with inflammatory arthritis. A user-centred step-by-step approach. <i>PLoS ONE</i> , 2022, 17, e0272235.	1.1	2
2998	In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113614.	2.5	38
2999	Tapering biologics in axial spondyloarthritis: A systematic literature review. <i>International Immunopharmacology</i> , 2022, 112, 109256.	1.7	1
3000	Mindfulness-based stress reduction to improve depression, pain and high patient global assessment in controlled rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	1
3001	Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	2
3002	Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211240.	1.2	3
3003	Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211141.	1.2	4
3004	Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211141.	1.2	8
3005	Incidence of rheumatoid arthritis at Marjan Teaching Hospital in Babylon, Iraq (2014â€“2019). <i>Medical Journal of Babylon</i> , 2022, 19, 358.	0.0	4
3006	Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211141.	1.2	1
3007	Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 224.	0.3	1
3008	Tocilizumab-induced granulomatous vasculitis and cutaneous actinomycosis in a patient with rheumatoid arthritis. <i>Postepy Dermatologii i Alergologii</i> , 2022, 39, 812-815.	0.4	1
3009	Physical Exercise and Low-Level Laser Therapy Systemic Effects on the Ankle Joint in an Experimental Rheumatoid Arthritis Model. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2022, 45, 248-260.	0.4	2

#	ARTICLE	IF	CITATIONS
3010	Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	9
3011	Molecular Modeling Guided Drug Designing for the Therapeutic Treatment of Rheumatoid Arthritis. <i>Cellular Microbiology</i> , 2022, 2022, 1-13.	1.1	2
3012	National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 751-765.	1.0	1
3013	Impact of a hybrid medical care model in the rheumatoid arthritis patient-reported outcomes: A non-inferiority crossover randomized study. <i>Journal of Telemedicine and Telecare</i> , 0, , 1357633X2211220.	1.4	3
3014	Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1661-1668.	0.5	11
3015	Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review. <i>Patient Preference and Adherence</i> , 0, Volume 16, 2609-2637.	0.8	3
3016	Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the â€œcomparison of STep-up and step-down therapeutic strategies in childhood ARthritisâ€™ (STARS) trial. <i>Pediatric Rheumatology</i> , 2022, 20, .	0.9	5
3017	The monocyte-to-osteoclast transition in rheumatoid arthritis: Recent findings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
3018	Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids. <i>Rheumatology</i> , 0, , .	0.9	0
3019	Scientific Knowledge of Rheumatoid Arthritis: A Bibliometric Analysis from 2011 to 2020. <i>Journal of Pain Research</i> , 0, Volume 15, 2761-2772.	0.8	5
3020	Remission or Not Remission, Thatâ€™s the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 1531-1547.	1.1	7
3021	Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients. <i>Drugs and Aging</i> , 2022, 39, 841-849.	1.3	8
3022	Potential of Disease-Modifying Anti-Rheumatic Drugs to Limit Abdominal Aortic Aneurysm Growth. <i>Biomedicines</i> , 2022, 10, 2409.	1.4	4
3023	Role of T CD4<sup>+</sup> cells, macrophages, Câ€™low threshold mechanoreceptors and spinal Ca<sub>v</sub>3.2 channels in inflammation and related painâ€™like symptoms in murine inflammatory models. <i>British Journal of Pharmacology</i> , 2023, 180, 385-400.	2.7	3
3024	Rheumatoid arthritis and mitochondrial homeostasis: The crossroads of metabolism and immunity. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
3025	Defining the relationship between pain intensity and disease activity in patients with rheumatoid arthritis: a secondary analysis of six studies. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	5
3026	Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30676.	0.4	0
3027	Long-term clinical results from 10 years follow-up after radiosynoviorthesis: a prospective observational study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
3028	Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. <i>Pharmaceutics</i> , 2022, 14, 1942.	2.0	3
3029	IL-6 regulates the differentiation of pathogenic Th17 cells. <i>European Journal of Immunology</i> , 2022, 52, 1842-1858.	1.6	6
3030	Overtreatment in rheumatoid arthritis: are there reasons for concern?. <i>RMD Open</i> , 2022, 8, e002212.	1.8	1
3031	Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. <i>Rheumatology and Therapy</i> , 0, , .	1.1	0
3032	Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3033	Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	1
3034	Development of Methotrexate Complexes Endowed with New Biological Properties Envisioned for Musculoskeletal Regeneration in Rheumatoid Arthritis Environments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10054.	1.8	1
3035	Management of chronic rheumatic diseases in women 18-45 years of age in Asia Pacific: insights from patient and clinician surveys. <i>Rheumatology International</i> , 0, , .	1.5	2
3036	Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3037	An intersectional analysis of lncRNAs and mRNAs reveals the potential therapeutic targets of Bi Zhong Xiao Decoction in collagen-induced arthritis rats. <i>Chinese Medicine</i> , 2022, 17, .	1.6	2
3038	IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
3039	Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?. <i>Journal of Clinical Medicine</i> , 2022, 11, 5674.	1.0	5
3040	How to balance valuable innovation with affordable access to medicines in Belgium?. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
3041	New insights into the pathogenesis and management of rheumatoid arthritis. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 256-263.	0.9	2
3042	Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
3043	Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. <i>Rheumatology</i> , 2023, 62, 2090-2097.	0.9	3
3044	Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
3045	The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study. <i>BMC Medicine</i> , 2022, 20, .	2.3	8

#	ARTICLE	IF	CITATIONS
3046	Serum level of IFN $\gamma$ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
3047	The effect of long non-coding RNAs in joint destruction of rheumatoid arthritis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
3048	Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
3049	A Case of Iatrogenic Cushing's Syndrome with Gonadal Axis Inhibition Caused by Long-Term Oral Glucocorticoids. <i>Advances in Clinical Medicine</i> , 2022, 12, 9065-9069.	0.0	0
3050	High Throughput Genetic Characterisation of Caucasian Patients Affected by Multi-Drug Resistant Rheumatoid or Psoriatic Arthritis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1618.	1.1	1
3051	Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3052	Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	14
3053	Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	6
3054	The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis. <i>Rheumatology and Therapy</i> , 0, , .	1.1	4
3055	Consistency of recommendations for pharmacotherapy of rheumatoid arthritis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
3056	Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis. <i>Biomolecules</i> , 2022, 12, 1483.	1.8	2
3057	A novel anti-TNF $\alpha$ drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
3058	The change of plasma metabolic profile and gut microbiome dysbiosis in patients with rheumatoid arthritis. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	9
3059	American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 74-80.	0.5	23
3060	Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy. <i>Healthcare (Switzerland)</i> , 2022, 10, 2004.	1.0	2
3061	Galectin-1: A Potential Biomarker Differentiating between Early Rheumatoid Arthritis and Spondyloarthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 6313.	1.0	1
3062	Risk of Liver Fibrosis in Methotrexate-Treated Patients: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	1
3063	Prevalence, Clinical Manifestations, and Treatment Pattern of Patients with Rheumatoid Arthritis Attending the Rheumatology Clinic at Tikur Anbessa Specialized Hospital, Ethiopia: A Cross-Sectional Study. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 221-229.	0.8	1



#	ARTICLE	IF	CITATIONS
3064	Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3065	Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More. <i>ACR Open Rheumatology</i> , 2022, 4, 1031-1041.	0.9	1
3066	Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study. <i>Rheumatology and Therapy</i> , 0, , .	1.1	1
3067	Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar <sc>YLB113</sc>: Results from a post-hoc analysis of a double-blind, randomized, phase <sc>III</sc> comparative study and its open-label extension in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 108-115.	0.9	1
3068	Management of Axial Spondyloarthritis – Insights into Upadacitinib. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3609-3620.	2.0	2
3069	Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	0
3070	Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region. <i>Pharmaceutics</i> , 2022, 14, 2328.	2.0	2
3072	The bone-protective mechanisms of active components from TCM drugs in rheumatoid arthritis treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3073	Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. <i>Gut and Liver</i> , 2023, 17, 288-298.	1.4	3
3074	Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3075	American College of Rheumatology/<sc>EULAR</sc> Remission Criteria for Rheumatoid Arthritis: 2022 Revision. <i>Arthritis and Rheumatology</i> , 2023, 75, 15-22.	2.9	18
3076	Digitally-supported patient-centered asynchronous outpatient follow-up in rheumatoid arthritis - an explorative qualitative study. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	5
3077	Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
3078	Adiponectin and Leptin as Biomarkers of Disease Activity and Metabolic Disorders in Rheumatoid Arthritis Patients. <i>Journal of Inflammation Research</i> , 0, Volume 15, 5845-5855.	1.6	3
3079	Age-related mechanisms in the context of rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2022, 18, 694-710.	3.5	10
3080	A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 61-79.	1.1	12
3081	Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials. <i>Rheumatology and Therapy</i> , 0, , .	1.1	0
3082	Metabolic Abnormalities, Cardiovascular Disease, and Metabolic Syndrome in Adult Rheumatoid Arthritis Patients: Current Perspectives and Clinical Implications. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 255-267.	0.8	5

#	ARTICLE	IF	CITATIONS
3083	Incidence and factors related to SARS-CoV-2 infection in a cohort of patients with rheumatoid arthritis from a health service provider in Colombia during the COVID-19 pandemic. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612211351.	1.1	0
3084	The Effect of Meditation, Mindfulness, and Yoga in Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1905.	1.1	10
3085	Associations between clinical metrics of joint deformity, disease duration, disease activity, functional capacity, quality of life, pain, and fatigue in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 0, , .	1.0	1
3086	Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting. <i>Drugs - Real World Outcomes</i> , 2023, 10, 51-60.	0.7	1
3088	Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2022, 20, .	0.9	2
3089	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 3-18.	0.5	335
3090	Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
3091	The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients. <i>Inflammopharmacology</i> , 0, , .	1.9	2
3092	Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13913.	1.8	8
3093	<i>Fasciola hepatica</i> extract suppresses fibroblast-like synoviocytes in vitro and alleviates experimental arthritis. <i>Advances in Rheumatology</i> , 2022, 62, .	0.8	0
3094	“Without Them, I Would Never Have Been Able to Carry on”•Levers for the Sustained Employment of Patients with Chronic Inflammatory Arthritis: A French Qualitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14616.	1.2	0
3095	Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3097	EC-18 prevents autoimmune arthritis by suppressing inflammatory cytokines and osteoclastogenesis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	3
3098	Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. <i>PLoS ONE</i> , 2022, 17, e0277566.	1.1	2
3099	The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritis. <i>Pharmacological Research</i> , 2022, 186, 106549.	3.1	11
3100	Epimedii Herba: An ancient Chinese herbal medicine in the prevention and treatment of rheumatoid arthritis. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
3101	Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3102	Better Clinical Results in Rheumatoid Arthritis Patients Treated Under a Multidisciplinary Care Model When Compared with a National Rheumatoid Arthritis Registry. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 269-280.	0.8	1

#	ARTICLE	IF	CITATIONS
3103	Examining the safety of relaxed drug monitoring for methotrexate in response to the COVID-19 pandemic. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	1
3104	<i>Angelicae Pubescentis Radix (Umbelliferae)</i> : Systematic review of traditional Chinese medicine for treating rheumatoid arthritis, including traditional usage, chemical components, active components, related inflammatory factors. <i>PhytoMedicine Plus</i> , 2023, 3, 100389.	0.9	2
3105	Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment. <i>Bioactive Materials</i> , 2023, 24, 37-53.	8.6	9
3106	Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study). <i>Chinese Medical Journal</i> , 2022, 135, 2200-2209.	0.9	1
3107	Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003â€“2018. <i>HemaSphere</i> , 2022, 6, e797.	1.2	4
3108	Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 1-9.	0.9	9
3109	Nationwide, large-scale implementation of an online system for remote entry of patient-reported outcomes in rheumatology: characteristics of users and non-users and time to first entry. <i>RMD Open</i> , 2022, 8, e002549.	1.8	1
3110	A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis. <i>RMD Open</i> , 2022, 8, e002615.	1.8	3
3111	Comparison of glucocorticoids and painkiller prescribed days between rheumatoid arthritis patients receiving early and late treatment with a biological agent via a population-based cohort study. <i>Medicine (United States)</i> , 2022, 101, e31986.	0.4	0
3112	Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
3114	Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolpment of the 2021 American College of Rheumatology guidelines. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
3115	The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 6894.	1.0	6
3116	Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial. <i>RMD Open</i> , 2022, 8, e002616.	1.8	1
3117	Clinical Significance of Diabetes-Mellitus-Associated Antibodies in Rheumatoid Arthritis. <i>Cells</i> , 2022, 11, 3676.	1.8	1
3118	Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study. <i>Clinical Rheumatology</i> , 2023, 42, 1047-1059.	1.0	5
3119	Validity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients. <i>PLoS ONE</i> , 2022, 17, e0278285.	1.1	1
3120	Clinical Advantage of Attaining Index-Based Remission Prior to Composite Remission in Treating Rheumatoid Arthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2022, 18, 574-579.	0.2	0
3121	Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors. <i>Pediatric Rheumatology</i> , 2022, 20, .	0.9	5

#	ARTICLE	IF	CITATIONS
3122	Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
3123	Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
3124	Receiver operating characteristic analysis using a novel combined thermal and ultrasound imaging for assessment of disease activity in rheumatoid arthritis. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3125	Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challenges. <i>Autoimmunity Reviews</i> , 2023, 22, 103260.	2.5	18
3126	Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data). <i>Sovremennaya Revmatologiya</i> , 2022, 16, 32-37.	0.1	1
3127	Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study. <i>RMD Open</i> , 2022, 8, e002614.	1.8	1
3128	Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort. <i>Medicina (Lithuania)</i> , 2022, 58, 1851.	0.8	3
3129	Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
3130	Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia. <i>Cureus</i> , 2022, , .	0.2	0
3131	Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	1
3132	Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate. <i>Rheumatology and Therapy</i> , 2023, 10, 375-386.	1.1	1
3133	Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study. <i>RMD Open</i> , 2022, 8, e002700.	1.8	2
3134	The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 1984.	1.1	4
3135	SARS-CoV-2 induces "cytokine storm" hyperinflammatory responses in RA patients through pyroptosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3136	Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors. <i>RMD Open</i> , 2022, 8, e002796.	1.8	3
3137	Etanercept embedded silk fibroin/pullulan hydrogel enhance cartilage repair in bone marrow stimulation. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
3138	Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	6
3139	Factors Associated With Quality Care Among Adults With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2022, 5, e2246299.	2.8	3

#	ARTICLE	IF	CITATIONS
3140	Calcium complexes of oxicams: new dimensions in rheumatoid arthritis treatment. <i>Future Medicinal Chemistry</i> , 0, , .	1.1	0
3141	A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
3142	Early intervention in psoriasis: Where do we go from here?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3143	Association between Rheumatic Disease Comorbidity Index and factors of poor prognosis in a cohort of 280 patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	3
3144	Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: a multicenter cross-sectional study. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	2
3145	Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. <i>RMD Open</i> , 2022, 8, e002658.	1.8	7
3146	Precautions before starting tofacitinib in persons with rheumatoid arthritis. <i>World Journal of Clinical Cases</i> , 0, 10, 13467-13469.	0.3	0
3147	Antirheumatic treatment, disease activity and risk of <i>Staphylococcus aureus</i> bacteraemia in rheumatoid arthritis: a nationwide nested case-control study. <i>RMD Open</i> , 2022, 8, e002636.	1.8	0
3148	Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3149	Regulatory Fibroblast-Like Synoviocytes Cell Membrane Coated Nanoparticles: A Novel Targeted Therapy for Rheumatoid Arthritis. <i>Advanced Science</i> , 2023, 10, .	5.6	11
3150	Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset. <i>BMJ Open</i> , 2022, 12, e051936.	0.8	0
3151	Efficacy and Safety of <i>ABBV</i> 373, a Novel Anti- Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial. <i>Arthritis and Rheumatology</i> , 2023, 75, 870-880.	2.9	11
3152	Use of Methotrexate in Girls and Women of Childbearing Age, Occurrence of Methotrexate-Exposed Pregnancies and Their Outcomes in Germany: A Claims Data Analysis. <i>Clinical Drug Investigation</i> , 2023, 43, 109-117.	1.1	3
3153	Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 468-475.	0.5	12
3154	Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. <i>RMD Open</i> , 2022, 8, e002593.	1.8	5
3155	A Case of Capillary Leak Syndrome and Intestinal Ischemia Caused by Rheumatoid Vasculitis. <i>Cureus</i> , 2023, , .	0.2	3
3156	Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1027.	1.8	3
3157	From Bench to Bedside in Rheumatoid Arthritis from the 2022 GISEA International Symposium. <i>Journal of Clinical Medicine</i> , 2023, 12, 527.	1.0	1

#	ARTICLE	IF	CITATIONS
3158	Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries. <i>Rheumatology and Therapy</i> , 0, , .	1.1	1
3159	Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy. <i>Advances in Therapy</i> , 2023, 40, 990-1004.	1.3	1
3160	A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases. <i>Virology Journal</i> , 2023, 20, .	1.4	7
3161	Factors associated with selection of targeted therapy in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2023, 18, e0280234.	1.1	0
3162	Effectiveness and safety in the management of chronic inflammatory diseases with etanercept and infliximab biosimilars in Colombian patients. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2023, , .	0.1	0
3163	Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs). <i>RMD Open</i> , 2023, 9, e002792.	1.8	7
3164	Matrix Metalloproteinase-9 Level in Synovial Fluid—Association with Joint Destruction in Early Rheumatoid Arthritis. <i>Medicina (Lithuania)</i> , 2023, 59, 167.	0.8	4
3165	Facilitators and barriers to adhere to monitoring disease activity with ePROs: a focus group study in patients with inflammatory arthritis. <i>Rheumatology International</i> , 2023, 43, 677-685.	1.5	5
3166	An AI-Powered Clinical Decision Support System to Predict Flares in Rheumatoid Arthritis: A Pilot Study. <i>Diagnostics</i> , 2023, 13, 148.	1.3	7
3167	Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience. <i>Rheumatology and Therapy</i> , 2023, 10, 405-419.	1.1	3
3168	Erosion-free rheumatoid arthritis: clinical and conceptual implications—a BARFOT study. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	5
3169	The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review. <i>Genes</i> , 2023, 14, 89.	1.0	2
3170	Semi-automated socio-anthropologic analysis of the medical discourse on rheumatoid arthritis: Potential impact on public health. <i>PLoS ONE</i> , 2022, 17, e0279632.	1.1	1
3171	Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings. <i>Journal of Clinical Medicine</i> , 2023, 12, 207.	1.0	6
3172	The prevalence of rheumatoid arthritis in Western Australia. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	2
3173	Retinal microvascular density analysis in patients with rheumatoid arthritis treated with hydroxychloroquine. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2023, 261, 1433-1442.	1.0	2
3174	Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2023, 13, 61.	1.1	1
3175	Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 286.	1.0	3

#	ARTICLE	IF	CITATIONS
3176	Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naïve, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. <i>RMD Open</i> , 2022, 8, e002683.	1.8	2
3177	Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients. <i>Annals of Translational Medicine</i> , 2022, 10, 1365-1365.	0.7	1
3178	JAK Inhibition in Patients with Rheumatoid Arthritis: Haemodynamic Effects and Impact on Micro- and Macrovascular Function. Study Design and Rationale. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 471.	0.3	0
3179	Anti-Arthritic and Anti-Cancer Activities of Polyphenols: A Review of the Most Recent In Vitro Assays. <i>Life</i> , 2023, 13, 361.	1.1	6
3181	Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1958.	1.8	4
3182	Correlation Between Total Bilirubin, Total Bilirubin/Albumin Ratio with Disease Activity in Patients with Rheumatoid Arthritis. <i>International Journal of General Medicine</i> , 0, Volume 16, 273-280.	0.8	3
3183	Telotristat Etiprate alleviates rheumatoid arthritis by targeting LGALS3 and affecting MAPK signaling. <i>Intractable and Rare Diseases Research</i> , 2023, 12, 45-57.	0.3	2
3184	Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy. <i>Life</i> , 2023, 13, 319.	1.1	4
3185	Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in FourÂPhase 3 Clinical Studies. <i>Rheumatology and Therapy</i> , 2023, 10, 463-476.	1.1	1
3186	Patient participation in defining best-practice rheumatology service provision in Aotearoa New Zealand: a qualitative study with service consumers. <i>BMC Rheumatology</i> , 2023, 7, .	0.6	1
3187	Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate. <i>Modern Rheumatology</i> , 2023, 34, 37-44.	0.9	4
3188	Epigenetic regulations in inflammatory diseases. , 2023, , 585-613.		0
3189	Barriers to the Diagnosis of Early Inflammatory Arthritis: A Literature Review. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 15, 11-22.	0.8	1
3190	A rare case of scleritis and multiple rheumatoid pulmonary nodules associated with seronegative rheumatoid arthritis. <i>Oxford Medical Case Reports</i> , 2023, 2023, .	0.2	1
3191	Factors Leading to Diagnostic and Therapeutic Delay of Rheumatoid Arthritis and Their Impact on Disease Outcome. <i>Cureus</i> , 2023, , .	0.2	1
3192	Treatment in Patients with Psoriatic Disease and Rheumatoid Arthritis: Seven Case Reports. <i>Clinics and Practice</i> , 2023, 13, 177-189.	0.6	2
3193	THU0191â€¦HAS THE DOSE OF METHOTREXATE IN RHEUMATOID ARTHRITIS BEEN OPTIMIZED BEFORE INITIATING BIOLOGICAL TREATMENT? RESULTS OF AN ALGERIAN MULTICENTER STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 315.2-315.	0.5	0
3194	An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2023, 15, 1759720X2311586.	1.2	4

#	ARTICLE	IF	CITATIONS
3195	Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+. <i>Rheumatology and Therapy</i> , 0, , .	1.1	0
3197	A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma. <i>Advances in Therapy</i> , 2023, 40, 2577-2594.	1.3	2
3198	Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF $\pm$ NANOBODY $\hat{A}$ ® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	9
3199	Non-pharmacological interventions in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2023, 22, 103323.	2.5	1
3200	Shared decision-making practices and patient values in pharmacist outpatient care for rheumatic disease: A multiple correspondence analysis. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, 26, .	0.9	1
3201	JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
3202	The development of COVID-19 treatment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	59
3203	Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison. <i>Rheumatology and Therapy</i> , 0, , .	1.1	0
3204	Glucocorticoide und Mineralocorticoide. , 2022, , 431-437.		0
3205	Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy. <i>PLoS ONE</i> , 2023, 18, e0281213.	1.1	3
3206	Ultrasound tenosynovitis: A differential feature of patients with seronegative rheumatoid arthritis. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2023, 19, 63-66.	0.2	0
3207	Krankheitsmodifizierende Arzneistoffe fĀr Autoimmunerkrankungen. , 2022, , 423-429.		0
3208	Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	3
3209	Editorial: Disease-modifying antirheumatic drugs: Approaches and lessons learned from traditional medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
3210	Mass balance study of [ <sup>14</sup> C]SHR0302, a selective and potent JAK1 inhibitor in humans. <i>Xenobiotica</i> , 2023, 53, 69-83.	0.5	2
3211	Post Hoc Analysis of a Randomized Controlled Trial on Fasting and Plant-Based Diet in Rheumatoid Arthritis (NutriFast): Nutritional Supply and Impact on Dietary Behavior. <i>Nutrients</i> , 2023, 15, 851.	1.7	3
3212	Microwave Radiometry for the Diagnosis and Monitoring of Inflammatory Arthritis. <i>Diagnostics</i> , 2023, 13, 609.	1.3	4
3213	HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study. <i>Viruses</i> , 2023, 15, 468.	1.5	0



#	ARTICLE	IF	CITATIONS
3214	MIR149 rs2292832 and MIR499 rs3746444 Genetic Variants Associated with the Risk of Rheumatoid Arthritis. <i>Genes</i> , 2023, 14, 431.	1.0	1
3215	High-sensitivity cardiac troponin T is associated with disease activity in patients with inflammatory arthritis. <i>PLoS ONE</i> , 2023, 18, e0281155.	1.1	0
3216	Global trends in research of fibroblasts associated with rheumatoid diseases in the 21st century: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
3217	Remodeling articular immune homeostasis with an efferocytosis-informed nanoimitator mitigates rheumatoid arthritis in mice. <i>Nature Communications</i> , 2023, 14, .	5.8	7
3218	Appearance of Ankylosing Spondylitis in a Middle-Aged Female Patient With a Long History of Rheumatoid Arthritis. <i>Cureus</i> , 2023, , .	0.2	1
3219	Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. <i>BMC Medicine</i> , 2023, 21, .	2.3	1
3220	Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: a large observational cohort study of Korean patients with rheumatoid arthritis. <i>RMD Open</i> , 2023, 9, e002722.	1.8	3
3221	Case report: Unusual development of hepatocellular carcinoma during immunosuppressive treatments against rheumatoid arthritis overlapping Sjögren's syndrome; cirrhotic steatohepatitis with liver inflammation and fibrosis lurks in autoimmune disorders. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
3222	Olive Oil and Nuts in Rheumatoid Arthritis Disease Activity. <i>Nutrients</i> , 2023, 15, 963.	1.7	3
3223	The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. <i>Clinical Rheumatology</i> , 2023, 42, 1503-1520.	1.0	3
3224	Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
3225	Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: a longitudinal study. <i>Clinical Rheumatology</i> , 2023, 42, 1537-1544.	1.0	1
3226	Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	3
3227	EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Middle Black Sea Journal of Health Science</i> , 0, , .	0.2	0
3228	Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic <sc> disease-modifying antirheumatic drugs</sc> in the treatment of patients with rheumatoid arthritis: Results from a local prospective study. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 689-698.	0.9	1
3229	MTHFR c.665C>T and c.1298A>C Polymorphisms in Tailoring Personalized Anti-TNF-Î± Therapy for Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4110.	1.8	2
3230	Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1734.	1.0	5
3231	Patients's perspectives towards biologic dose reduction in psoriasis: a qualitative study. <i>Archives of Dermatological Research</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
3232	Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application. <i>Rheumatology</i> , 0, , .	0.9	0
3233	Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis. <i>Heliyon</i> , 2023, 9, e14008.	1.4	2
3234	Circulating PCSK9 relates to aggravated disease activity, Th17/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients. <i>Irish Journal of Medical Science</i> , 2023, 192, 3187-3194.	0.8	7
3235	Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. <i>RMD Open</i> , 2023, 9, e002789.	1.8	4
3236	Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease. <i>Rheumatology International</i> , 2023, 43, 969-973.	1.5	1
3237	Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data. <i>Rheumatology and Therapy</i> , 0, , .	1.1	0
3239	Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial. <i>Chinese Medical Journal</i> , 2023, 136, 331-340.	0.9	1
3240	Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. <i>RMD Open</i> , 2023, 9, e002924.	1.8	0
3241	Sarcopenia in Rheumatoid arthritis. A narrative review. <i>Journal of Frailty, Sarcopenia and Falls</i> , 2023, 8, 44-52.	0.4	8
3243	Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2023, 10, 707-727.	1.1	3
3244	Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial. <i>Trials</i> , 2023, 24, .	0.7	1
3245	Evaluation and surgical management of the rheumatoid foot and ankle. , 2023, , 389-426.		0
3246	Do Disease-Modifying Anti-rheumatic Drugs and Exercise Therapy Have a Combined Effect on Disease Activity in Patients with RA? A Scoping Review. <i>Current Rheumatology Reports</i> , 0, , .	2.1	0
3247	Biomaterials as tools for re-balancing skewed immunity in rheumatoid arthritis. , 2023, , 233-263.		0
3248	Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab. <i>PLoS ONE</i> , 2023, 18, e0282564.	1.1	2
3250	Changes in Bone Metabolism in Patients with Rheumatoid Arthritis during Tumor Necrosis Factor Inhibitor Therapy. <i>Journal of Clinical Medicine</i> , 2023, 12, 1901.	1.0	0
3251	Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3252	Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease. <i>RMD Open</i> , 2023, 9, e002842.	1.8	4

#	ARTICLE	IF	CITATIONS
3253	Simultaneous quantitative analysis and in vitro anti-arthritis effects of five polyphenols from Terminalia chebula. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	1
3254	Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. <i>BMJ Open</i> , 2023, 13, e063198.	0.8	1
3255	Sarcopenia and COVID-19 Outcomes. <i>Clinical Interventions in Aging</i> , 0, Volume 18, 359-373.	1.3	6
3256	Aetiologies of Acute Complications in Autoimmune Rheumatologic Diseases: A Hospital-Based Cross-Sectional Study. <i>Cureus</i> , 2023, , .	0.2	0
3257	14-3-3 $\beta$ Cytokine as a New Biomarker to Assess Rheumatoid Arthritis Disease Activity. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2023, 59, 141-153.	0.2	0
3258	Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. <i>RMD Open</i> , 2023, 9, e002898.	1.8	6
3259	Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
3260	Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab. <i>Rheumatology International</i> , 2023, 43, 881-888.	1.5	1
3262	Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. <i>Pharmaceuticals</i> , 2023, 16, 465.	1.7	2
3263	How to self-examine for tender and swollen joints: co-producing a training video for people with rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2023, 7, i6-i11.	0.3	1
3264	Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	4
3265	Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study. <i>BMC Rheumatology</i> , 2023, 7, .	0.6	0
3266	Treatment goals for rheumatoid arthritis: patient engagement and goal collection. <i>Journal of Comparative Effectiveness Research</i> , 0, , .	0.6	0
3267	Feasibility of methotrexate discontinuation following tocilizumab and methotrexate combination therapy in patients with long-standing and advanced rheumatoid arthritis: a 3-year observational cohort study. <i>Fukushima Journal of Medical Sciences</i> , 2023, 69, 11-20.	0.1	0
3268	Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review. <i>Clinical Rheumatology</i> , 2023, 42, 2651-2676.	1.0	4
3270	Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry. <i>JMIR Research Protocols</i> , 0, 12, e43230.	0.5	0
3271	Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1815-1824.	1.3	4
3272	Robust analyses for radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , 2023, 9, e002543.	1.8	0

#	ARTICLE	IF	CITATIONS
3273	Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
3274	Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report. <i>World Journal of Clinical Cases</i> , 0, 11, 2474-2481.	0.3	1
3275	Rheumatoid Arthritis from Easy to Complex Disease: From the "2022 GISEA International Symposium". <i>Journal of Clinical Medicine</i> , 2023, 12, 2781.	1.0	2
3276	A Framework of Faster CRNN and VGG16-Enhanced Region Proposal Network for Detection and Grade Classification of Knee RA. <i>Diagnostics</i> , 2023, 13, 1385.	1.3	1
3277	Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	18
3278	Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study. <i>European Journal of Epidemiology</i> , 2023, 38, 809-819.	2.5	6
3279	Management of Rheumatoid Arthritis With a Digital Health Application. <i>JAMA Network Open</i> , 2023, 6, e238343.	2.8	8
3280	Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis. <i>Rheumatology International</i> , 2023, 43, 1515-1523.	1.5	2
3281	Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia. <i>Journal of Pragmatic and Observational Research</i> , 0, Volume 14, 29-38.	1.1	0
3282	The effect of JuanBiQiangGu granules in combination with methotrexate on joint inflammation in rheumatoid arthritis: a randomized controlled trial. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
3283	Adherence to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study. <i>Rheumatology International</i> , 0, , .	1.5	1
3284	N-benzyl-N-methyldecan-1-amine and its derivative mitigate 2,4- dinitrobenzenesulfonic acid-induced colitis and collagen-induced rheumatoid arthritis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
3285	The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	0
3286	Evaluating the Effect of Delayed Diagnosis on Disease Outcome in Fibromyalgia: A Multi-Center Cross-Sectional Study. <i>Journal of Pain Research</i> , 0, Volume 16, 1355-1365.	0.8	2
3298	What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. <i>Clinical Rheumatology</i> , 2023, 42, 2267-2278.	1.0	5
3302	Role of Liquid Biopsies in Rheumatoid Arthritis. <i>Methods in Molecular Biology</i> , 2023, , 237-246.	0.4	0
3303	Short communication: Differences in clinical outcomes according to the healthcare regime in Colombian patients with rheumatoid arthritis. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2023, 30, 124-128.	0.1	0
3349	Wound Healing from Bench to Bedside: A PPPM Bridge Between Physical Therapies and Chronic Inflammation. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2023, , 221-232.	0.6	0

#	ARTICLE	IF	CITATIONS
3356	Role of PET/CT in diagnosing and monitoring disease activity in rheumatoid arthritis: a review. <i>Annals of Nuclear Medicine</i> , 2024, 38, 165-175.	1.2	0
3362	Glucocorticoide und Mineralocorticoide. , 2023, , 463-469.		0